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Aporphines are a group of tetracyclic alkaloids that belong to the ubiquitous 
tetrahydroisoquinoline family. The aporphine template is known to be associated with a range of 
biological activities. Aporphines have been explored as antioxidants, anti-tuberculosis, 
antimicrobial and anticancer agents. Within the Central Nervous Systems (CNS), aporphine 
alkaloids are known to possess high affinity for several clinically valuable targets including 
dopamine receptors (predominantly D1 and D2), serotonin receptors (5-HT1A and 5-HT7) and α 
adrenergic receptors. Aporphines are also inhibitors of the acetylcholinesterase enzyme – a clinical 
target for the treatment of Alzheimer’s disease. Considering the diverse profile of aporphine 
alkaloids at CNS receptors they can be considered as “privileged scaffold” for the design of CNS 
drugs.  
The aporphine alkaloid nantenine is a 5-HT2A receptor antagonist and has moderate affinity 
for the 5-HT2A receptor. Selective 5-HT2A antagonists have therapeutic potential for the treatment 
of a number of neuropsychiatric disorders including depression, schizophrenia and sleep disorders. 
The aporphine core of nantenine serves as a valuable lead for the identification of selective 5-HT2A 
antagonists.  
In order to understand the structural tolerance of the aporphine core required for 5-HT2A 
antagonism an exhaustive Structure Activity Relationship (SAR) study was designed. Accordingly, 
a diverse library of nantenine analogues was synthesized and evaluated for affinity at the 5-HT2A 
v 
 
receptor. Results from the SAR studies demonstrate that the nitrogen atom of nantenine is required 
for affinity and that introduction of a phenyl ring at the C4 position is detrimental for 5-HT2A 
receptor affinity. At the C3 position, introduction of halogen atoms is beneficial for 5-HT2A 
antagonistic activity. Furthermore, a library of C3 analogues having hydrophobic substituents as 
well as ring D indole analogues is currently being evaluated for affinity at the 5-HT2A receptors. 
These compounds will further expand our understanding of the tolerance of the aporphine core 
required for 5-HT2A antagonism.  
In order to rationalize the affinity of certain high affinity ligands, molecular docking studies 
were conducted. Selected compounds were docked into a homology model of the 5-HT2A receptor 
to extract information about possible binding modes. Based on results of these studies, it is 
concluded that the interaction of C3 halogenated aporphine analogues with Phe339/Phe340 
residues might be responsible for their enhanced affinity. Information obtained from molecular 
docking studies is being utilized for design of advanced generations of analogues.  
Finally, a novel series of flexible tris-(phenylalkyl)amines were synthesized and evaluated 
to test the importance of a rigid aporphine core as well as incorporation of N-phenylalkyl 
substituents. These compounds featuring a halogen substituent in ring C, were found to have high 
affinity and selectivity for the 5-HT2B receptor, with some of the compounds being more potent 
than the selective 5-HT2B antagonist SB200646. Results from this study indicate that ring C of 
these compounds is generally tolerant for halogen substitution. The synthetic feasibility of this 
newly identified template (4 high-yielding synthetic steps from commercially available materials) 
makes this scaffold attractive for the synthesis of larger libraries of analogs and promise for 
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1.1 Aporphine Alkaloids 
1.1.1    Background & Occurrence 
Aporphine alkaloids are natural and synthetic alkaloids that possess a tetracyclic framework. 
Chemically they incorporate a tetrahydroisoquinoline substructure and belong to the isoquinoline 
class of alkaloids. More than 500 members of this class of alkaloids have been isolated. Aporphine 
alkaloids are widely distributed in Annonaceae, Lauraceae, Monimiaceae, Menispermaceae, 
Hernandiaceae and other plant families.1 Both naturally occurring and synthetic aporphine 





1.1.2    Biosynthesis of Aporphine Alkaloids 
Extensive research has indicated that a majority of aporphine alkaloids are biosynthesized from 
the tetrahydrobenzylisoquinoline alkaloid (S)-reticuline (2).3-5 The biosynthesis of (S)-reticuline 
from L-tyrosine is shown in Figure 2. In the first step the amino acid L-tyrosine (3) undergoes a 
phenolic oxidation to generate catechol 4, which then undergoes decarboxylation to generate 
amine 5. Alternatively 3 can also undergo transamination to produce ketoacid 6 followed by 
decarboxylation to produce aldehyde 7. Amine 5 and aldehyde 7 are then subjected to an enzymatic 





subsequent transformations to produce (S)-reticuline (2). (S)-reticuline can then be transformed 
to aporphines via a direct phenolic oxidation as shown in Figure 3. An alternate biosynthetic 





 Several groups have synthesized aporphine alkaloids using biomimetic strategies that 







1.1.3    Common Synthetic Approaches to Aporphine Alkaloids: 
There are several synthetic routes to aporphine alkaloids reported. A summary of some of the 
common approaches is mentioned here. Pioneering work done by Neumeyer and co-workers as 
well as Zhang and co-workers involved the use of an acid catalyzed rearrangement of morphine 
(23) (Figure 5).11-16 This route offers easy access for the synthesis of C10 and C11 aporphine 
analogues.  
 
Another common approach involves the synthesis of aporphine alkaloids from a benzyl-
tetrahydroisoquinoline type precursor. The synthesis of the benzyl-tetrahydroisoquinoline 
precursor (28) is typically accomplished through a Pictet-Spengler reaction or a Bischler-
Napieralski reaction (Figure 6).17-20 Recent development of chiral Pictet-Spengler catalysts and 
chiral imine reducing agents has allowed the construction of the requisite precursor compounds 




Transformation of benzyl tetrahydroisoquinoline derivatives to aporphine alkaloids has 
been reported using several conditions. An earlier approach involves a Pschorr cyclization for the 
formation of the biaryl bond (Figure 7). The requisite aryl radical (32) can be generated through 
the decomposition of a diazonium salt (31) in the presence of a copper or zinc catalyst.23,24  
 
Another approach involves the use of an oxidative photocylization reaction on a stilbene-




Recent advances in palladium catalyzed cross coupling reactions has led to its application 
in the synthesis of aporphine alkaloids (Figure 9). Several groups including ours have reported 
optimized conditions for this reaction.26-29  
 
Alternative methods for the construction of the biaryl bond involves i) intramolecular 
oxidation through the use of oxidation reagents such as ferric chloride and hypervalent iodine 





Another less commonly used approach for the synthesis of aporphines involves their 
synthesis via phenanthrene alkaloids.33,34  
 
1.1.4    Pharmacological Effects of Aporphine Alkaloids: 
Aporphine alkaloids exhibit a plethora of effects within the CNS. There are a number of aporphine 
alkaloids reported as ligands at dopamine and serotonin receptors.1,35 Ligands at the D1 and D2 
dopamine receptor subtypes have a potential role in the treatment of Parkinson’s disease, 
schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), depression, and drug abuse.36-
38 Ligands at the 5-HT1A serotonin receptor subtype have been useful in the treatment of anxiety, 
schizophrenia and depression.39-42  
Aporphines are also ligands at the 5-HT2A and 5-HT7 receptors. Selective 5-HT2A ligands 
have promising applications in the treatment of drug abuse and insomnia. Mixed dopamine/5-HT2A 
ligands have potential for the alleviation of symptoms of depression and schizophrenia.43,44 
Ligands at the 5-HT7 receptor have shown promising results for the treatment of sleep disorders, 
migraine and depression.45-47 Moreover aporphines possessing affinity at the dopamine and 
serotonin receptors have potential use as PET (Positron Emission Tomography) and SPECT 
(Single Photon Emission Computed Tomography) radiotracers for brain imaging studies.48 
Aporphines are also reported as inhibitors of the enzyme Acetylcholinesterase and as antagonists 
of the α1-adrenergic receptor and thus have potential therapeutic role in the treatment of 
Alzheimer’s disease and hypertension respectively.49-52  
SAR at Dopamine receptors:  
Extensive Structure Activity Relationship (SAR) studies done on aporphine alkaloids have 
produced selective D1 and D2 ligands.  
9 
 
Apomorphine (44, Apokyn®) which is an FDA approved drug for the treatment of advanced 
Parkinson’s disease is a non-selective dopamine agonist. 44 has affinity for both D1 (Ki = 250 nM) 
and D2 (Ki = 13 nM) receptors.
53,54 Apomorphine analogues with R-configuration at C6a 
(compounds 45 and 46) displayed dopamine agonist activity whereas analogues with S-
configuration at C6a (compound 47) displayed dopamine antagonistic activity.55,56 Typically an 
N-propyl group enhances selectivity for the D2 receptor (compare 44 with 45).
57 A C11 OH group 
is important for binding at the D1 receptor (compare 48 and 44).
12,58  Molecular docking studies 
have suggested this OH group to be involved in a hydrogen bond interaction with the D1 receptor.
59 
Replacement of the C10 OH group with a methyl group results in significant loss of affinity at the 
dopamine receptors (compare 49 and 44).13 Ortho-dihydroxyl substitution at C10-C11 enhances 
affinity at dopamine receptors; shifting this unit to other positions resulted in inactive 
compounds.60 Small lipophilic groups at the C2 position enhance selectivity at D2 receptor 
(compare 50, 51 with 44) indicating the presence of a lipophilic pocket in the receptor interacting 
with this part of the molecule.16,61,62 
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SAR at Serotonin receptors: 
As discussed earlier, a C10 methyl group significantly diminishes affinity for dopamine 
receptors; however this also results in increased affinity for the serotonin 5-HT1A receptor subtype 
(compound 49).63,64 This observation resulted in the proposal of a methyl pocket which has been 
further validated by synthesis and evaluation of aporphines possessing small alkyl groups at C10 
position.65 Analogues with R-configuration at C6a (compound 49) displayed 5-HT1A agonist 
activity whereas analogues with S-configuration at C6a (compound 52) displayed 5-HT1A 
antagonistic activity. Moreover it has been observed that aporphine analogs lacking hydroxyl 





Smaller substituents on the nitrogen atom (methyl or hydrogen) increase affinity and 
selectivity for the 5-HT1A receptor.
65 At the C2 position, a methoxy group seems to increase 
selectivity towards the 5-HT1A type.
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Compound 54 (N-methyllaurotenanine) is a naturally occurring aporphine alkaloid that 
possesses good affinity at both 5-HT1A and 5-HT7 receptor.
67 Recent SAR studies show that 
modification of the phenolic OH at C9 is detrimental for affinity at 5-HT2A receptor, however it is 
not essential for affinity at 5-HT1A and 5-HT7 receptors.
68 Similarly Nantenine (55) is a naturally 
occurring aporphine alkaloid reported to have dual antagonist effects at the 5-HT2A and α1A 
receptors.69-72  
SAR at Alpha-adrenergic receptors:  
The aporphine alkaloid Boldine (56) is an α1 antagonist having higher affinity for the α1A 
subtype. SAR studies indicate that the presence of a hydroxyl group at the C2 position increases 
affinity at the α1A and α1B receptor subtypes. Introduction of a halogen atom at the C3 position 
resulted in increased affinity for the α1A receptor. Moreover, the presence of a catechol moiety at 
C10/C11 led to increased selectivity for the α1D receptor subtype. At the α2 receptor, boldine 





Similar to the trend seen for dopamine receptors, an N-methyl group is best tolerated across 
all alpha adrenergic receptor subtypes (when compared to N-propyl and NH). Moreover 
aporphines having an S-configuration at C6a have greater affinity across all alpha adrenergic 
subtypes compared to R-configuration.51  
SAR at Acetylcholinesterase enzyme:  
Naturally occurring alkaloids Nuciferine (57), N-methylasimilobine (58) and Magnoflorine 
(59) possess acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activity, 
which are clinical targets for the treatment of Alzheimer ’s disease.49,50 SAR studies of nuciferine 
have shown that the presence of a C2 OH increases AChE inhibitory activity. This observation has 
been validated by molecular docking studies, where the C2 OH group is involved in a hydrogen 




Apart from CNS effects, aporphine alkaloids also possess several non-CNS activities 
including inhibition of platelet aggregation, anti-Human Immunodeficiency Virus 1 (HIV-1) 
integrase activity, anthelmintic, lesihmanicidal and cytotoxicity. 74-78 
A summary of the pharmacological action of aporphines within the CNS is shown in 
Table 1.  
 
Table 1: Summary of clinical significance of aporphines as CNS agents 
Receptor Activity Clinical Significance Reference 
D1 Agonist Parkinson’s disease 12,53, 54 
D1 Antagonist Schizophrenia, Obesity 58 
D2 Agonist Parkinson’s disease, Restless Leg Syndrome 61, 62 
D2 Antagonist Schizophrenia, Bipolar disorder 57 
5-HT1A Agonist Anxiety, Parkinson’s disease 59, 63-66 
5-HT1A Antagonist Schizophrenia, Cognitive dysfunction 63, 64 
5-HT2A Antagonist Sleep disorder, Drug abuse, Depression 69-72 
5-HT7 Antagonist Depression, Migraine, Sleep disorder 67, 68 











1.2 5-HT2A Antagonists: 
1.2.1 Background: 
The human 5-HT2A receptor, first cloned in 1990 is a subtype of the 5-HT2 receptors, the latter 
being a subfamily of the serotonin 5-HT (5-hydroxytryptamine) receptor.79 This receptor is an 
excitatory receptor and belongs to the G-Protein Coupled Receptor (GPCRs) superfamily of 
receptors.  
 
Like other 5-HT receptors, serotonin (60) is an endogenous ligand at the 5-HT2A receptor. 
The 5-HT2A receptor is distributed mainly in the cerebral cortex, neocortex, hippocampus and 
thalamus regions of the brain. In the periphery, 5-HT2A receptors are located in platelets, vascular 
smooth muscles and uterine smooth muscles. In the CNS 5-HT2A receptor signaling is associated 
with the pathogenesis of migraine headaches, depression, anxiety and cognitive impairment of 
various diseases. It is also associated with various other processes such as vascular smooth muscle 
contraction, uterine contraction and platelet aggregation.80  
 
1.2.2 Clinical Significance of 5-HT2A Antagonists: 
Antagonists at the 5-HT2A receptor are heavily pursued due to their great clinical significance. 
Selective and non-selective 5-HT2A antagonists find applications in a wide array of CNS disorders 
such as insomnia, anxiety, schizophrenia, depression and memory loss. Selective blockade of 5-




The selective 5-HT2A antagonist volinanserin (M100907) (61) was shown to increase total 
sleep time in elderly human patients.81 Similarly when the 5-HT2A antagonist eplivanserin (SR-
46,349) (62) was co-administered with the clinically available drug zolpidem, beneficial 
synergistic effects were observed in animal models of insomnia.82 Compound 61, 62 and other 
selective 5-HT2A antagonists such as pruvanserin (EMD 281014) (63), nelotanserin (APD-125) 
(64) and pimavanserin (ACP-103) (65) were evaluated in Phase III clinical trials for the treatment 
of insomnia. 83 
Another important therapeutic potential of 5-HT2A antagonists is in the treatment of drug 
abuse symptoms. There is ample evidence of 5-HT2A antagonists showing promising results for 
treatment of drug abuse symptoms. 
 
For example the popular drug of abuse MDMA (ecstasy) is believed to cause some of its 
adverse effects through the 5-HT2A receptor. Accordingly volinanserin (61) and ketanserin (66), a 
mixed 5-HT2A/2C antagonist were found to attenuate hyperthermia - one of the most profound side 
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effects of MDMA.84 Ketanserin (66) was also shown to reduce MDMA induced neuronal apoptosis. 
85,86 Furthermore, MDMA induced perceptual changes and emotional excitation were found to be 
attenuated by ketanserin in healthy humans.87  
 
Furthermore, volinanserin (61) reduced reinstatement of cocaine seeking behavior and 
cocaine induced hyperlocomotor activity in rats.88 Co-administration of ketanserin (66) with 
pergolide (D2 receptor agonist) was shown to reduce methaphetamine sensitization in rats.
89 
Similarly the 5-HT2A antagonist amperozide (67) was shown to suppress alcohol abuse in rat 
models.90  
5-HT2A antagonists also have therapeutic potential for the treatment of depression. 
Currently all atypical antipsychotics have 5-HT2A antagonistic properties, which may contribute 
to their antidepressant efficacy.91 5-HT2A antagonist by themselves also have been shown to cause 
antidepressant effects. For example the highly selective 5-HT2A antagonist pruvanserin (63) 
increased swimming and reduced immobility in rats in the forced swim test-a direct measure of its 
ability to decrease depression.92 Similarly volinanserin (61) decreased immobility time in rats that 
were withdrawn from chronic nicotine exposure.93 BIP-1 (68) a 5-HT2A antagonist was found to 




5-HT2A antagonists also have therapeutic potential as anti-anxiety drugs and for the 
treatment of schizophrenia. Eplivanserin (62) was shown to antagonize anxiolytic actions of DOI 
(69, 2,5-Dimethoxy-4-iodoamphetamine) in mice using the elevated plus maze model.95  
Similarly administration of ketanserin (66) and volinanserin (61) resulted in blockage of 
postnatal fluoxetine induced anxiety in rat.96 Co-administration of risperidone (a drug approved 
for treatment of schizophrenia) with ritanserin (70), a mixed 5-HT2A/2C antagonist, produced 
superior results in decreasing negative symptoms of schizophrenia in human patients.97 Similarly 
improvement in cognitive abilities of schizophrenic patients followed by the administration 
volinanserin (61) has been reported.98  
 
5-HT2A antagonists also have promising application in the treatment of Parkinson’s disease. 
Administration of ritanserin (70) resulted in reduced motor symptoms in a mouse model of 
Parkinson’s disease.99 Similarly administration of volinanserin (61) produced anti-Parkinson’s 
effects in mice.100  
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5-HT2A antagonists also have a potential for the therapeutic intervention of other conditons 
such as cardiac ischemia, atherosclerotic lesions, diabetes and asthma.101-104 
 
1.2.3 Structural Classification of 5-HT2A Antagonists: 











Amongst the above mentioned structural categories, alkyl-piperazines/alkyl-piperidines 






1.2.4 5-HT2A Antagonist Pharmacophore: 
In order to design better and selective 5-HT2A antagonists several groups have proposed 5-HT2A 
antagonist pharmacophore models through the conformational analysis of several 5-HT2A 
antagonists. Considering the wide structural variations amongst available 5-HT2A antagonists, it is 
difficult to have a single pharmacophore. A brief summary is mentioned below. Figure 27 shows 
the pharmacophore model proposed by Glennon and co-workers.105 This model which is based on 
the structure of (+)-LSD, does not differentiate between agonist and antagonist.  
 
Another model proposed by Holtje-Jendretzki included several ligand sites that could be 
involved in hydrogen bonding and hydrophobic interactions and one site that could be involved in 
an ionic interaction.106 Compounds included in this model had a phenyl-methyl-piperidine unit in 
common, and it was considered to be a pivotal feature for the design of 5-HT2A antagonists. 
Moreover this antagonist model was found to partially overlap with an agonist model (proposed 
by the same authors) and hence it was suggested that agonist and antagonist of the 5-HT2A receptor 
could have some common binding features.  
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Pharmacophore models independently proposed by Andersen and Mokrosz were found to 
possess striking similarities despite studying different classes of 5-HT2A antagonists.
107,108 Figure 
28 shows the models proposed by Andersen (Model I) and Mokrosz (Model II).  
 
Both the groups proposed a triangular arrangement of groups in their respective models. 
The distance between the center of two aromatic rings as well as the distance between the center 
of each aromatic ring and the basic nitrogen atom was found to be critical for binding affinity. As 
per the Andersen model, ideal distance between each aromatic ring is 5.1 Å and the distance 
between the basic nitrogen atom and each aromatic ring was 7.1 Å (ring A) and 8.1 Å (ring B). On 
the other hand as per the Mokrosz model, the distance between the centers of two aromatic ring 
was between 4.6 Å to 7.3 Å, while the distance between the basic nitrogen atom and each aromatic 
ring was 5.2 Å-8.4 Å (ring A) and 5.7 Å to 8.5 Å (ring B). It is to be noted that none of the above 
models predicted a perfect triangular arrangement of groups, in other words the distance between 
the basic nitrogen atom from one aromatic ring is different from the distance between nitrogen 
atom and other aromatic ring.  
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Klabunde and Evers proposed two pharmacophore models: Class I (linear) and Class II 
(triangular).109 Class I pharmacophore defines four required features for binding: i) protonated 
nitrogen atom (PI) ii) two Hydrophobic Aromatic Rings (HYA) iii) Hydrogen Bond Acceptor 
(HBA) (Figure 29, Model I). In Class II pharmacophore there are three essential features: i) 
protonated nitrogen atom (PI) ii) aromatic ring (AR) and iii) hydrophobic group (HY) (Figure 29, 
Model II) 
 
A similar classification of pharmacophore model into linear and triangular fashion has been 
reported by Rowley and coworkers.110  
Figures 27, 28 and 29 shows different proposed pharmacophore models for 5-HT2A 
antagonists. Looking at the different models, it can be concluded that 5-HT2A antagonists could 
possibly have more than one binding mode. Also it is possible to have some common binding 






1.2.5 Recent Review of 5-HT2A Antagonists: 
A recent review of 5-HT2A antagonists is described here. (For the sake of brevity, only work 
published after 2005 is discussed.)  
Xiong and co-workers reported the synthesis and evaluation of phenethyl-piperazine based 
selective 5-HT2A antagonists (83-87) for the treatment of insomnia (Figure 30).
111  
 
SAR data from this study indicated that the presence of lipophilic substituents in the phenyl 
ring enhanced 5-HT2A antagonistic affinity (compare 84 with 83). Compound 85 having a 2,4-
difluoro substitution in the phenyl ring was the most potent compound identified in this series. 
However stability studies indicated that 85 has a poor half-life of 9 min. Replacement of the 
methylene linker in 85 with a carbonyl linker (compound 86) resulted in extension of the half-life 
to 60 min, while still retaining the 5-HT2A antagonist potency.  
In a separate study, the same group investigated the effect of replacing the pyrazole ring in 
compound 83 with various fused arylpyrazole rings (compounds 88-92, Figure 31).112 Compounds 
having a fused phenylpyrazole ring were found to have comparable affinity to their mono-cyclic 
pyrazole analogue (compare 81 and 85). Although the fused phenylpyrazole containing 
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compounds had similar 5-HT2A affinity, they displayed less selectivity for the 5-HT2A receptor 
compared to their mono-cyclic pyrazole analogues.  
 
Yoo and co-workers reported the synthesis and evaluation of aryl sulfonamides (93-100) 
as 5-HT2A antagonists.
113 These compounds feature either a cyclohexylmethyl (Figure 32) or a 
cyclopropylmethyl group (Figure 33) on the nitrogen of the sulfonamide functionality. Compounds 
with the N-cyclohexylmethyl group (93-96) displayed enhanced affinity at the 5-HT2A receptor 




These compounds also displayed better selectivity for the 5-HT2A receptor (over the 5-HT7 
receptor but not over 5-HT2C receptor). Thus compound 93 has an affinity of 0.5 nM (Ki) for the 
5-HT2A receptor and showed 3000 times higher affinity for the 5-HT2A receptor over 5-HT7 
receptor. Modifications of the phenyl piperazine group revealed that a 4-fluoro phenyl ring 
improved the 5-HT2A receptor affinity the most, which is consistent with other reported 5-HT2A 
antagonists. Moreover modification of the aryl part of the aryl sulfonamide moiety suggested that 
the 2-naphthyl ring was better tolerated for the 5-HT2A receptor affinity.  
 
The synthesis and evaluation of novel imidazobenzazepine compounds as dual H1/5-HT2A 
antagonists (101-105) for the treatment of sleep disorders was reported by Gianotti and co-
workers.114 In this novel zwitterionic series of compounds, the affinity at both H1 and 5-HT2A 
receptors was found to be affected by modification of the acid side chain. Only compound 103 that 
incorporates a 2,2-dimethylpropanoic acid side chain substitution on the piperazine ring was found 
to have a balanced affinity for both H1 and 5-HT2A receptor (Figure 34). Substitution with other 
acid side chains resulted in compounds having increased affinity for H1 but not 5-HT2A receptor. 
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Modifications of the imidazole ring by addition of small lipophilic or small electron withdrawing 
groups resulted in compounds that displayed poor selectivity over the 5-HT2C receptor. 
 
Heffernan and co-workers reported the design and synthesis of novel indole containing 
compounds as dual Norepinephrine Reuptake Inhibitors (NRIs) and 5-HT2A receptor antagonists 
(Figure 35).115 Their approach was to first generate a common pharmacophore for NRIs using 
Montel Carlo conformational analysis, followed by virtual screening to identify dual NRIs and 5-
HT2A antagonist ligands that fit in the given pharmacophore model. A library of analogues (106-
111) based on this hit, was synthesized and evaluated for binding affinity at human Norepinephrine 
Transporter (hNET) and 5-HT2A receptor. In this series of compounds, cyclic tertiary amine 
analogues (110 and 111) were found to have superior potency at the 5-HT2A receptor, compared 
to their acyclic counterparts. Increasing the alkyl chain length between the basic amine and indole 




Enzensperger and co-workers reported the synthesis and evaluation of novel azecine 
ligands (112-117) at the 5-HT2A and Dopamine D1 and D2 receptor systems with the goal of 
improving selectivity for the 5-HT2A receptor.
116  
 
Evaluation of analogues revealed that expansion of the central 10 membered azecine ring 
(112) to regioisomeric 11 membered central ring containing compounds (113 and 114) is tolerated 
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for affinity at 5-HT2A and D1 receptor, but does not enhance affinity at these targets. Furthermore 
replacement of the N-methyl group with an N-ethyl group or NH group resulted in decreased or 
complete loss of affinity respectively. 
Swain and co-workers reported the synthesis and evaluation of low molecular weight aryl 
diazepines (118-123) as 5-HT2A ligands.
117 SAR results indicated that small lipophilic groups were 
tolerated at the para position of the aromatic ring (118 and 119). Replacement of the secondary 
amine (of the tert-butyl amine moiety) with tertiary amines resulted in dramatic loss in 5-HT2A 
affinity indicating the necessity of a hydrogen bond donor (compare 120 and 122). Incorporation 
of 5 or 6 membered cyclic alkyl groups also resulted in small increase in affinity (123).   
 
Shireman and co-workers reported the synthesis of aryl pyrimidine derivatives (124-127) 
as 5-HT2A antagonists.
118 Compound 124 identified through a high throughput screen is a non-
selective 5-HT2A antagonist. In order to decrease the basicity of the pyrimidine ring and hence 
increase the selectivity towards 5-HT2A receptor, the amino group was replaced with small 




Ladduwahetty and co-workers reported the synthesis and evaluation of non-basic 5-HT2A 
receptor antagonists.119 Initially discovered compound 128 displays poor 5-HT2A receptor affinity. 
It is thought that although the amide in 128 can act as a hydrogen bond acceptor, the restricted 
rotation of 128 prevents it from reaching a suitable binding position. Subsequent SAR studies led 
to the discovery of 129-131 that displayed 24-73 times selectivity over the 5-HT2C receptor.  
 
Overall, diverse structural classes of compounds have been pursued as 5-HT2A antagonists. 
As discussed previously due to their wide structural variations, more than one pharmacophore 
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model is needed to guide the design of 5-HT2A antagonists. Furthermore the requirement of a basic 
nitrogen atom proposed by these pharmacophore models is now questionable following the 
discovery of non-basic 5-HT2A antagonists.
119 As can be inferred from the above examples, a 
common problem that lies in the development of 5-HT2A antagonists is the issue of selectivity over 
other subtypes. A truly selective 5-HT2A antagonist with desirable pharmacokinetic properties 
would be valuable for clinical applications.   
 
1.3 Conclusions 
Aporphine alkaloids are a group of natural as well as synthetic alkaloids that possess a diverse 
range of pharmacological actions. At the CNS, aporphine alkaloids are ligands at several clinically 
valuable targets such as the dopamine, serotonin, alpha adrenergic receptors and at the 
acetylcholinesterase enzyme. From the several SAR studies done on aporphine alkaloids it can be 
inferred that small structural changes on the aporphine scaffold can generate ligands that have 
selective affinity for a particular receptor as well as ligands with unique multi receptor profile. 
Such ligands have a potential to be developed as a clinical agent for treatment/mitigation of 
neuropsychiatric disorders as seen with apomorphine. Moreover, such ligands can also serve as 
unique pharmacological tools for the study of receptor functions. Considering the diverse profile 
of aporphine alkaloids at the CNS receptors, they can be considered as “privileged scaffolds” for 
CNS drug design.  
Known 5-HT2A antagonists are a structurally diverse class of compounds. 5-HT2A 
antagonists have therapeutic potential for the treatment of several CNS maladies such as insomnia, 
drug abuse, depression, anxiety, schizophrenia, Parkinson’s disease and memory loss. Several 5-
HT2A antagonist pharmacophore models have been proposed to facilitate and guide future design 
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of 5-HT2A antagonists. Although different, these models share some common features such as: i) 
a basic nitrogen atom, ii) one or two aromatic rings and iii) hydrophobic binding region.  
Furthermore, no truly selective 5-HT2A antagonist is clinically available. Considering the 
widespread role of 5-HT2A receptor in the progression of several neuropsychiatric disorders there 
is an unmet need for selective and potent 5-HT2A antagonists.  
There is limited information available on aporphines as ligands at the 5-HT2A receptor. The 
rich CNS pharmacology of aporphine alkaloids makes them an attractive starting point for being 
developed as 5-HT2A antagonists. Such an endeavor would allow us to understand the structural 
features of an aporphine scaffold that are required for 5-HT2A antagonism. Moreover this study 
would also produce ligands that will be useful as valuable pharmacological tools. Overall such an 





































As discussed in the previous chapter, aporphine alkaloids have a diverse range of pharmacological 
actions. Specifically at the CNS, aporphine alkaloids are ligands at dopamine, serotonin and alpha 
adrenergic receptors. At serotonin receptors, aporphine alkaloids have been studied in depth as 
ligands at the 5-HT1A and 5-HT7 receptors. However not much work has been done in studying 
aporphines as ligands at the 5-HT2A receptor. Ligands at the 5-HT2A receptor have valuable 
applications in the treatment of insomnia, drug abuse and several neuropsychiatric disorders such 
as depression, anxiety, schizophrenia and Parkinson’s disease. The aporphine scaffold can be 
considered as a privileged scaffold for CNS drug design and can be used for the development of 
novel 5-HT2A ligands.  
 
2.2 Nantenine As A Lead For The Identification of New 5-HT2A Antagonists 
Nantenine (55) is an aporphine alkaloid isolated from the fruit of Nandina domestica Thunberg.120 
Indra and co-workers in 2002 showed that nantenine inhibited 5-hydroxy-L-tryptophan (l-5-HTP) 
induced head-twitch response by blocking 5-HT2A receptors in mice.
72 Later the same group 
reported SAR studies showing nantenine as an antagonist at the 5-HT2A and α1 receptors.
70,71 
Studies done by Fantegrossi revealed the ability of nantenine to block and reverse MDMA induced 
physiological effects such as hyperthermia, locomotor stimulation and head-twitch responses in 
mice. These anti-MDMA effects of nantenine were attributed to its antagonism at 5-HT2A and α1 
receptors.121  
Research in our group has focused on the synthesis and evaluation of nantenine analogues 
as 5-HT2A antagonists. The first step in this direction that was accomplished previously, was to 
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synthesize nantenine and screen it across available CNS receptors via the Psychoactive Drug 
Screening Program (PDSP) of the NIH. Results from this screening showed that nantenine is 
highly selective for the α1A receptor (Ki = 2 nM) compared to other α1A subtypes. However, at the 
5-HT2A receptor nantenine was found to have moderate affinity (Ki = 850 nM).
69 In order to 
improve the potency and selectivity of nantenine analogues for the 5-HT2A receptor, a systematic 
SAR study was initiated. A brief discussion of our previous findings is described.  
 
2.2.1 Previous Structure Activity Relationship (SAR) Studies:28,122,123 
Table 2 shows the apparent binding affinity (Ke) values for a series of C1 (132-138), C2 
(139-143) and N6 (144-146) nantenine analogues. At the C1 position the effect of alkyl group 
substitution was studied through compounds 132-138. Progressive increase in the alkyl chain 
length at this position, resulted in increased affinity. As seen in Table 2, the C1 ethyl analogue 
(132, Ke = 890 nM) was found equipotent to nantenine. Substitution with propyl (133, Ke = 297 
nM) and butyl (134, Ke = 274 nM) groups resulted in three times increase in potency. The n-
hexyloxy analogue (136, Ke = 71 nM) which was the most potent compound identified in this 
series, was 11 times more potent than nantenine. Other potent compounds identified in this series 










Table 2: Previous Structure Activity Relationship (SAR) data of nantenine. 
 
Compound R1 R2 R3 5-HT2A-Ke (nM) 
132 Et OMe Me 890 
133 n-Pr OMe Me 297 
134 n-Bu OMe Me 274 
135 n-Pen OMe Me 171 
136 n-hex OMe Me 71 
137 Cyclopropylmethyl OMe Me 68 
138 Allyl OMe Me 70 
     
139 Me OEt Me 378 
140 Me OnPr Me 485 
141 Me OnBu Me 943 
142 Me OnPen Me > 10,000 
143 Me OBn Me 154 
     
144 Me OMe H > 10,000 
145 Me OMe Et > 10,000 
146 Me OMe Pr > 10,000 
     
Nantenine 
(55) 
Me OMe Me 850 
 
At the C2 position, replacement of the methoxy group with small alkoxy groups was 
tolerated. Thus replacement with ethoxy (139, Ke = 378 nM) and propyloxy (140, Ke = 485 nM) 
resulted in 2 and 1.7 times increase in potency respectively. However replacements with larger 
alkoxy groups were detrimental for 5-HT2A receptor affinity (141, Ke = 943 nM; and 142, Ke > 
10,000 nM). Compound 143 (Ke = 154 nM) with a benzyloxy group at the C2 position was the 
most potent compound in this series.  
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None of the N6 analogues (144-146) had affinity for the 5-HT2A receptor. This suggests 
that the N-Methyl group is important for affinity at the 5-HT2A receptor.  
Flexible analogues 147-150 (Figure 40) were synthesized and evaluated for 5-HT2A 
receptor affinity in order to examine the importance of molecular rigidity. None of the flexible 
compounds had affinity for the 5-HT2A receptor, thus suggesting that an intact aporphine scaffold 
is critical for 5-HT2A receptor affinity.  
 
2.2.2 Summary of Previous Findings: 
The following conclusions were drawn from previous SAR studies:    
1. Intact aporphine core is required for 5-HT2A receptor affinity. 
2. At the C1 position, progressive increase in alkyl chain length results in increased affinity 
for the 5-HT2A receptor.  
3. Only small alkyl groups are tolerated at the C2 position.  
4. The N-methyl group is critical for affinity.   




2.3 Rationale & Central Hypothesis: 
Rationale: Previous SAR studies of nantenine have focused on modifications at the C1, C2 and 
N6 position. However, in order to understand the structural features of nantenine required for 5-
HT2A antagonism there is a need to carry out an exhaustive SAR study. Such a study will provide 
information which will be valuable for the design of selective and potent 5-HT2A ligands. 
Moreover it is highly likely that such studies will generate novel ligands having selective 5-HT2A 
receptor affinity as well as ligands with unique multi-receptor affinities. In order to make this 
ultimate goal a reality, we expanded our SAR study to relatively unexplored positions of the 
nantenine template. Accordingly it was decided to study structural modifications at the C3, C4 and 
ring D positions of nantenine.  
C3 analogues were designed to test the effect of hydrophobic substitution at these position 
on 5-HT2A receptor affinity. The design of C4 phenyl analogues was predicated on the hypothesis 
that the addition of a phenyl moiety at the C4 position would enhance the 5-HT2A receptor affinity 
(given the pharmacophoric similarity to known 5-HT2A ligands). The synthesis of ring D analogues 
was based on the idea of replacing the “phenyl methylenedioxy” unit of nantenine with 
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heteroaromatic rings as potential bioisosteres. Moreover oxygen containing isochroman analogues 
were also synthesized to test the effect of replacing the N6 nitrogen atom with an oxygen atom.  
Central Hypothesis: The central hypothesis tested behind this work is that structural 
modifications of nantenine will generate potent and selective 5-HT2A antagonists.  
 
2.4 Results: 
2.4.1 C4 Phenyl Analogues: 
Rationale: 9-aminomethyl-9,10-dihydroanthracene (AMDA, 151a) is a structurally unique high 
affinity selective 5-HT2A antagonist (Ki = 20 nM).
124 The 3-methoxy analogue of AMDA 
compound 151b is 2.5 times more potent than AMDA via hydrogen bonding interactions between 
the methoxy group and 5-HT2A receptor side chains.
125 AMDA is speculated to have a different 





We envisaged that incorporation of a phenyl group at the C4 position of the aporphine nucleus 
would engender improved affinity for the 5-HT2A receptor, based on its structural resemblance to 
the AMDA template.  
As discussed earlier, in previous SAR studies it was observed that C1 alkoxy substituents 
increased affinity at the 5-HT2A receptor.
28,122 As a result it was decided to retain C1 alkoxy 
substituents for a series of C4 phenyl analogues. The synthesis of C1 alkoxy/C4 phenyl aporphine 




Thus as shown in Scheme 1, the synthesis started with commercially available compound 
153 (vanillin) which was protected as a benzyl ether to afford compound 154. Reaction of 154 
under Henry Reaction conditions provided the Michael acceptor compound 155. Treatment of 155 
with phenyl magnesium bromide furnished the Michael adduct 156, which after reduction with 
SnCl2, gave primary amine 157. Amine 157 was then coupled with readily available acid 158 (6-
bromo-3,4-(methylenedioxy)phenylacetic acid)127 in presence of CDI to afford amide 159. 
Bischler-Napieralski reaction of amide 159, followed by reduction of the intermittent imine with 
NaBH4, gave the secondary amine 160. Compound 161, which was the precursor for the 
intramolecular biaryl coupling reaction was easily obtained from 160 after protection with a Boc 
group.  
 
With compound 161 in hand an intramolecular C-H activation reaction was attempted 
using conditions that were previously optimized in our lab.29 We were delighted to find that 
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treatment of 161 with Pd(OAc)2 and di-tert-butyl (methyl) phosphonium tetrafluroborate under 
microwave reaction conditions afforded 162 in an excellent yield of 88 %. Removal of the benzyl 
group was accomplished using catalytic hydrogenation conditions to furnish the key precursor 
compound 163.  
Scheme 2 shows the synthesis of C1 alkoxy/C4 phenyl aporphine analogues from phenol 
163. Thus 163 was subjected to Williamson ether synthesis to install several alkyl groups as seen 
in compounds 164a-h. Subsequent Boc deprotection followed by reductive amination to install an 
N-methyl functionality afforded our target compounds 165a-h.  
 Previous SAR studies indicated that an N-substituent larger than a methyl group is 
detrimental to 5-HT2A receptor affinity.
28 Nevertheless, in order to see the extent to which small 
N-alkyl groups can be tolerated when a C4 phenyl ring is present on the nantenine nucleus, N6 
alkyl/C4 phenyl analogues were synthesized. Scheme 3 shows the synthesis of N6 alkyl/C4 phenyl 
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analogues from the key precursor compound 163. Sequential O-methylation and Boc deprotection 
of phenol 163, gave compound 166. Reductive amination of 166 with 
cyclopropanecarboxaldehyde afforded the N-cyclopropylmethyl analogue 165k. Alternatively 166 
was converted to the acetamide 167, followed with reduction to furnish the N-ethyl analogue 165j. 
Finally phenol 163 was subjected to Boc deprotection and reductive amination to afford analogue 
165i. 
Analogs 165a-k were evaluated for affinity across various 5-HT (serotonin) receptors at 
the Psychoactive Drug Screening Program (PDSP).128,129 A detailed experimental procedure is 
described in section 2.6. Briefly, the compounds were initially screened in a primary radioligand 
binding assay that measures inhibition of serotonin binding at a compound concentration of 10 
µM. Compounds with inhibition values less than 50 % at a particular receptor, are deemed inactive 
at that receptor. Compounds that displayed more than 50 % inhibition of serotonin binding in the 
primary assays, were evaluated for determination of Ki values in secondary assays.  Table 3 shows 
the results of the primary (% inhibition) assay.  
As shown in Table 3, surprisingly all compounds displayed a remarkable selectivity profile. 
All the compounds were inactive at the 5-HT2A receptor and at most other sites. Interestingly, the 
majority of compounds were active at the 5-HT2B receptor (except compound 165h). 165c and 
165f were also active at the 5-HT1B receptor.  
Table 4 shows the data for the secondary assay. All the tested compounds displayed 









Percent inhibition (%)a 
Compound 5-HT1A 5-HT1B 5-HT1D 5-HT1E 5-HT2A 5-HT2B 5-HT2C 5-HT3 5-HT5A 5-HT7 
165a 5.5 22.6 34.5 10.1 33.5 92.2 31.9 8 -12.2 36.1 
165b -0.9 20.6 29.7 10.3 40.1 83.3 13.5 -2.7 -7.6 26 
165c 27 51.7 22.4 2.1 32.3 84 13.1 0.7 5.2 8.6 
165d 18.4 41.4 24 7.3 40.9 76.1 48 11.6 17.6 -5.1 
165e -13.5 4.3 13.4 2.4 19.9 63.6 49.3 0.8 -6.2 -14.6 
165f -9.8 60.2 31.9 27.4 42.9 77.1 32.4 7.7 5.2 6.9 
165g 19.2 19.4 22.6 3.3 47.8 72.1 28.8 8.3 -9.8 24.7 
165h 25.9 2.1 9.8 -0.1 15.8 24.4 -6.6 -7.4 -9.3 -22.6 
165i 24.2 -5.2 15.8 11 29.2 50.3 -2.3 4.1 1.8 31.3 
165j 3.3 23.6 27.4 5 12.8 88.4 -1.6 -4.1 -12.1 8.9 
165k 13.3 16.2 22.4 3.5 9.6 73.7 9.4 -13.3 -18.2 18.3 
55b nac 100.3 nac 60 89.3 92.8 103.0 44.6 92.8 96.7 










b Corresponding Ki data previously reported in reference 69 





Table 4: Secondary assay data for analogues 165a-k 
 
Ki ± SEMa (nM) 
Compound 5-HT1Bb 5-HT2Bc 
165a ndd 96 ± 12 
165b nd 209 ± 27 
165c 1,608 ± 210 307 ± 40 
165d nd 601 ± 78 
165e nd 663 ± 86 
165f 2,466 ± 320 299 ± 39 
165g nd 416 ± 54 
165h nd nd 
165i nd 715 ± 92 
165j nd 419 ± 54 
165k nd 1,429 ± 180 
55 100 ± 3 543 ± 53 
Ergotamine 10 - 
SB206553 - 23 
a Values represent mean ± SEM for at least three independent experiments 
b hot ligand = [3H]GR125743 
c hot ligand = [3H]LSD 
d nd = not determined (<50 % inhibition in primary assay) 
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In contrast to our expectations all the C4 phenyl compounds displayed no affinity for the 
5-HT2A receptor. This clearly indicates that a phenyl group at the C4 position of nantenine is 
detrimental for 5-HT2A receptor affinity. This in turn might be due to the inability of the 5-HT2A 
binding cavity to accommodate the C4 phenyl group or due to a steric clash between a receptor 
side chain and the C4 phenyl group.  
Surprisingly all the compounds displayed affinity for the 5-HT2B receptor with remarkable 
selectivity. Compound 165a had the highest affinity for the 5-HT2B receptor (Ki = 96 nM). 
Nantenine was found to have poor affinity for the 5-HT2B receptor (Ki = 534 nM).
69 Thus when 
nantenine is compared to compound 165a it is apparent that the C4 phenyl substituent positively 
impacts 5-HT2B affinity and selectivity 
A clear trend between the length of alkyl group at the C1 position and 5-HT2B receptor 
affinity was observed. Thus with increasing C1 alkyl chain length, the 5-HT2B receptor affinity 
was found to decrease as evident from compound 165a to 165e. A similar trend was also observed 
with respect to the size of the N6 alkyl substituent in compounds 165i to 165j. Thus the larger the 
N-alkyl group the lower is the 5-HT2B receptor affinity. Both the trends suggest that the binding 
pocket occupied by the C1 alkyl and N6 alkyl groups are small and do not accommodate larger 
substituents. The C1 cyclopropylmethyl analogue (165f, Ki = 299 nM) has similar affinity 
compared to the propyl analogue (165c, Ki = 307 nM), which indicates that some degree of 
branching is tolerated. The allyl analogue (165g, Ki =416 nM) had reduced affinity compared to 
its saturated analogue (165c, Ki = 307 nM) suggesting that saturation in this part of the alkyl chain 
is not tolerated. A phenolic OH group is not well tolerated for 5-HT2B receptor affinity as indicated 
by 165i (Ki = 715 nM). 
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165a which was the compound with the highest affinity identified in this series was 
selected for further assays. In order to investigate the selectivity profile, compound 165a was 
screened across a broad panel of CNS receptors. In addition to the 5-HT receptors noted in Table 
4, compound 165a did not display any affinity across the following receptors (< 50 % inhibition 
in primary assays): α1A, α1B, α1D, β1, β2, β3, BZP rat brain site, CB2, D1, D2, D3, D4, D5, DAT, DOR, 
GABAA, H1, H2, H3, H4, KOR, M2, M3, M4, M5, MOR, NET, NMDA, SERT, sigma-1, sigma-2. 
165a showed affinities for the following receptors other than 5-HT2B: 5-HT6 (627 nM), α2a (719 
nM), α2B (3220 nM), α2C (433 nM) M1 (> 10,000 nM) and PBR (2897 nM). In the 5-HT2B functional 
activity testing, 165a displayed antagonistic activity (IC50 = 1 µM). It is also of relevance that no 
5-HT2B agonist activity was found. 
5-HT2B receptors are widely distributed in the cardiac muscles and regulate cardiomyocyte 
development and growth.130 Activation of 5-HT2B receptors in these regions is related to 
pulmonary hypertension and fatal cardiac failure.131 Moreover the anti-obesity drug fenfluramine 
and the anti-Parkinson’s disease drug pergolide were withdrawn from the US market because of 
severe valvular heart diseases induced by agonism of 5-HT2B receptors.
132-134 As a result, 5-HT2B 
agonists are considered as anti-targets in any drug discovery program. Since 165a does not have 
any agonist activity, it can be considered to be a good lead for developing 5-HT2B antagonists.  
5-HT2B antagonists are considered as emerging therapeutics for the treatment of migraine, 
Irritable Bowel Syndrome (IBS), pulmonary hypertension, liver fibrosis and lung fibrosis.135-138 
However, due to the high homology of the 5-HT2B receptor with 5-HT2A and 5-HT2C receptors, it 
is difficult to obtain selective 5-HT2B antagonists.
139 Figure 43 shows some selective 5-HT2B 





Although 165a has low affinity for the 5-HT2B receptor in comparison to 168 and 169, 
165a to the best of our knowledge is the most potent 5-HT2B aporphinoid antagonist known till 
date.140. Although not as potent as 168 or 169, compound 165a is a highly selective 5-HT2B 
antagonist and is a promising lead for the development of selective and highly potent 5-HT2B 
antagonists. Moreover 165a represents a new class of pharmacophore for the development of 5-
HT2B antagonists.   
Since all the C4 phenyl nantenine compounds were tested as a mixture of diastereomers, it 
remains to be determined the extent to which the two chiral centers present impact 5-HT2B receptor 
affinity and activity. For future studies the individual diastereomers of 165a should be evaluated 
at 5-HT2B receptors. Moreover the steric and electronic tolerance of the phenyl ring needs to be 
determined. Analogues of 165a having different substitutions on the phenyl ring should be 






2.4.2 Isochroman Analogues: 
Rationale: Molecular docking studies indicate that the protonated amine nitrogen (N6) of 
aporphines is required for binding to the 5-HT2A receptor via interactions with an aspartate residue 
(Asp 155) in the ligand cavity.123 Figure 44 shows a docking pose of nantenine (55) in the binding 
cavity of the 5-HT2A receptor. As can be seen, the carboxylate side chain of Asp155 forms a salt 
bridge interaction (shown as a dashed line) with the protonated nitrogen atom of nantenine (55).  
 
Figure 44: Docking pose of nantenine (55) in the 5-HT2A receptor binding cavity 
 
However, the requirement of this salt bridge interaction has not been rigorously tested via 
synthesis and evaluation of appropriate analogs. Moreover with regards to the previously reported 




investigated.28 As a result, the synthesis and evaluation of oxygen containing analogues 
(isochroman compounds like 170) as N6 isosteres was undertaken.  
 
Figure 46 shows the approach used for the synthesis of compound 170. Thus the 
isochroman compound 170 was synthesized via an intramolecular C-H activation in compound 
171, which in turn was synthesized using an Oxa Pictet-Spengler reaction between the alcohol 172 
and aldehyde 173.  
 
The Oxa Pictet-Spengler reaction is the oxygen variant of the classical Pictet-Spengler 
reaction.141,142 Figure 47 shows a proposed mechanism for the Oxa Pictet-Spengler reaction 
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between 172 and 173. Thus in presence on an acid catalyst, alcohol 172 attacks the activated 
carbonyl carbon in 174, to generate intermediate 175. Internal proton transfer followed by loss of 
water results in formation of oxocarbenium intermediate 177. 
 Subsequent cyclization followed by re-aromatization leads to the formation of the 
isochroman compound 171. The use of a Dean-Stark apparatus helps in driving the equilibrium in 
the forward direction by removing water from the system. 
Using this strategy (shown in Figure 47), synthesis of ring A isochroman analogues was 
accomplished as shown in Scheme 4. The synthesis commences with the commercially available 
acid 179 (isovanillic acid). Treatment of 179 with benzyl bromide afforded the dibenzylated 
intermediate 180 which after reduction with Lithium Aluminum Hydride (LAH) afforded the 
alcohol 181. Treatment of 181 with the easily accessible aldehyde 173 under Oxa Pictet-Spengler 
reaction conditions furnished the isochroman 182. With 182 in hand, the stage was set to attempt 
an intramolecular C-H activation reaction which would furnish intermediate 183.  Prior synthesis 
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of the aporphine template using this reaction utilized ligands such as 2′-(diphenylphosphino)-N,N′-
dimethyl-(1,1′-biphenyl)-2-amine (PhDavePhos, Table 5, Ligand A), di-tert-butyl (methyl) 
phosphonium tetrafluroborate (Table 5, Ligand B), 2-Dicyclohexylphosphino-2'-(N,N-
dimethylamino)biphenyl (Table 5, Ligand D) and tricyclohexylphosphine.29   
 
In order to make a direct comparison between the synthesis of aporphine alkaloids and the 
isochroman scaffold, we screened ligands A-D as shown in Table 5. As seen in Table 5, 
tricyclohexylphosphine tetrafluoroborate was found as the optimal catalyst with a yield of 93 % 
for the cyclization of 171 to 170. Other ligands resulted in lower isolated yields (ligands A and B) 
or gave no reaction (ligand D).  
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Table 5: Microwave assisted C-H activation on compound 171 with various ligands 
 
Entry Ligand Temperature ( °C) Yielda (%) 
1 A 135 40 
2 B 140 22 
3 C 140 93 
4 D 140 No Reaction 
a Isolated yield after purification 
Accordingly in the presence of Pd(OAc)2 and tricyclohexylphosphine tetrafluoroborate, 
compound 182 was smoothly transformed to 183 in 90 % yield. Catalytic hydrogenation of 183 
afforded phenol 184, which was subsequently derivatized to furnish the target isochroman 
analogues 170 and 185a-d. Scheme 5 shows the synthesis of ring D isochroman analogues. The 
commercially available acid 186 was first converted to the ester 187 followed by reduction to 
furnish alcohol 172. The C-H activation step from 189a-d proceeded to give target isochroman 
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compounds 185e-h in excellent yields indicating tolerance of a variety of substitution pattern in 
the lower aromatic ring.  
 The effect of catalyst loadings and catalyst structure on the C-H activation reaction was 
also examined. In case of cyclization from 189a to 185e we observed a decrease in isolated yield 
with lower catalyst loadings. With 5 % Pd(OAc)2/10 % tricyclohexylphosphine tetrafluoroborate 
catalytic system the isolated yield of 185e was 76 %. This was slightly improved to 82 % when 
10 % Pd(OAc)2/20 % tricyclohexylphosphine tetrafluoroborate catalytic system was employed. 
The best yield observed was 89 % which was obtained 17 % Pd(OAc)2/34 % 
tricyclohexylphosphine tetrafluoroborate catalytic system. Overall the synthesis of novel 
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isochroman heterocycles in excellent yields was achieved via a palladium catalyzed C-H activation 
reaction.143  
Analogues 170 and 185b were screened at a concentration of 10 µM in multi-well format 
for intrinsic (agonist) and antagonist activity at the human 5-HT2A and α1A receptors using the 
Fluorescence Imaging Plate Reader (FLIPR) based functional assay that detects receptor mediated 
mobilization of internal calcium with a calcium sensitive fluorescent dye (see section 2.6 for a 
detailed experimental procedure). Table 6 shows the apparent binding affinities of 170 and 185b.  
 
Table 6: Apparent binding affinities for isochroman compounds 170 and 185b 
 
Compound Ke ± SEM
a (nM) 
5-HT2A α1A 
170 >3000 >3000 
185b >3000 >3000 
(±)-55b 850 ± 6 36 ± 7 
Prazosin - 1.1 ±0 .4 
Ketanserinb,c 32 - 
a Values represent mean ± SEM for at least three independent experiments 
b Corresponding data previously reported in reference 69  





As seen in Table 6, isochroman compounds 170 and 185b were found to be completely 
devoid of affinity for the 5-HT2A and α1A receptors. This suggest that the presence of N6 nitrogen 
atom is critical for affinity at both these receptors.144  
Indra and co-workers had proposed a binding mode of nantenine at the 5-HT2A receptor.
70 
Their study which was based on a homology model of the rat 5-HT2A receptor, showed the N6 
nitrogen atom involved in a strong H-bond interaction with the Asp155 residue of the 5-HT2A 
receptor. Previous molecular docking studies done in our group also confirmed this H-bond 
interaction between the protonated N6 nitrogen atom and the Asp155 residue in a homology model 
of the human 5-HT2A receptor.
123 Furthermore Sowdhamini and co-workers docked several 5-
HT2A antagonists like ketanserin, haloperidol and clozapine and displayed the presence of an H-
bond interaction between Asp155 and the protonated amine functionality of a particular ligand.145 
Findings from the above mentioned studies are now corroborated by this study which shows that 
both 170 and 185b lacking the nitrogen atom are devoid of 5-HT2A receptor affinity. 
Table 7: Cytotoxicity data for compound 185e  
 
Cell line Percent growth inhibitor 
IGROV (ovarian cancer) 69.25 % 




The cytotoxic evaluations of nantenine (55) at the human colon cancer cell lines HCT-116 
and Caco-2 were previously reported.28 Results from this study indicated that an N-methyl 
functionality is preferred for cytotoxicity over other N-substituted aporphines. In order to study 
the importance of the N6 nitrogen on the cytotoxic activity of nantenine, all the isochroman 
heterocycle containing analogues (except 185b) were screened for cytotoxicity at the NCI-60 DTP 
Human Tumor Cell Line Screen.146 Detailed experimental procedures and results of the cytotoxic 
screen are described in section 2.7 and appendix C respectively. All tested compounds were found 
to have moderate to low cytotoxic activity, thus indicating that the nitrogen atom of nantenine is 
not absolutely required for its cytotoxic activity. Compound 185e displayed 69.25 % inhibition of 
cell growth against the IGROV1 (ovarian) cancer cell line as well as 75.81 % inhibition of cell 
growth against the T-47D (breast) cancer cell line.  
Synthesis of phenanthrene alkaloids via isochroman analogues: 
As an extension to this work, the opportunity to transform the isochroman heterocyles to 
the phenanthrene alkaloid scaffold was initiated. Compounds containing the phenanthrene nucleus 
have been shown to possess a wide range of biological activities including anticancer,147-149 
antimicrobial150,151, anxiolytic and sedative activities.152 Phenanthrene alkaloids in particular 
possess anti-inflammatory153, antitumour154 and anti-acetylcholinesterase, anti-α-glucosidase and 
antifungal activities.155 Phenanthrene alkaloids are also known precursors for the synthesis of 
aporphine alkaloids.33,34  
Scheme 6 summarizes previous methods for the synthesis of phenanthrene alkaloids. Route 
A shows the synthesis of phenanthrene alkaloid 195 from dibenzo[d,e,g]chromanone compound 
191. Compound 191 was accessed from 190 via a radical-mediated cyclization using toxic tin 
reagents.156 Another approach previously reported for the synthesis of phenanthrene alkaloids is 
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shown in route B. Thus compound 194 containing the phenanthrene core was obtained via a 
photocyclization reaction of stilbene 193.157 Alternatively phenanthrene alkaloids can be accessed 
through an aryne mediated cycloaddition as shown in route C. 158,159 These methods have several 
drawbacks including the use of toxic tin reagents and uncontrolled regioselectivity during the 
biaryl bond formation process.  
 
Our strategy to synthesize phenanthrene alkaloid scaffold from the isochroman motif, 
involved cleavage of the isochroman moiety to reveal a phenanthrene ethyl alcohol unit, which 
could be easily transformed to the phenanthrene alkaloid moiety. Initial attempts to cleave the 
isochroman ring in 185e using zinc dust and acetyl chloride resulted in a complex mixture of 
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products. After experimenting with a number of acidic cleavage conditions, it was found that 
treatment with 33% HBr-AcOH afforded the desired alcohol 200 along with the acetate 199 
(Scheme 7). Acetate 199 could be easily hydrolyzed to the alcohol 200. Alcohol 200 was subjected 
to oxidation using Dess-Martin Periodinane, followed by reductive amination to generate the 
known phenanthrene alkaloid 201. 
 
As shown in Scheme 6, the requisite biaryl motif for the synthesis of phenanthrene 
alkaloids was obtainted via a radical mediated cyclization (63 % yield), photocyclization (30-54 % 
yield) or via aryne mediated cycloaddition (15 % yield). In comparison to these previous methods, 
our method involves a high yielding palladium catalyzed biaryl coupling reaction (90 %), tolerant 
of a variety of substitution patterns in both aryl rings. Furthermore this method avoids the use of 
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toxic tin reagents as well as results in the formation of a single product. Hence this method serves 
as a good alternative for the synthesis of phenanthrene alkaloids.  
Overall a novel method for the synthesis of two biologically relevant scaffolds viz. 
isochroman and phenanthrenes has been developed. These method involves high yielding Oxa 
Pictet-Spengler reaction and a microwave assisted intramolecular C-H activation as the key 
reactions. Moreover the isochroman analogues 170 and 185b confirm results from molecular 
docking studies that basic a nitrogen atom is required for affinity at the 5-HT2A receptors. These 
novel oxygen isosteres of aporphine alkaloids, also have moderate cytotoxic profile and hence are 














2.4.3 Ring D Indole-Aporphine Analogues: 
Rationale: Based on molecular docking studies, the “methylenedioxy unit” of C1 nantenine 
analogues is involved in a hydrogen bond interaction with a serine (Ser242) residue of the 5-HT2A 
receptor.123  Figure 48 shows the 2D representation of the binding pose of the C1 propyl analogue 
(133) and C1 pentyl analogue (202). The hydrogen bond interaction between the oxygen of the 









Figure 48: Docking pose of compound 133 (top) and 202 (bottom) in the 5-HT2A receptor binding 
cavity ( Pecic, S.; Makkar, P.; Chaudhary, S.; Reddy, B. V.; Navarro, H. A.; Harding, W.W.; 
Bioorg. Med. Chem., 2010, 18, 5562) 
 
 
It is hypothesized that the phenyl methylenedioxy unit of nantenine can be replaced with 
other heteroaromatic rings with similar electronic characteristics. Amongst the numerous known 
heteroaromatic rings, the indole unit is considered as a privileged scaffold for drug design.160,161. 
There were seven indole containing commercial drugs in the top 200 bestselling drugs of 2012 (by 
US retail sales).162 Moreover, the indole nucleus is found in several marketed CNS drugs such as 
sumatriptan (Imitrex), rizatriptan (Maxalt), pindolol and oxypertine among others.163,164 
Furthermore, the indole nucleus has also been reported in several 5-HT2A ligands.
165-168 
Considering the rich CNS pharmacology of indoles and aporphine alkaloids, it was decided to 






Previously Bremner and co-workers had reported the synthesis and evaluation of 
compound 208 as an α1A antagonist (Ki = 4 nM).
169. The structure of compound 208 bears great 
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resemblance to the general structure of the proposed fused indole aporphine analogues (207). The 
only difference between the two structures is the alkyl group attached to the nitrogen atom. In the 
initial SAR studies conducted on nantenine, it was revealed that the incorporation of an N-propyl 
functionality results in selective affinity for the α1A receptor.
28 Shortening the alkyl chain to an N-
methyl group resulted in combined affinities for the 5-HT2A and α1A receptors. Based on these 
observations it is expected that this change (from N-propyl in 208 to N-methyl group in 207) will 
enhance the affinity for the 5-HT2A receptor.  
 
As shown in Figure 51, Bremner and co-workers accomplished the synthesis of 208 via a 
Fischer indole synthesis reaction on compound 209.169 Compound 209 was synthesized after 8 
steps from the commercially available amine 210.  In order to shorten the synthetic route and to 
allow a late stage modification of the nitrogen functionality, ketone 211 was targeted as a precursor 
for the synthesis of the desired indole-aporphine analogues. (See Scheme 8) 
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 Scheme 8 shows the initial approach that was used to synthesize the fused indole-aporphine 
analogues via ketone 211. Acyl Pictet-Spengler reaction between carbamate 212 and acetal 213 
proceeded smoothly to provide intermediate 214. Initial attempts to transform ester 214 directly to 
the ketone 211 using PPA170 was unsuccessful. As a result ester 214 was first hydrolyzed to the 
acid 215, which would be more facile to convert to the ketone 211. Next we attempted the 
cyclization reaction of 215 to 211 using several acid catalysts. Initial experiments with PTSA171, 
HCl172 and PPA173 resulted in either no product formation or led to the formation of decomposed 
products. However treatment with a mixture of TFA (catalytic) and TFAA174 smoothly 
transformed 215 to the desired ketone 211 in 67 % yield. Once 211 was synthesized Fischer indole 
synthesis conditions were employed to furnish novel fused indole-aporphine derivatives 217a-d.  
Having synthesized 217a-d, the next step was to reduce the N-carbamate functionality to 
an N-methyl group. Unfortunately the initial attempt of reduction using LAH did not produce the 
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desired product but instead resulted in the formation of phenanthrene derivative 219. Other efforts 
to avoid the formation of this unexpected product (as shown in Table 8) were also unsuccessful. 
Thus using less equivalents of LAH (1.2 equiv., entry 2) resulted in the formation of 219 as the 
sole product. Coop and his co-workers had reported the use of L-selectride as a reagent for 
carbamate deprotection of opium alkaloids and its derivatives.175 Unfortunately the use of L-
selectride (entry 3) proved unsuccessful as was the case with NaBH4 (entry 4). Efforts to hydrolyze 
the carbamate group using NaOH (entry 5) were also not fruitful.  
 
                                  Table 8: Reduction of 217d to 219 
 
Entry Reagents Conditions Result 
1 LAH (2 equiv.) THF, 0 ºC - rt-reflux, 6 h 219 
2 LAH (1.2 equiv.) THF, 0 ºC, 4 h 219 
3 NaBH4 MeOH, reflux, 16 h No Reaction 
4 L-Selectride THF, 0 ºC-rt-reflux, 48 h No Reaction 





A plausible mechanism for the formation of 219 is proposed in Figure 52. Thus reduction 
of carbamate 217d would first furnish intermediate 222, which would subsequently be reduced to 
the iminium 224. At this stage deprotonation of the relatively acidic proton H7 can lead to ring A 
opening, to furnish imine 225, which on subsequent reduction gets transformed into 219. 
Phenanthrene alkaloids have been reported to be synthesized from aporphine alkaloids under basic 
Hofmann’s degradation conditions and involve an aporphinoid intermediate with a quaternary 
ammonium group. In the case of intermediate 224, the iminium nitrogen has the same formal 
charge as in a quaternary ammonium group, and hence it is very likely that the phenanthrene 225 
is synthesized from 224. Carbamate reductions in aporphine alkaloids have been achieved 
successfully using LAH.69,122 Although mechanistically similar, the formation of phenanthrene 
type of compounds is not reported in the case of aporphines. It is possible, that the presence of an 




Unable to control the reduction of the carbamate group, an alternative approach to 
synthesize the desired fused indole-aporphine compounds was initiated shown in Scheme 9. This 
approach involves the synthesis of ketone 226 already having the N-methyl functionality, thus 
precluding the necessity of a protection-deprotection sequence.  
 
The new synthesis commenced with the commercially available amine 227, which was first 
reacted with succinic anhydride followed by esterification to furnish the amide 228. Amide 228 
was then reacted under Bischler-Napieralski conditions to produce iminium ion 229, which on 
reduction with NaBH4 was converted to the ester 230.  Having already optimized the conditions 
for the intramolecular cyclization, we found that hydrolysis of ester 230 followed by treatment of 
the intermittent acid with TFA (catalytic) and TFAA afforded the desired ketone 226. Treatment 
of ketone 226 with commercially available phenylhydrazines 216a-i under Fischer indole synthesis 
conditions furnished the desired novel fused indole-aporphine compounds 218a-i.  
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Overall novel fused indole aporphine compounds (218a-i) were synthesized via a short 
synthetic sequence comprising of 7 steps. Compounds 218a-i are being currently evaluated for 
affinity at serotonin 5-HT receptors through the PDSP. We expect these compounds to have 
enhanced affinity for the 5-HT2A receptor. Binding affinity data from these compounds will help 
understand the importance of the phenyl methylenedioxy unit for 5-HT2A antagonism. Moreover, 
















2.4.4 C3 Analogues: 
 
Rationale: 3-bromo nantenine (232) is 16 times more potent than nantenine at the 5-HT2A receptor 
(Ke = 48 nM).
28  Molecular docking studies indicate that the C3 bromine atom of 232 lies in close 
proximity to the Phe339/Phe340 residues of the 5-HT2A receptor.
176  Figure 54 shows a docking 
pose of 232 in the 5-HT2A receptor. It is thus hypothesized that analogues (233a-b) with small 
hydrophobic functional groups at this position should enhance the affinity at the 5-HT2A receptor 




Figure 54: Docking pose of 3-bromo nantenine (232) in the 5-HT2A receptor binding cavity 
 
Synthesis of the target C3 analogues is shown in Scheme 10. The synthesis commences 
with compound 214, which was condensed with nitromethane to afford the nitrostryene derivative 
235. LiBH4 mediated reduction of 235 produced primary amine 236, which was coupled with the 
acid 158 in the presence of CDI to furnish the amide 237. Amide 237 was first treated with PCl5 
to generate the intermediate Bischler-Napieralski product, which on reduction followed by Boc 




 Microwave assisted biaryl coupling reaction of 238 was achieved using Pd(OAc)2 and di-
tert-butyl (methyl) phosphonium tetrafluoroboarate to furnish 239 in 93 % yield. Catalytic 
hydrogenation of 239 produced phenol 240 in 88 % yield. 240 was then first treated with NBS to 
install a bromine atom at the C3 position followed by O-methylation to generate the Suzuki 
coupling precursor compound 241.  
Initial attempts to synthesize 242a from 241 under thermal conditions resulted in the 
formation of an inseparable 9:1 mixture of 242a: 241 (52 % yield, ratio determined by NMR). In 
order to improve the outcome of this reaction, microwave reaction conditions were explored. The 
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use of microwave irradiation in chemistry is gaining increasingly popularity due to superior 
reaction rates, selectivity and better yields than thermal conditions.177,178 More particularly the 
application of microwave irradiations towards Suzuki coupling reaction is now commonplace.179-
181  
Table 9: Optimization efforts for microwave accelerated Suzuki coupling reaction: 
 
Entrya Solvent Metal Catalyst Base Conditions Yieldsb, c 
1 Toluene 0.05 % Pd(PPh3)4 Na2CO3 Thermal, 100 °C, 16 h 52 % (9:1) 
2 Toluene 0.05 % Pd(PPh3)4 Na2CO3 MW, 120 °C, 20 min 82 % (9:1) 
3 Toluene 0.1 % Pd(PPh3)4 Na2CO3 MW, 120 °C, 20 min 87 % (9:1) 
4 Toluene 0.2 % Pd(PPh3)4 Na2CO3 MW, 120 °C, 20 min 81 % (9:1) 
5 Toluene 0.05 % Pd(dppf)Cl2 Na2CO3 MW, 120 °C, 20 min No Reaction 
6 1,4 dioxane 0.05 % Pd(PPh3)4 Na2CO3 MW, 110 °C, 20 min 70 % (7:3) 
7 Toleune 0.05 % Pd(PPh3)4 CsF MW, 110 °C, 30 min 85 % (9:1) 
8 DMF 0.05 % Pd(PPh3)4 K2CO3 MW, 140 °C, 10 min No Reaction 
9 Toluene 0.05 % Pd(PPh3)4 Na2CO3 MW, 120 °C, 20 min 77 % (9:1) 
aEntries 1-8: phenyl boronic acid used, entry 9: allyl boronic acid pinacol ester used 
bIsolated yields 





Table 9 summarizes our optimization for the microwave assisted Suzuki coupling reaction. 
Thus treatment of 241 with phenyl boronic acid (entry 1) in the presence of 0.05 % Pd(PPh3) 
resulted in the formation of an inseparable 9:1 mixture of 242a and 241. Other attempts to 
completely transform 241 to 242a also had similar outcomes. Increasing the catalyst loadings to 
0.01 % (entry 3) and 0.2 % (entry 4) also gave a 9:1 mixture of 242a and 241. No reaction product 
was formed with the use of 0.05 % Pd(dppf)Cl2 (entry 5). Changing the solvent to 1,4 dioxane 
(entry 6) or DMF (entry 8) resulted in a diminished yield or no reaction respectively. Changing 
the base to CsF had an outcome similar to the use of Na2CO3. Using a different boronic acid 
coupling partner (entry 9) also gave us a 9:1 mixture of the corresponding product.  
Nevertheless the inseparable mixtures (242a or 242b and 241) obtained after this step was 
subjected to boc deprotection and reductive amination. The resulting mixture of (242a or 242b and 
241) were purified using preparative Thin Layer Chromatography to furnish the desired 
compounds 233a and 233b.  
Prior to this work, there were limited reports of Suzuki coupling reactions attempted on the 
aporphine scaffold. Hedberg and Linnanen have independently reported the synthesis of C10 and 
C11 aporphine analogues using the Suzuki coupling reaction.65,182 Both groups however used the 
corresponding aryl triflates as the Suzuki coupling precursor. This work is the first Suzuki coupling 
reaction reported on an aporphinoid aryl bromide substrate. Furthermore, the microwave reaction 
conditions developed for the Suzuki coupling reaction are highly efficient compared to reaction 
under thermal conditions. This synthetic manipulation thus sets the stage for the rapid generation 
of C3 analogues as well as analogues at other positions. 
Analogues 233a and 233b are currently being evaluated for affinity at the serotonin 
receptors through the PDSP. It is expected that these compounds will have enhanced 5-HT2A 
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receptor potency by virtue of hydrophobic interactions of the C3 substituents. Based on this 
information, 5-HT2A antagonists having modifications at more than one position (for example C1 
and C3) will be synthesized.  
 
2.6 Conclusions: 
Selective 5-HT2A antagonists have therapeutic potential in the mitigation of several 
neuropsychiatric disorders such as sleep disorders, depression, anxiety, schizophrenia and drug 
abuse. However, there are very few truly selective 5-HT2A antagonists known at this time (and 
furthermore no such compound is clinically available). As a result, there is an unmet need to 
identify and develop new selective 5-HT2A antagonists. The privileged aporphine scaffold present 
in the naturally available alkaloid nantenine, is an attractive target for developing selective 5-HT2A 
antagonists. However, in order to understand the structural tolerance of the nantenine scaffold for 
5-HT2A antagonism, an exhaustive SAR study was initiated.  
Accordingly a library of nantenine analogues having structural modifications at the C3, C4 
positions, oxygen containing isosteric analogues and ring D indole analogues was designed and 
successfully synthesized. The C4 phenyl analogues were synthesized with the aim of enhancing 5-
HT2A receptor affinity (via structural similarity to known 5-HT2A pharmacophores). However, 
SAR studies of these analogues indicate that introduction of phenyl ring at the C4 position of 
nantenine is detrimental for 5-HT2A receptor affinity. Surprisingly these compounds displayed 
affinity and selectivity for the 5-HT2B receptor. The isochroman analogues were devoid of any 
affinity for 5-HT2A receptor, thus indicating that a basic nitrogen atom is required for affinity at 
the 5-HT2A receptor. This result also corroborated findings from previous molecular docking 
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studies, suggesting a salt bridge interaction between the basic nitrogen atom and Asp155. All the 
isochroman compounds also displayed low to moderate cytotoxicity, thus indicating that the 
nitrogen atom might not be critical for cytotoxic effects of nantenine and other aporphines. A 
library of C3 analogues and fused indole aporphine analogues are currently being evaluated for 5-
HT2A affinity. These compounds are expected to have enhanced 5-HT2A affinity.  
This work has positively impacted the field of medicinal chemistry. Results from current 
SAR studies have expanded our understanding of the structural tolerance of the aporphine core 
required for 5-HT2A antagonism. This information will be useful for the design of future 
aporphinoid 5-HT2A antagonists. Moreover, novel lead molecules such as compound 165a 
(selective 5-HT2B antagonist) or compound 185e (cytotoxic agent against IGROV1-ovarian cancer 
cell line and T-47D-breast cancer cell line) were identified.  
From a synthetic chemistry perspective this work has significant outcomes. i) a method 
utilizing palladium catalyzed C-H activation for the synthesis of two bioactive scaffolds-
isochroman analogues and phenanthrene alkaloids was developed. ii) novel fused indole aporphine 
alkaloids were synthesized iii) a microwave accelerated Suzuki coupling reaction has been 
developed, enabling the rapid generation of C3 aporphine analogues.  
To continue our quest for developing novel aporphine 5-HT2A antagonists, information 
obtained from previous and current SAR studies will be used to guide the future design of 
analogues. For example, information obtained from the evaluation of fused indole aporphine 
analogues will be used for the design of other ring D heterocyclic isosteres. Similarly nantenine 
analogues having a combination of 5-HT2A preferring moieties at the C1 and C3 positions will also 
be synthesized and evaluated.  
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Overall a systematic exploitation of the untapped potential of aporphine alkaloids will lead 




General methods and instrumentation: 
All glass apparatus were oven-dried prior to use. A CEM Discover microwave reactor was used to 
carry out microwave-assisted C-H arylation reactions. HRESIMS spectra were obtained using an 
Agilent 6520 Q-TOF instrument. 1H NMR and 13C NMR spectra were recorded using a Bruker 
DPX-500 spectrometer (operating at 500 MHz for 1H; 125 MHz for 13C) using CDCl3 as solvent. 
Tetramethylsilane (δ 0.00 ppm) served as an internal standard in 1H NMR and 13C NMR unless 
stated otherwise. Chemical shift (δ 0.00 ppm) values are reported in parts per million and coupling 
constants in Hertz (Hz). Splitting patterns are described as singlet (s), doublet (d), triplet (t), and 
multiplet (m). Melting points were obtained on a Mel-Temp capillary electrothermal melting point 
apparatus. Reactions were monitored by TLC with Whatman Flexible TLC silica gel G/UV 254 
precoated plates (0.25 mm). TLC plates were visualized in UV light (254 nm) and by staining with 
phosphomolybdate spray reagent, vanillin or iodine. Flash column chromatography was performed 
with silica gel 60 (EMD Chemicals, 230-400 mesh, 0.04-0.063 mm particle size). Preparative thin 
layer chromatography was performed with silica gel GF plates (Analtech, catalog # 02003). All 
chemicals and reagents were obtained from Sigma-Aldrich and Fischer Scientific (USA) in reagent 




A) Synthesis of C4 Phenyl analogues: 
1-(benzyloxy)-2-methoxy-4-(2-nitro-1-phenylethyl) benzene (156): Phenylmagnesium bromide 
(9.5 g, 53 mmol) was added to anhydrous THF (50 mL) under N2 atmosphere at 0 ºC. To this 
reaction mixture, a cold solution of compound 155 (5.0 g, 18 mmol) in anhydrous THF (60 mL) 
was added dropwise over 30 min. The reaction mixture was allowed to stir at 0 ºC for another 1 h, 
and then at rt for 16 h. HCl (1M solution, 10 mL) was added and the reaction was stirred for 1 h. 
The THF was evaporated to get a crude residue to which water (60 mL) was added. The crude 
mixture was then extracted with ethyl acetate (3 x 30 mL). The combined organic layer was dried 
over Na2SO4, and evaporated under vacuum to afford a brown oil which was purified on silica gel, 
eluting in 5-20 % acetone-petroleum ether to provide 156 as a yellow powder; 32 %; mp 75 °C-
77 °C; 1H NMR (500 MHz, CDCl3): δ 7.40 (d, 2H, J = 7.5 Hz), 7.37-7.29 (m, 6H), 7.22 (d, 2H, J 
= 7.3 Hz), 6.82 (d, 1H, J = 8.2 Hz), 6.73-6.70 (m, 2H), 5.11 (s, 2H), 4.93 (d, 2H, J = 8.0 Hz), 4.83 
(t, 1H, J = 8.0 Hz), 3.83 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 149.9, 147.6, 139.3, 137.0, 132.1, 
129.0, 128.5, 127.9, 127.6, 127.5, 127.2, 119.4, 114.0, 111.7, 79.4, 71.0, 56.0, 48.6; HRESIMS: 
calcd. for C22H21NO4Na [M+Na]
+ 386.1369; found 386.1361. 
2-(4-(benzyloxy)-3-methoxyphenyl)-2-phenylethan-1-amine (157): Compound 156 (0.5 g, 1.4 
mmol) and tin (II) chloride (6.2 g, 28 mmol) were dissolved in ethanol (60 mL). The resulting 
reaction mixture was refluxed for 16 h. The reaction was cooled to rt and the solvent evaporated. 
To the crude residue obtained, ethyl acetate (50 mL) was added followed by the addition of 1 M 
NaOH to adjust to pH 8. The organic layers were extracted with ethyl acetate (2 x 30 mL). The 
combined organic layer was dried over Na2SO4, and evaporated under vacuum to afford 157 as 




yl)acetamide (159): A solution of bromoacid 158 (0.07 g, 0.3 mmol) in anhydrous THF (30 mL) 
under N2 atmosphere was cooled to 0 ºC. To this solution CDI (0.04 g, 0.3 mmol) was added in 
three portions over a period of 30 min at 0 ºC. The resulting reaction mixture was allowed to stir 
for 1.5 h at 0 ºC, after which the temperature was raised to rt and allowed to stir for another 1 h. 
The solution was again cooled to 0 ºC and allowed to stir for 30 min, after which a solution of 157 
(0.09 g, 0.3 mmol) in anhydrous THF (10 mL) was added dropwise. The resulting reaction mixture 
was allowed to stir for 30 min at 0 ºC and then at rt for another 15 h. The precipitate was filtered 
and washed with ether affording 159 as a white solid; 60 % ; mp 99 °C-103 °C ; 1H NMR (500 
MHz, CDCl3): δ 7.42 (d, 2H, J = 7.2 Hz), 7.36 (dd, 2H, J = 7.2, 7.2 Hz), 7.31-7.24 (m, 2H), 7.24 
(s, 1H), 7.19 (t, 1H, J = 7.2 Hz), 7.14 (d, 2H, J = 7.2 Hz), 6.87 (s, 1H), 6.77 (d, 1H, J = 8.2 Hz), 
6.67 (s, 1H), 6.63 (s, 1H) 6.61 (s, 1H), 5.95 (s, 2H), 5.33 (broad s, 1H), 5.10 (s, 2H), 4.03 (t, 1H, J 
= 8.1 Hz), 3.82-3.50 (m, 5H), 3.49 (s, 2H); 13C NMR (125 MHz, CDCl3): δ 169.5, 147.0, 141.6, 
134.4, 128.6, 128.5, 127.8, 127.3, 127.2, 126.7, 119.8, 113.9, 112.7, 111.8, 110.7, 101.9, 71.0, 
55.9, 49.9, 43.8, 43.7; HRESIMS: calcd. for C31H29BrNO5 [M+H]
+ 576.1209; found 576.1200 
tert-butyl 7-(benzyloxy)-1-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-6-methoxy-4-phenyl-
3,4-dihydroisoquinoline-2(1H)-carboxylate (161): Compound 158 (5.0 g, 8.7 mmol) was 
dissolved in dichloromethane (50 mL) and the resulting solution was cooled to 0 ºC and allowed 
to stir for 20 min. PCl5 (2.7 g, 13 mmol) was added in 3 portions over a period of 30 min. The 
resulting reaction mixture was allowed to stir at 0 ºC for 30 min and then at rt for the next 16 h. 
To this reaction mixture 20 mL NaHCO3 was added and the organic layers were extracted with 
dichloromethane (2 x 10 mL). The combined organic layers were dried over Na2SO4, and 
evaporated under vacuum to get the intermediate imine as a brown oil, which was used without 
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further purification. Sodium borohydride (1.3 g, 34 mmol) was added to the solution of intermittent 
imine (4.8 g, 8.6 mmol) in methanol (50 mL) at 0 ºC. The reaction mixture was then brought to rt 
and allowed to stir for 4 h. After 4 h, methanol was evaporated to get a crude mixture, to which 
water (30 mL) was added, followed by extraction with ethyl acetate (3 x 30 mL) The combined 
organic layers were dried over Na2SO4, and evaporated under vacuum to get an intermediate amine 
(29) which was used in the next step without purification. The crude amine (160, 4.8 g, 8.2 mmol), 
(Boc)2O (2.84 mL, 2.7 g, 12.3 mmol) and DIPEA (2.83 mL, 2.1 g, 16 mmol) and DMAP (catalytic) 
were dissolved in dichloromethane (100 mL). The resulting reaction mixture was stirred at rt for 
16 h. After 16 h, the reaction mixture was evaporated to dryness and the crude product was purified 
on silica gel eluting with 30 % ethyl acetate-petroleum ether to afford 161 as a white solid; 85 % ; 
mp 67 °C-70 °C; rotamers observed, all signals reported; 1H NMR (500 MHz, CDCl3): δ 7.48-
7.42 (2H), 7.40-7.29 (m, 7H), 7.23-7.19 (2H), 7.04-6.79 (1H), 6.84, 6.70 (1H), 6.54-6.51 (1H), 
6.31, 6.26 (1H), 5.95-5.85 (2H), 4.48-4.44, 4.24-4.20 (1H), 4.16-4.0 (1H), 3.62-3.61 (3H), 3.25-
3.07 (2H), 2.96-2.89 (1H), 1.38-1.30, 1.17 (9H); 13C NMR (125 MHz, CDCl3): δ 154.0, 148.4, 
147.3, 147.2, 146.8, 142.5, 137.4, 130.6, 129.6, 129.1, 129.0, 128.7, 128.6, 128.0, 127.9, 127.3, 
127.2, 127.1, 127.0, 115.3, 112.7, 112.50, 112.48, 112.4, 112.3, 112.1, 111.3, 110.8, 101.6, 101.5, 
79.6, 76.8, 71.3, 71.2, 56.0, 55.9, 54.2, 53.5, 45.1, 44.6, 44.0, 42.4, 41.8, 28.2, 28.0, 14.2; 
HRESIMS: calcd. for C36H36BrNO6Na [M+Na]
+ 680.1624; found 680.1618. 
tert-butyl 1-(benzyloxy)-2-methoxy-4-phenyl-4,5,6a,7-tetrahydro-6H [1,3] 
dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline-6-carboxylate (162): Compound 161 (0.1 g, 
0.2 mmol), Pd(OAc)2 (0.006 g, 0.03 mmol), K2CO3 (0.04 g, 0.3 mmol) and di-tert-butyl methyl 
phosphonium tetrafluoroborate (0.02 g, 0.06 mmol) were dissolved in DMSO (1 mL) in a 10 mL 
microwave reaction vial. The reaction mixture was then irradiated with microwaves at 140 ºC, 200 
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psi for 10 min. The resulting crude was purified directly on a silica gel column chromatography 
using 30 % ethyl acetate-petroleum ether to afford 162 as a white solid; 88 %; mp 149 °C-152 °C; 
1H NMR (500 MHz, CDCl3): δ 8.04 (s, 1H), 7.38-7.35 (m, 4H), 7.35-7.30 (m, 4H), 7.29-7.22 (m, 
2H), 6.76 (s, 1H), 6.22 (s, 1H), 5.99 (d, 1H, J = 1.0 Hz), 5.97 (d, 1H, J = 1.0 Hz), 4.82 (d, 1H, J = 
10.5 Hz), 4.74 (broad s, 1H), 4.70 (d, 1H, J = 10.5 Hz), 4.40 (broad s, 1H), 4.01 (m,1H), 3.59 (s, 
3H), 3.08 (m, 1H), 2.86 (m, 2H), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 154.5, 151.9, 146.7, 
146.4, 143.6, 141.2, 137.2, 133.9, 131.4, 129.1, 128.8, 128.7, 128.2, 127.9, 127.2, 126.4, 125.4, 
111.2, 109.8, 108.3, 100.9, 80.0, 74.5, 55.9, 52.4, 46.1, 45.3, 35.2, 28.6; HRESIMS: calcd. for 
C36H35NO6Na [M+Na]
+ 600.2362; found 600.2348. 
tert-butyl 1-hydroxy-2-methoxy-4-phenyl-4,5,6a,7-tetrahydro-6H 
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline-6-carboxylate (163): Compound 162 
(0.3 g, 0.7 mmol) was dissolved in methanol-THF mixture (50 mL; 1:1), followed by the addition 
of 10 % Pd/C (10 mg). The resulting suspension was stirred for 6 h under hydrogen atmosphere. 
After 6 h, the reaction mixture was subjected to vacuum filtration over celite. The filtrate was then 
evaporated under reduced pressure to afford a crude residue, which was purified using silica gel 
column chromatography in 30 % ethyl acetate – petroleum ether, to afford 163 as a white solid; 
90 % ; mp 225 °C-227 °C; 1H NMR (500 MHz, CDCl3): δ 8.04 (s, 1H), 7.37-7.35 (m, 2H), 7.31-
7.29 (m, 1H), 7.21 (m, 2H), 6.77 (s, 1H), 6.15 (s, 2H), 5.99 (s, 1H), 5.97 (s, 1H), 4.80 (m, 1H), 
4.37 (m, 1H), 4.01 (dd,1H, J = 4.0, 11.5 Hz), 3.63 (s, 3H), 3.08 (t, 1H, J = 9.0 Hz), 2.90 (m, 2H), 
1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 154.5, 146.3, 146.2, 146.5, 141.5 141.2, 131.0, 129.1, 
129.0, 128.6, 127.1, 126.6, 109.4, 109.0, 108.4, 100.9, 80.0, 56.2, 52.6, 45.9, 45.3, 35.4, 28.6; 
HRESIMS: calcd. for C29H29NO6Na [M+Na]
+ 510.1893; found 510.1880. 
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General procedure for the synthesis of 165a-i and 165k: (Using 165a as a representative) 
Methylation: Compound 163 (0.05 g, 0.10 mmol) was dissolved in acetonitrile (20 mL) followed 
by the addition of methyl iodide (0.1 mL, 0.02 g, 0.23 mmol) and K2CO3 (0.03 g, 0.21 mmol). The 
resulting reaction mixture was refluxed for 16 h. After 16 h the reaction mixture was cooled to rt 
and was subjected to vacuum filtration. The filtrate was then evaporated affording a crude product 
methylated product which was purified on a silica gel column using 20 % ethyl acetate-petroleum 
ether. Boc deprotection: The methylated product (0.05 g, 0.1 mmol) and ZnBr2 (0.2 g, 1.0 mmol) 
were dissolved in dichloromethane (20 mL). The resulting reaction mixture was stirred at rt for 16 
h. After 16 h, the reaction mixture was vacuum filtered, and the filtrate collected. To this filtrate 
saturated NaHCO3 solution (10 mL) was added. The organic layer was then extracted with 
dichloromethane (2 x 10 mL). The combined organic layer was dried over Na2SO4, and evaporated 
under vacuum to get the secondary amine (0.04 g). Reductive amination: This secondary amine 
(0.04 g, 0.1 mmol) was dissolved in dichloromethane (10 mL) followed by the addition of 37 % 
formaldehyde solution in water (0.03 mL, 1.0 mmol) and sodium triacetoxyborohydride (0.1 g, 0.5 
mmol). The resulting reaction mixture was stirred at 16 h. After 16 h, saturated NaHCO3 solution 
(20 mL) was added to the reaction mixture. The organic layers were then extracted with 
dichloromethane (2 x 20 mL). The combined organic layer was dried over Na2SO4, and evaporated 
under vacuum to get a crude product, which was purified on a preparative TLC plate using 0.02 % 
methanol-DCM as the solvent system to give 165a. (Note: Compounds 165b-h were prepared 
similarly; For 165k After O-methylation and Boc deprotection steps, reductive amination was done 
using cyclopropanecarboxaldehyde (0.06 g, 0.87 mmol) and sodium triacetoxyborohydride (0.04 





g]benzo[de]quinoline (165a): white solid; 56 %; mp 109 °C-114 °C; 1H NMR (500 MHz, CDCl3): 
δ 7.96 (s, 1H), 7.32-7.25 (m, 4H), 7.22-7.18 (m, 1H), 6.77 (s, 1H), 6.46 (s, 1H), 5.99 (d, 1H, J = 
1.5 Hz), 5.97 (d, 1H, J = 1.5 Hz), 3.99 (d, 1H, J = 3.9 Hz), 3.74 (s, 3H), 3.68 (s, 3H), 3.01 (dd, 1H, 
J = 3.8, 13.6 Hz), 2.95 (dd, 1H, J = 4.1, 16.8 Hz), 2.84 (dd, 1H, J = 4.4, 11.5 Hz), 2.61 (m,1H), 
2.38 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 152.1, 146.9, 146.5, 146.4, 144.8, 131.1, 130.8, 
128.80, 128.4, 128.0, 126.6, 126.1, 125.6, 111.7, 108.9, 108.3, 100.9, 62.6, 60.13, 60.11, 55.8, 
44.9, 44.1, 35.4; HRESIMS: calcd. for C26H26NO4 [M+H]
+ 416.1862; found 416.1830 
1-ethoxy-2-methoxy-6-methyl-4-phenyl-5,6,6a,7-tetrahydro-4H 
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165b): light brown solid; 45 %; mp 
113 °C-116 °C; 1H NMR (500 MHz, CDCl3): δ 8.03 (s, 1H), 7.32-7.24 (m, 4H), 7.21-7.17 (m, 
1H), 6.76 (s, 1H), 6.45 (s, 1H), 5.99 (d, 1H, J = 1.4 Hz), 5.96 (d, 1H, J = 1.4 Hz), 3.99 (s, 1H), 
3.97-3.89 (m, 1H), 3.77-3.69 (m, 4H), 3.03-2.94 (m, 4H), 2.61 (t, 1H, J = 15.5 Hz), 2.39 (s, 3H), 
1.30 (t, 3H, J = 7.1 Hz); 13C NMR (125 MHz, CDCl3): δ 152.2, 146.9, 146.0 (x2), 143.8, 131.0, 
130.6, 128.8, 128.3, 128.0, 127.0, 126.1, 125.9, 111.6, 109.2, 108.2, 100.8, 68.6, 62.7, 60.1, 55.8, 
44.8, 44.1, 35.3, 15.7; HRESIMS: calcd. for C27H28NO4 [M+H]
+ 430.2018; found 430.2019 
2-methoxy-6-methyl-4-phenyl-1-propoxy-5,6,6a,7-tetrahydro-4H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165c): white solid; 36 %; mp 113 °C-
117 °C ; 1H NMR (500 MHz, CDCl3): δ 8.01 (s, 1H), 7.32-7.25 (m, 4H), 7.21-7.15 (m, 1H), 6.77 
(s, 1H), 6.45 (s, 1H), 5.99 (d, 1H, J = 1.3 Hz), 5.95 (d, 1H, J = 1.3 Hz), 3.98 (d, 1H, J = 3.8 Hz), 
3.84-3.79 (m, 1H), 3.72 (s, 3H), 3.62-3.57 (m, 1H), 3.01 (dd, 1H, J = 3.8, 8.6 Hz), 2.94 (d, 2H, J 
= 10.5 Hz), 2.84 (dd, 1H, J = 4.4, 11.5 Hz), 2.60 (t,1H, J = 13.4 Hz), 2.40 (s, 3H), 1.76-1.67 (m, 
2H), 0.95 (t, 3H, J = 7.4 Hz); 13C NMR (125 MHz, CDCl3): δ 152.2, 146.9, 146.3 (x2), 144.0, 
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130.9, 130.5, 128.8, 128.4, 127.9, 126.9, 126.1, 125.8, 111.8, 109.4, 108.2, 100.8, 74.7, 62.7, 60.1, 
55.8, 44.8, 44.2, 35.4, 23.5, 10.5; HRESIMS: calcd. for C28H30NO4 [M+H]
+ 444.2175; found 
444.2172 
1-butoxy-2-methoxy-6-methyl-4-phenyl-5,6,6a,7-tetrahydro-4H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165d): light brown solid; 26 %; mp 
118 °C -123 °C; 1H NMR (500 MHz, CDCl3): δ 8.00 (s, 1H), 7.31-7.25 (m, 4H), 7.21-7.18 (m, 
1H), 6.76 (s, 1H), 6.45 (s, 1H), 5.99 (d, 1H, J = 1.2 Hz), 5.96 (d, 1H, J = 1.2 HZ), 3.98 (d, 1H, J = 
3.3 Hz), 3.86-3.82 (m, 1H), 3.72 (s, 3H), 3.66-3.62 (m, 1H), 3.02-2.93 (m,3H), 2.84 (dd, 1H, J = 
4.4, 11.4 Hz), 2.60 (t,1H, J = 13.4 Hz), 2.38 (s, 3H), 2.84 (dd, 1H, J = 7.1, 11.4 Hz), 2.60 (t, 3H, J 
= 13.4 Hz), 2.38 (s, 3H), 1.74-1.63 (m, 2H), 1.49-1.36 (m, 2H), 0.9 (t, 3H, J = 7.4 Hz); 13C NMR 
(125 MHz, CDCl3): δ 152.2, 146.9, 146.3 (x2), 144.0, 130.9, 130.5, 128.8, 128.4, 127.9, 126.9, 
126.1, 125.8, 111.7, 109.3, 108.1, 100.8, 72.8, 62.7, 60.2, 55.8, 44.8, 44.2, 35.3, 32.3, 19.2, 13.8; 
HRESIMS: calcd. for C29H32NO4 [M+H]
+ 458.2331; found 458.2329 
1-(hexyloxy)-2-methoxy-6-methyl-4-phenyl-5,6,6a,7-tetrahydro-4H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165e): brown solid; 40%; mp 108 °C-
110 °C; 1H NMR (500 MHz, CDCl3): δ 7.99 (s, 1H), 7.32-7.27 (m, 4H), 7.21-7.15 (m, 1H), 6.76 
(s, 1H), 6.44 (s, 1H), 5.98 (d, 1H, J = 1.5 Hz), 5.96 (d, 1H, J = 1.5 Hz), 3.98 (d, 1H, J = 3.8 Hz), 
3.87-3.80 (m, 1H), 3.72 (s, 3H), 3.65-3.60 (m, 1H), 3.01-2.99 (m, 1H), 2.84 (d, 2H, J = 12.4 Hz), 
2.84 (dd, 1H, J = 4.3, 11.5 Hz), 2.60 (t,1H, J = 13.4 Hz), 2.38 (s, 3H), 1.75-1.62 (m, 2H), 1.46-
1.32 (m. 2H), 1.31-1.21 (m, 4H), 0.87 (t, 3H, 6.8 Hz); 13C NMR (125 MHz, CDCl3): δ 152.2, 
108.1, 100.8, 73.1, 62.7, 60.2, 55.8, 44.8, 44.2, 35.4, 31.7, 30.2, 25.8, 22.6, 14.1; HRESIMS: calcd. 
for C31H36NO4 [M+H]




[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165f): light brown solid; 58 %; mp 
114 °C-118 °C; 1H NMR (500 MHz, CDCl3): δ 8.13 (s, 1H), 7.32-7.28 (m, 4H), 7.23-7.21 (m, 
1H), 6.79 (s, 1H), 6.47 (s, 1H), 6.02 (d, 1H, J = 1.2 Hz), 5.99 (d, 1H, J = 1.2 Hz), 4.02 (d, 1H, J = 
3.7 Hz), 3.78-3.73 (m, 4H), 3.45 (dd, 1H, J = 7.6, 9.8 Hz), 3.05-2.96 (m, 3H), 2.87 (dd, 1H, J = 
4.3, 11.4 Hz), 2.61 (t, 1H, J = 13.3 Hz), 2.41 (s, 3H), 1.21-1.16 (m, 1H), 0.52-0.49 (m, 2H), 0.21-
0.13 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 152.2, 146.9, 146.2 (
128.8, 128.3, 127.9, 127.1, 126.0, 125.9, 111.6, 109.5, 108.1, 100.8, 77.7, 62.6, 60.2, 55.7, 44.8, 
44.2, 35.4, 11.0, 3.4, 3.0; HRESIMS: calcd. for C29H30NO4 [M+H]
+ 456.2175; found 456.2172 
1-(allyloxy)-2-methoxy-6-methyl-4-phenyl-5,6,6a,7-tetrahydro-4H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165g): brown solid; 60 %; mp 132 °C-
135 °C; 1H NMR (500 MHz, CDCl3): δ 8.02 (s, 1H), δ 7.33-7.28 (m, 4H), 7.24-7.21 (m, 1H), 6.79 
(s, 1H), 6.48 (s,1H), 6.08-5.98 (m, 3H), 5.31 (dd, 1H, J = 1.2, 17.2 Hz), 5.19 (d, 1H, J = 10.4 Hz), 
4.4 (dd, 1H, J = 5.9, 11.9 Hz), 4.25 (dd, 1H, J = 5.7, 11.9 Hz), 4.02 (d, 1H, J = 3.5 Hz), 3.76 (s, 
3H), 3.05-2.96 (m, 3H), 2.87 (dd, 1H, J = 4.3, 11.5 Hz), 2.64 (t, 1H, J = 13.4 Hz), 2.41 (s, 3H); 
13C NMR (125 MHz, CDCl3): δ 152.2, 146.9, 146.4, 146.3, 143.4, 134.3, 131.0 ,130.8, 128.8, 
128.4, 128.0, 127.1, 126.1, 125.7, 111.7, 109.3, 108.2, 100.9, 73.7, 62.6, 60.1, 55.8, 44.9, 44.2, 
35.4; HRESIMS: calcd. for C28H28NO4 [M+H]
+ 442.2018; found 442.2013 
1-((4-bromobenzyl)oxy)-2-methoxy-6-methyl-4-phenyl-5,6,6a,7-tetrahydro-4H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165h): brown solid; 45 %; mp 147 °C-
151 °C; 1H NMR (500 MHz, CDCl3): δ 7.87 (s, 1H), 7.35 (d, 2H, J = 8.3 Hz), 7.31-7.28 (m, 2H), 
7.24-7.19 (m, 3H), 7.10 (d, 2H, J = 8.3 Hz), 6.74 (s, 1H), 6.45 (s, 1H), 5.99 (d, 1H, J = 1.5 Hz), 
5.94 (d, 1H, J = 1.5 Hz), 4.81 (d, 1H, J = 10.9 Hz), 4.69 (d, 1H, J = 10.9 Hz), 3.99 (d, 1H, J = 3.8 
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Hz), 3.73 (s, 3H), 2.99-2.90 (m, 3H), 2.83 (m, 1H), 2.46 (m, 1H), 2.31 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 152.1, 146.8, 146.4, 146.2, 142.6, 135.9, 131.0, 130.6, 128.8, 128.4, 128.0, 127.6, 
126.1, 125.6, 121.9, 111.7, 108.1, 100.9, 73.7, 62.5, 60.1, 55.8, 44.8, 44.2, 35.2; HRESIMS: calcd. 
for C32H29NO4 [M+H]
+ 572.1280; found 572.1251 
2-methoxy-6-methyl-4-phenyl-5,6,6a,7-tetrahydro-4H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinolin-1-ol (165i): brown solid; 35 %; mp 188 °C-191 °C; 1H NMR (500 MHz, 
CDCl3): δ 7.97 (s, 1H), 7.31-7.29 (m, 4H), 7.22-7.20 (m, 1H), 6.80 (s, 1H), 6.44 (s,1H), 6.14 (s, 
1H), 6.00 (broad s, 2H), 4.01 (d, 1H, J =3.6 Hz), 3.81 (s, 3H), 3.07-2.96 (m, 2H), 2.88 (dd, 1H, J 
= 4.3 11.4 Hz), 2.69-2.63 (m, 1H), 2.41 (s, 3H) 13C NMR (125 MHz, CDCl3): δ 147.0, 146.2, 
146.0, 145.9, 141.0, 130.6, 128.8,128.6, 128.0, 126.1, 126.0, 125.7, 119.1, 109.9, 109.1, 108.3, 
100.8, 62.7, 60.4, 56.1, 44.7, 44.2, 35.2; HRESIMS: calcd. for C25H24NO4 [M+H]+ 402.1705; 
found 402.1708 
6-(cyclopropylmethyl)-1,2-dimethoxy-4-phenyl-5,6,6a,7-tetrahydro-4H-
[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]quinoline (165k): light brown oil; 31 %; 1H NMR 
(500 MHz, CDCl3): δ 7.95 (s, 1H), 7.37 (d, 2H, J = 7.2 Hz), 7.28-7.25 (m, 2H), 7.20-7.17 (m, 1H), 
6.77 (s, 1H), 6.48 (s, 1H), 5.99 (d, 1H, J = 1.5 Hz), 5.97 (d, 1H, J = 1.5 Hz), 3.99 (s, 1H), 3.75 (s, 
3H), 3.66 (s, 3H), 3.34 (dd, 1H, J = 3.5, 13.5 Hz), 3.29 (dd, 1H, J = 1.3, 11.5 Hz), 3.01 (dd, 1H, J 
= 3.7, 13.8 Hz), 2.94 (dd, 1H, J = 2.2, 9.6 Hz), 2.79 (dd, 1H, J = 5.8, 13.5 Hz), 2.57 (t, 1H, J = 
13.6 Hz), 2.37-2.33 (m, 1H), 1.20 (s, 1H), 0.76-0.68 (m, 1H), 0.45-0.40 (m, 1H), 0.32-0.20 (m, 
1H), 0.09-0.04 (m, 1H); 13C NMR (125 MHz, CDCl3): δ 149.5 (x2), 144.4, 144.0, 143.9, 143.2, 
142.2, 128.9, 126.4, 125.4, 124.3, 123.5, 123.2, 109.2, 106.5, 105.8, 98.4, 57.7, 56.8, 55.8, 53.6, 
53.3, 42.5, 32.8, 4.9, 2.5 (x2); HRESIMS: calcd. for C29H30NO4 [M+H]





g]benzo[de]quinolin-6-yl)ethan-1-one (167): A solution of acetic acid (0.02 g, 0.35 mmol) in 
anhydrous THF (30 mL) under N2 atmosphere was cooled to 0 ºC. To this solution CDI (0.05 g, 
0.32 mmol) was added in three portions over a period of 30 min at 0 ºC. The resulting reaction 
mixture was allowed to stir for 1.5 h at 0 ºC, after which the temperature was raised to rt and 
allowed to stir for another 1 h. The solution was again cooled to 0 ºC and allowed to stir for 30 
min, followed by the addition of the intermediate secondary amine (0.13 g, 0.32 mmol) in 
anhydrous THF (10 mL) was added dropwise. The resulting reaction mixture was allowed to stir 
for 30 min at 0 ºC and then at rt for another 15 h. The product was filtered and washed with ether 
to afford 167 as a white solid (87%) which was used without further purification. 
6-ethyl-1,2-dimethoxy-4-phenyl-5,6,6a,7-tetrahydro-4H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinoline (165j): Lithium aluminum hydride (0.03 g, 0.86 mmol) was carefully 
transferred to a 50 mL three necked round bottom flask under nitrogen, and anhydrous THF (15 
mL) added. The resulting suspension was cooled to 0 ºC. After 15 min, a solution of 167 (0.078 g, 
0.17 mmol) in THF (15 mL) was added dropwise to the suspension. The resulting reaction mixture 
was stirred for another 15 min at 0 ºC, and then at rt for 7 h. After 7 h the reaction mixture was 
cooled to 0 ºC and water was carefully added. The resulting suspension was filtered over celite 
and filtrate was evaporated to dryness. Saturated NaHCO3 solution (20 mL) was added and 
extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
and evaporated under vacuum to get a crude product which was purified on a preparative TLC 
plate using 0.02 % methanol-DCM as the solvent system, to afford 165j as light brown oil ; 35 %; 
1H NMR (500 MHz, CDCl3): δ 7.95 (s, 1H), 7.35 (d, 2H, J = 9.3 Hz), 7.29-7.25 (m, 2H), 7.21-
7.17 (m, 1H), 6.77 (s, 1H), 6.47 (s, 1H), 5.99 (s, 1H), 5.97 (s, 1H), 3.98 (s, 1H), 3.74 (s, 3H), 3.66 
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(s, 3H), 3.26 (dd, 1H, J = 4.1, 16.9 Hz), 3.07-2.99 (m, 2H), 2.95-2.90 (m, 1H), 2.82 (dd, 1H, J = 
5.0, 14.3 Hz), 2.59 (m, 1H), 2.50-2.39 (m, 1H), 0.92 (t, 3H, J = 8.8 Hz); 13C NMR (125 MHz, 
CDCl3): δ 151.91 (x 2), 146.7, 146.4, 146.3, 144.6, 131.3, 128.8, 127.8, 126.8, 126.0, 125.7, 111.7, 
108.9, 108.3, 100.8, 60.1, 59.2, 55.8, 55.2, 47.5, 44.8, 35.3, 10.8; HRESIMS: calcd. for 
C27H28NO4 [M+H]
+ 430.2018; found 430.1993 
 
B) Synthesis of isochroman analogues: 
benzyl 2-(4-(benzyloxy)-3-methoxyphenyl)acetate (180): A solution of 179 (5.0 g, 27.47 mmol), 
K2CO3 (7.58 g, 54.94 mmol) and benzyl bromide (6.5 mL, 54.94 mmol) in anhydrous acetonitrile 
(150 mL) was refluxed for 4 h. After 4 h, the reaction was cooled to rt and was subjected to vacuum 
filtration. The filtrate was then evaporated under reduced pressure. The resulting crude was 
purified on silica gel column chromatography using 10 % ethyl acetate-petroleum ether, to afford 
180 as a pale yellow solid; 95 % ; mp 50 °C -53 °C; 1H NMR (500 MHz, CDCl3): δ 7.42 (d, 2H, 
J = 7.3 Hz), δ 7.37-7.27 (m, 8H), δ 6.81 (d, 2H, J = 7.9 Hz), δ 6.74 (dd, 1H, J = 8.2, 1.8 Hz), δ 
5.13 (d, 4H, J = 4.8 Hz), δ 3.84 (s, 3H), δ 3.59 (s, 2H); 13C NMR (125 MHz, CDCl3): δ 171.5, 
149.6, 147.3, 137.1, 135.8, 128.55 (x 2), 128.54, 128.2, 128.1, 127.8, 127.2 (x 2), 126.9, 121.4, 
114.0 (x 2), 112.9 (x 2), 71.0, 66.6, 55.9, 40.9; HRESIMS: calcd for C23H22O4Na[M+Na]
+ 
386.1444; found 386.1446 
2-(4-(benzyloxy)-3-methoxyphenyl)ethanol (181): Lithium Aluminum Hydride (1.09 g, 28.8 
mmol) was added to a three neck round bottom flask under argon, followed by the addition of 
anhydrous THF (70 mL). The resulting suspension was cooled to 0 °C and stirred for 30 min, 
followed by drop wise addition of a solution of 180 (2.0 g, 5.76 mmol) in anhydrous THF (50 mL). 
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The resulting reaction mixture was allowed to stir at 0 °C for another 30 min, and then at rt for 3 
h. After 3 h the reaction mixture was cooled to 0 °C, and water (2 mL) was carefully and drop wise 
added, followed by the addition of 2N NaOH solution (10 mL). The reaction mixture was allowed 
to stir for 30 min, after which it was subjected to vacuum filtration using celite as the filter aid. 
The filtrate was evaporated under reduced pressure. Water (30 mL) was added to the crude, which 
was then extracted dichloromethane (3 x 20 mL). The combined organic layer was dried over 
Na2SO4, and evaporated under reduced pressure to give 181 as a white solid; 85 %; mp 53 °C -
57 °C; 1H NMR (500 MHz, CDCl3): δ 7.43 (d, 2H, J = 7.5 Hz), 7.36 (t, 2H, J = 7.5 Hz), 7.29 (t, 
1H, J = 7.2 Hz), 6.82 (d, 1H, J = 8.1 Hz), 6.77 (d, 1H, J = 1.8 Hz), 6.70 (dd, 1 H, J = 8.1, 1.9 Hz), 
5.13 (s, 2H), 3.88 (s, 3H), 3.83 (q, 2H, J = 6.2 Hz), 2.80 (t, 2H, J = 6.4 Hz); 13C NMR (125 MHz, 
CDCl3): δ 149.7, 146.8, 137.3, 131.5, 128.5 (x 2), 127.7, 127.2 (x 2), 120.9, 114.3, 112.8, 71.1, 
63.7, 56.0, 38.7; HRESIMS: calcd for C16H18O3Na[M+Na]
+ 281.1154; found 281.1156 
7-(benzyloxy)-1-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-6-methoxyisochroman (182): To 
a three neck round bottom flask attached with a Dean stark apparatus, a solution of 181 (1.2 g, 
4.65 mmol), 173 (0.56 g, 2.32 mmol) and PTSA (catalytic) in anhydrous toluene (100 mL) was 
added. The resulting reaction mixture was for refluxed for 18 h. After 18 h, the reaction mixture 
was cooled to rt and transferred to a separatory funnel containing water (30 mL). The aqueous 
layer was extracted with ethyl acetate (2 x 20 ml). The combined organic layer was dried over 
Na2SO4, and evaporated under reduced pressure. The resulting crude was purified on a silica gel 
column chromatography using 30 % ethyl acetate-petroleum ether to afford 182 as a white solid; 
63 %; mp 71 °C -75 °C; (a mixture of rotamers as evident from NMR data-all signals observed 
are reported); 1H NMR (500 MHz, CDCl3): δ 7.42 (dd, 2H, J = 7.5, 7.5 Hz), 7.36 (m, 2H), 7.30 
(m, 1H), 7.00 (s, 0.5H), 6.81 (s, 0.5H), 6.72 (m, 1H), 6.62 (m, 1H), 6.53 (m, 0.5H), 5.94 (m, 2H), 
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5.13 (d, 1H, J = 2.9 Hz), 5.07 (s, 1H), 4.81 (d, 1H, J = 8.3 Hz),4.07 (m, 1H), 3.88 and 3.86 (s, 3H), 
3.72 (m, 1H), 3.14 (dd, 1H, J = 14.4, 2.8 Hz), 2.7 (m, 2H), 2.64 (m, 1H); 13C NMR (125 MHz, 
CDCl3): δ 148.41, 148.40, 147.4, 147.10, 147.05, 146.5, 146.3, 145.9, 137.22, 137.21, 132.5, 131.4, 
129.4, 128.6, 128.4, 127.87, 127.84, 127.32, 127.28, 127.0, 126.7, 122.4, 114.8, 112.5, 112.0, 
111.9, 111.8, 111.54, 111.50,100.0, 108.0, 101.6, 100.8, 75.0, 71.4, 62.9, 62.5, 56.0, 42.6, 42.2, 
28.7; HRESIMS: calcd for C25H23BrO5 [M+H]
+ 483.0807; found 483.0802 
1-(benzyloxy)-2-methoxy-4,5,6a,7-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2 
g]benzo[de]chromene (183): Compound 182 (100 mg, 0.207 mmol), Pd(OAc)2 ,(0.009 g, 0.042 
mmol), K2CO3 (0.057 g, 0.414 mmol) and tricyclohexyl phosphine tetrafluoroborate ( 0.031 g, 
0.083 mmol) were dissolved in DMSO (1 mL) in a 10 mL microwave reaction vial. The reaction 
mixture was then irradiated with microwaves at 140 °C, 200 psi for 10 min. The resulting crude 
was purified directly on a silica gel column chromatography using 20 % acetone- petroleum ether 
to afford 183 as a white solid; 90 % ; mp 105 °C -108 °C; 1H NMR (500 MHz, CDCl3): δ 7.99 (s, 
1H), 7.36 (m, 2H), 7.30 (m, 3H), 6.72 (s,1H), 6.63 (s, 1H), 5.96 (d, 1H, J = 1.5 Hz), 5.93 (d,1H, J 
= 1.5 Hz), 4.84 (d, 1H, J = 10.5 Hz), 4.71 (d,1H, J = 10.5 Hz), 4.48 (dd, 1H, J = 13.5, 5.0 Hz), 
4.25 (dd, 1H, J =12.0, 6.5 Hz), 3.88 (s,3H), 3.80 (td, 1H, J = 10.0, 3.5 Hz), 3.13 (m, 1H), 2.83 (dd, 
1H, J = 12.5,7.5 Hz), 2.73 (t,1H, J = 13.5 Hz), 2.61 (dd, 1H, J = 16.0, 3.0 Hz); 13C NMR (125 
MHz, CDCl3): δ 152.5, 146.5, 143.0, 137.1, 129.2, 128.7 (x 2), 128.1 (x 2), 127.9, 127.47, 127.45, 
126.8, 125.4, 110.8, 109.4, 108.5, 100.9, 74.7, 73.3, 64.7, 55.9, 36.5, 28.1; HRESIMS: calcd for 
C25H22O5Na [M+Na]
+ 425.1365; found 425.1360 
2-methoxy-4,5,6a,7-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2g]benzo[de]chromen-1-ol 
(184): Compound 183 (0.3 g, 0.746 mmol) was dissolved in methanol-THF mixture (50mL, 1:1), 
followed by the addition of activated palladium over charcoal (10 mg). The resulting suspension 
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was stirred for 6 h under hydrogen atmosphere. After 6 h the reaction mixture was subjected to 
vacuum filtration over celite. The filtrate was then evaporated under reduced pressure to afford a 
crude residue, which was purified using silica gel column chromatography using 20 % ethyl acetate 
– petroleum ether, to afford 184 as a white solid; 91 %; mp 108 °C -112 °C; 1H NMR (500 MHz, 
CDCl3): δ 7.96 (s, 1H), 6.75 (s, 1H), 6.57 (s, 1H), 6.12 (s, 1H), 5.97 (dd, 2H, J = 7.5, 1.5 Hz), 4.54 
(dd, 1H, J =13.5, 5.4 Hz), 4.25 (dd,1H, J =11.4, 6.0 Hz), 3.92 (s, 3H), 3.81 (td, 1H, J =11.9, 3.6 
Hz), 3.12 (m,1H), 2.87 (dd, 1H, J =13.7, 5.3 Hz), 2.80 (t, 1H, J =13.5 Hz), 2.57 (dd,1H, J =16.2, 
3.4 Hz); 13C NMR (125 MHz, CDCl3): δ 146.4, 146.2, 146.15, 146.12, 140.7, 128.8, 127.5, 125.6, 
122.4, 118.6, 100.8, 73.4, 64.9, 56.2, 36.5, 27.9; HRESIMS: calcd for C18H16O5 [M+H]
+ 312.0998; 
found 312.0995 
General procedure for the synthesis of 170 and 185a-d: Compound 184 (0.03 g, 0.096 mmol) 
was dissolved in anhydrous acetonitrile (10 mL) followed by the addition of appropriate alkyl 
halide (0.1152 mmol) and K2CO3 (0.198 g, 1.44 mmol). The resulting reaction mixture was 
refluxed for 6 h. After 6 h the reaction mixture was cooled to rt and was subjected to vacuum 
filtration. The filtrate was then evaporated and the resulting crude was purified using on a silica 
gel prep TLC plate using 30 % ethyl acetate-petroleum ether to afford the respective compounds.  
1,2-dimethoxy-4,5,6a,7-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-g]benzo[de]chromene 
(170): White Solid; 95 %; mp 106 °C -109 °C; 1H NMR (500 MHz, CDCl3): δ 7.99 (s, 1H), 6.78 
(s,1H), 6.64 (s, 1H), 5.99 (d, 2H, J = 4.4 Hz), 4.52 (dd, 1H, J = 13.4, 5.25 Hz), 4.27 (dd, 1H, J 
=11.4, 6.5 Hz), 3.91 (s, 3H), 3.84 (td, 1H, J =11.9, 3.5 Hz), 3.71 (s, 3H), 3.15 (m, 1H), 2.88 (dd, 
1H, J =13.7,5.4 Hz), 2.82 (t, 1H, J =13.5 Hz), 2.63 (dd, 1H, J =16.3, 2.9 Hz); 13C NMR (125 MHz, 
CDCl3): δ 152.4, 146.6, 146.5, 144.5, 129.3, 127.4, 127.3, 126.1, 125.4, 110.8, 108.85, 108.70, 
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100.9, 73.3, 64.7, 60.2, 55.9, 36.6, 28.1; HRESIMS: calcd for C19H18O5 [M]
+ 326.1154; found 
326.1151  
2-methoxy-1-propoxy-4,5,6a,7-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]chromene (185a): White Solid; 86 %; mp 110 °C-113 °C; 1H NMR (500 MHz, 
CDCl3): δ 8.03 (s, 1H), 6.77 (s, 1H), 6.63 (s, 1H), 6.01 (s, 1H), 5.98 (s, 1H), 4.51 (dd, 1H, J = 13.3, 
5.2 Hz), 4.27 (dd, 1H, J = 11.6, 6.5 Hz), 3.89 (s, 3H), 3.85 (m, 2H), 3.64 (m, 1H), 3.15 (m, 1H), 
2.87 (t, 2H, J =13.7 Hz), 2.63 (dd,1H, J = 16.3, 3.0 Hz), 1.7 (m, 2H), 0.99 (t, 3H, J = 7.4 Hz); 13C 
NMR (125 MHz, CDCl3): δ 152.5, 146.46, 146.43, 143.7, 129.1, 127.4, 127.0, 126.4, 125.6, 110.8, 
109.2, 108.5, 100.9, 74.8, 73.4, 64.8, 55.9, 36.6, 28.1, 23.4, 10.5; HRESIMS: calcd for C21H22O5 
[M]+ 354.1467; found 354.1463 
1-(allyloxy)-2-methoxy-4,5,6a,7-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]chromene (185b): White Solid; 87 %; mp 120 °C-124 °C; 1H NMR (500 MHz, 
CDCl3): δ 8.02 (s, 1H), 6.77 (s,1H), 6.63 (s, 1H), 6.07 (m,1H), 6.00 (s,1H), 5.98 (s, 1H), 5.31 (dd, 
1H, J = 17.2, 1.4 Hz), 5.20 (d, 1H, J = 10.3 Hz), 4.52 (dd, 1H, J = 5.35, 5.15 Hz),4.41 (dd, 1H, J 
= 12.0, 5.9 Hz), 4.27 (m, 2H), 3.89 (s, 3H), 3.83 (td, 1H, J = 11.9, 3.6 Hz), 3.14 (m, 1H), 2.88 (dd, 
1H, J = 13.6, 5.2 Hz), 2.80 (t, 1H, J = 13.5 Hz), 2.63 (dd, 1H, J =16.3, 3.0 Hz); 13C NMR (125 
MHz, CDCl3): δ 152.5, 146.53, 146.50, 143.1, 134.1, 129.2, 127.4, 127.3, 126.5, 125.5, 117.6, 
110.8, 109.1, 108.6, 100.9, 73.7, 73.3, 64.7, 55.9, 36.6, 28.1; HRESIMS: calcd for C21H20O5Na 
[M+Na]+ 375.1209; found 375.1202 
1-(cyclopropylmethoxy)-2-methoxy-4,5,6a,7-tetrahydro [1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]chromene (185c): White Solid; 95 %; mp 95 °C-98 °C; 1H NMR (500 MHz, CDCl3): 
δ 8.13 (s,1H), 6.76 (s,1H), 6.62 (s,1H), 6.00 (s,1H), 5.98 (s,1H), 4.52 (dd, 1H, J = 12.8, 4.2 Hz), 
4.27 (dd, 1H, J = 11.5, 6.75 Hz), 3.89 (s, 3H), 3.85 (m,1H), 3.76 (m,1H), 3.45 (t, 1H, J = 8.5 Hz), 
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3.15 (m, 1H), 2.87 (dd, 1H, J = 13.7, 4.9 Hz), 2.80 (t, 1H, J = 13.5 Hz), 2.62 (d, 1H, J = 16.3 Hz), 
1.21 (m, 1H), 0.53 (d, 2H, J = 8.1 Hz), 0.20 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 152.5, 146.4, 
146.4, 143.4, 129.1, 127.3, 127.1, 126.5, 126.7, 110.7, 109.4, 108.5, 100.9, 77.8, 73.4, 64.8, 55.9, 
36.6, 28.1, 11.0, 3.4, 3.1; HRESIMS: calcd for C22H22O5Na [M+Na]
+ 389.1365; found 389.1363 
2-methoxy-1-(prop-2-yn-1-yloxy)-4,5,6a,7-tetrahydro-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]chromene (185d): White Solid; 90 %; mp 160 °C-164 °C; 1H NMR (500 MHz, 
CDCl3): δ 8.01 (s, 1H), 6.76 (s, 1H), 6.64 (s, 1H), 6.01 (s, 1H), 5.99 (s, 1H), 4.60 (dd,1H, J = 15.2, 
2.4 Hz), 4.50 (m, 1H), 4.27 (dd, 1H, J = 11.3, 6.5 Hz), 3.90 (s, 3H), 3.82 (td, 1H, J = 11.9, 3.6 Hz), 
3.15 (m, 1H), 2.87 (dd, 2H, J = 13.6, 5.2 Hz), 2.80 (t, 1H, J = 13.5 Hz), 2.63 (dd, 1H, J = 16.4, 2.9 
Hz), 2.39 (t, 1H, J = 2.3 Hz); 13C NMR (125 MHz, CDCl3): δ 152.4, 146.6 (x 2), 142.0, 129.3, 
128.0, 127.5, 126.9, 125.3, 110.7, 109.3, 108.3, 100.9, 79.0, 75.3, 75.0, 64.7, 59.8, 55.9, 36.6, 28.1; 
HRESIMS: calcd for C21H18O5Na [M+Na]
+ 373.1052; found 373.1046  
methyl 2-(3,4-dimethoxyphenyl)acetate (187): A solution of compound 55 (5.00 g, 27.62 mmol) 
and conc. H2SO4 (catalytic) in anhydrous methanol (50 mL) was refluxed for 30 min. After 30 min, 
the reaction mixture was cooled to rt and was evaporated under reduced pressure. To the resulting 
crude water (30 mL) was added, followed by extraction with dichloromethane (3 x 30 mL). The 
combined organic layers were dried over Na2SO4, and were evaporated under reduced pressure to 
afford 186 as brown oil. (5.29 g, 99 %). Data in accordance with previously reported.183   
2-(3,4-dimethoxyphenyl)ethanol (172): In a three neck round bottom flask, a solution of CaCl2 
(1.26 g, 11.52 mmol) in ethanol (50 mL) was added under argon atmosphere. The resulting solution 
was cooled to 0 °C, followed by the addition of NaBH4 (0.22 g, 5.76 mmol) at the same temperature. 
The resulting suspension was allowed to stir at 0 °C for 30 min, after which a solution of 187 (1.05 
g, 3.84 mmol) in ethanol (50 mL) was added at the same temperature. The resulting reaction 
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mixture was allowed to stir at 0 °C for another 30 min, and then at rt for 15 h. After 15 h, a mixture 
of water and dichloromethane (50 mL, 1:1) was added to the reaction mixture which was then 
sonicated for 1 h. The resulting mixture was then subjected to vacuum filtration over celite. The 
filtrate was collected and evaporated under reduced pressure. Water (50 mL) was added to the 
resulting crude, which was then extracted with dichloromethane (3 x 20 mL). The combined 
organic layer was dried over Na2SO4, and evaporated under reduced pressure to afford 172 as a 
white solid. (0.63g, 70 %); mp 63 °C-67 °C; 1H NMR (500 MHz, CDCl3): δ 6.82 (s, 1H), δ 6.78 
(d, 1H), δ 6.75 (d, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.83 (t, 2H, J = 6.5 Hz), 2.81 (t, 2H, J = 6.5 Hz); 
13C NMR (125 MHz, CDCl3): δ 149.0, 147.7, 130.9, 120.9, 112.2, 111.3, 63.7, 55.9, 55.8, 38.7; 
HRESIMS: calcd for C10H14O3Na[M+Na]
+ 205.0841; found 205.0842 
General procedure for the synthesis of 189a–d:  
To a three neck round bottom flask attached with a Dean stark apparatus, a solution of 172 (2 
equiv.) in anhydrous toluene (10 mL), 188a-d (1 equiv.) and PTSA (catalytic) were added. The 
resulting reaction mixture was refluxed for 18 h. After 18 h, the reaction mixture was cooled to rt 
and transferred to a separatory funnel containing water (20 mL). The aqueous layer was extracted, 
with ethyl acetate (3 x 20 mL). The combined organic layer was dried over Na2SO4, and evaporated 
under reduced pressure. The resulting crude was purified on a silica gel column chromatography 
using 10-30 % ethyl acetate-petroleum ether to afford 189a-d. 
1-(2-bromo-4,5-dimethoxybenzyl)-6,7-dimethoxyisochroman (189a): White Solid; 73 %; mp 
107 °C-110 °C; 1H NMR (500 MHz, CDCl3): δ 7.06 (s, 1H), 6.89 (s, 1H), 6.72 (s, 1H), 6.63 (s,1H) 
5.00 (d, 1H, J = 6.1 Hz), 4.16 (m, 1H), 3.89 (s, 3H), 3.88 (s, 3H), 3.87 (s,3H), 3.86 (s, 3H), 3.78 
(m, 1H), 3.35 (dd, 1H, J = 14.4, 3.3 Hz), 3.06 (dd,1H, J = 14.4, 9.0 Hz); 13C NMR (125 MHz, 
CDCl3): δ 148.2, 148.0, 147.6, 147.3, 130.2, 129.4, 126.0, 115.2, 114.6, 114.5, 111.3, 108.3, 75.2, 
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62.8, 56.1, 56.0, 55.9, 55.8, 42.3, 28.6; HRESIMS: calcd for C20H23BrO5Na [M+Na]
+ 445.0621; 
found 445.0618 
1-(2-bromo-5-methoxybenzyl)-6,7-dimethoxyisochroman (189b): White Solid; 72 %; mp 
92 °C-95 °C;  1H NMR (500 MHz, CDCl3): δ 7.47 (d, 1H, J = 8.8 Hz), 6.94 (d, 1H, J = 3.1 Hz), 
6.71 (m, 2H), 6.64 (s, 1H), 5.03 (dd, 1H, J = 9.3, 3.0 Hz), 4.16 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 
3.80 (s, 3H), 3.79 (m, 1H), 3.36 (dd, 1H, J = 14.3, 3.3 Hz), 3.08 (dd, 1H, J = 14.3, 9.3 Hz), 2.90 
(m, 1H), d 2.71 (td, 1H, J = 16.1, 4.6 Hz); 13C NMR (125 MHz, CDCl3): δ 158.7, 147.7, 147.4, 
139.2, 133.1, 129.4, 126.0, 117.8, 115.2, 113.8 (x 2), 108.3, 74.7, 62.8, 55.95, 55.90, 55.4, 43.0, 
28.6; HRESIMS: calcd for C19H21BrO4Na [M+Na]
+ 415.0515; found 445.0516 
1-(2-bromo-4-methoxybenzyl)-6,7-dimethoxyisochroman (189c): White Solid; 74 %; mp 
98 °C-103 °C; 1H NMR (500 MHz, CDCl3): δ 7.27 (d, 1H, J = 8.4 Hz), 7.16 (d, 1H, J = 2.5 
Hz),6.85 (dd, 1H, J = 8.4, 2.5 Hz), 6.71 (s, 1H), 6.63 (s, 1H), 4.99 (dd, 1H, J = 9.1, 2.2 Hz), 4.14 
(m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.81 (s, 3H), 3.79 (m, 1H), 3.34 (dd, 1H, J = 14.4, 3.3 Hz), 
3.06 (m, 1H), 2.88 (m, 1H), 2.70 (dt, 1H, J =16.0, 4.5 Hz); 13C NMR (125 MHz, CDCl3): δ 158.7, 
147.6, 147.3, 132.4, 130.2, 129.6, 126.0, 124.8, 117.8, 113.8, 113.4, 111.4, 108.3, 62.5, 55.9, 55.8, 
55.5, 41.9, 28.6; HRESIMS: calcd for C19H21BrO4Na [M+Na]
+ 415.0515; found 445.0514 
1-(2-bromobenzyl)-6,7-dimethoxyisochroman (189d): Clear Oil; 59 %; 1H NMR (500 MHz, 
CDCl3): δ 7.60 (d, 1H, J = 8.0 Hz),7.37 (dd, 1H, J = 1.5, 7.6 Hz), 7.32 (m, 1H), 7.13 (ddd, 1H, J 
= 7.6, 7.6,1.5 Hz), 6.70 (s,1H), 6.64 (s, 1H), 5.05 (dd,1H, J = 9.3, 3.0 Hz), 4.15 (m,1H), 3.89 (s, 
3H), 3.80 (s, 3H), 3.78 (m, 1H), 3.40 (dd, 1H, J = 14.3,3.3 Hz), 3.12 (m, 1H), 2.89 (m, 1H), 2.73 
(td, 1H, J =13.3, 7.6 Hz); 13C NMR (125 MHz, CDCl3): δ 147.7, 147.3, 138.3, 132.7, 132.2, 129.5, 
128.1, 127.2, 126.2, 126.0, 114.4, 108.3, 74.7, 62.4, 55.9, 55.8, 42.9, 28.6; HRESIMS: calcd for 
C18H19BrO3Na [M+Na]
+ 385.0410; found 385.0409 
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General procedure for the synthesis of 185e–h 
Compound 189a-d (1 equiv.), Pd(OAc)2 ,(0.2 equiv.), K2CO3 (2 equiv.) and tricyclohexyl 
phosphine tetrafluoroborate (0.4 equiv.) were dissolved in DMSO (1 mL) in a 10 mL microwave 
reaction vial. The reaction mixture was then irradiated with microwaves at 140 ºC, 200 psi for 10 
min. The resulting crude was purified directly on a silica gel column chromatography using 20 % 
acetone- petroleum ether to afford 185e-h   
1,2,9,10-tetramethoxy-4,5,6a,7-tetrahydrodibenzo[de,g]chromene (185e): White Solid; 89 %; 
mp 110 °C-112°C;  1H NMR (500 MHz, CDCl3): δ 8.12 (s, 1H), 6.77 (s, 1H), 6.62 (s, 1H), 4.54 
(dd, 1H, J = 12.8, 6.0 Hz), 4.26 (dd, 1H, J = 11.4, 6.4 Hz), 3.92 (s, 3H), d 3.91 (s, 3H) 3.90 (s, 3H), 
3.82 (ddd, 1H, J = 11.8, 11.8, 3.6 Hz), 3.68 (s, 3H), 3.14 (m, 1H), d 2.89 (m, 2H), 2.62 (dd, 1H, J 
=11.4, 3.2 Hz); 13C NMR (125 MHz, CDCl3): δ 152.4, 148.1, 147.5, 144.3, 127.9, 127.6, 127.4, 
126.0, 124.3, 111.5, 111.2, 110.6, 73.5, 64.8, 60.2, 55.9, 55.88, 55.85, 36.0, 28.2; HRESIMS: 
calcd for C20H22O5Na [M+Na]
+ 365.1365; found 365.1360 
1,2,9-trimethoxy-4,5,6a,7-tetrahydrodibenzo[de,g]chromene (185f): White Solid; 84 %; mp 
107 °C-110°C;  1H NMR (500 MHz, CDCl3): δ 8.37 (d, 1H, J = 8.8 Hz), 6.88 (dd, 1H, J = 8.8, 2.5 
Hz), 6.83 (d,1H, J = 2.5 Hz), 6.63 (s, 1H), 4.57 (dd, 1H, J = 13.0,5.4 Hz), 4.29 (dd, 1H, J = 11.4, 
6.5 Hz), 3.91 (s, 3H), 3.87 (s, 3H), 3.83 (m,1H), 3.70 (s, 3H), 3.15 (m, 1H), 2.94 (m, 2H), 2.64 (dd, 
1H, J = 16.3, 2.8 Hz); 13C NMR (125 MHz, CDCl3): δ 158.7, 152.4, 144.6, 136.8, 129.6, 127.4, 
127.3, 126.0, 124.7, 113.8, 112.3, 110.6, 73.3, 64.8, 60.0, 55.9, 55.2, 37.0, 28.2; HRESIMS: calcd 
for C19H20O5 [M+H]
+ 313.1440; found 313.1434 
1,2,10-trimethoxy-4,5,6a,7-tetrahydrodibenzo[de,g]chromene (185g): Brown Oil; 86 %; 1H 
NMR (500 MHz, CDCl3): δ 8.09 (d, 1H, J = 2.1 Hz), 7.20 (d, 1H, J = 8.3 Hz), 6.84 (dd, 1H, J = 
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8.3, 2.1 Hz), 6.69 (s, 1H), 4.54 (dd, 1H, J = 13.5, 4.95 Hz), 4.29 (dd, 1H, J =11.4, 6.6 Hz), 3.92 (s, 
3H), 3.86 (s, 3H), 3.82 (dd, 1H, J =11.5, 3.45 Hz), 3.73 (s, 3H), 3.17 (m, 1H), 2.95 (dd, 1H, J = 
13.5, 5.1 Hz), 2.83 (t, 1H, J =13.5 Hz), 2.65 (dd, 1H, J =16.2, 2.5 Hz); 13C NMR (125 MHz, 
CDCl3): δ 158.7, 152.4, 145.1, 132.8, 129.0, 128.2, 127.5, 127.1, 126.0, 113.8, 112.2, 110.5, 73.6, 
64.8, 60.3, 55.9, 55.3, 35.6, 28.2; HRESIMS: calcd for C19H20O5 [M+H]
+ 313.1440; found 
365.1434 
1,2-dimethoxy-4,5,6a,7-tetrahydrodibenzo[de,g]chromene (185h): Colorless Oil; 79 %; 1H 
NMR (500 MHz, CDCl3): δ 8.42 (d, 1H, J = 7.9 Hz), 7.28 (m, 3H), 6.68 (s, 1H), 4.57 (dd, 1H, J 
= 13.5, 5.2 Hz), 4.29 (dd, 1H, J = 11.4, 6.4 Hz), 3.92 (s, 3H), 3.84 (ddd, 1H, J = 11.8, 11.8, 3.6 
Hz), 3.71 (s, 3H) d 3.18 (m, 1H), 3.00 (dd, 1H, J = 13.7, 5.15 Hz), 2.91 (t, 1H, J =13.6 Hz), 2.65 
(dd, 1H, J =16.4, 3.2 Hz); 13C NMR (125 MHz, CDCl3): δ 151.4, 150.4, 134.0, 128.3, 128.2, 127.7, 
127.3, 127.0, 126.9, 124.2, 111.6, 106.7, 73.3, 65.5, 59.8, 56.5, 36.5, 29.9; HRESIMS: calcd for 
C18H16O3 [M]
+ 280.1096; found 280.1094  
2-(3,4,6,7-tetramethoxyphenanthren-1-yl)ethanol (200): 33 % HBr-AcOH (20 mL) was added 
to a two neck round bottom flask containing compound 185e (0.5 g, 1.46 mmol) at 10 °C. The 
resulting reaction mixture was allowed to stir at the same temperature for 30 min, after which water 
(10 mL) was added. The aqueous layers were extracted with dichloromethane (2 x 20 mL). The 
combined organic layer was dried over Na2SO4, and evaporated to get a crude residue, which was 
purified on a silica gel column using 30-70 % ethyl acetate hexane, to afford compound 199 ( 0.22 
g) and compound 200 (0.31 g). Compound 199 was then dissolved in anhydrous methanol (10 mL), 
followed by the addition of 20 % NaOH solution (10 mL). The reaction mixture was stirred at rt 
for 2h, after which the organic layer was evaporated to get a crude mixture. Water (10 mL) was 
added to this crude, and the aqueous layers were extracted with dichloromethane (3 x 10 ml). The 
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combined organic layer was dried over Na2SO4, and evaporated under reduced pressure to get 
compound 200 as a pale yellow solid;  98 %  
2-(3,4,6,7-tetramethoxyphenanthren-1-yl)ethyl acetate (199): Brown Oil; 1H NMR (500 MHz, 
CDCl3): δ 9.28 (s, 1H), 7.80 (d, 1H, J = 9.1 Hz), 7.56 (d, 1H, J = 9.1 Hz), 7.21 (s, 1H), 7.20 (s, 
1H), 4.41 (t, 2H, J = 7.5 Hz), 4.08 (s, 3H), 4.05 (s, 3H), 4.03 (s, 3H), 3.92 (s, 3H), 3.41 (t, 2H, J = 
7.5 Hz), 2.07 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 173.4, 152.6, 151.1, 150.8, 147.5, 132.8, 
130.5, 128.2, 127.3, 127.0, 126.6, 122.8, 116.6, 111.2, 110.1, 66.9, 62.3, 58.9, 58.0, 35.4, 32.0, 
23.3; HRESIMS: calcd for C22H24O6Na [M+Na]
+ 407.1471; found 407.1462  
2-(3,4,6,7-tetramethoxyphenanthren-1-yl)ethanol (200): White Solid; mp 134 °C-136 °C; 1H 
NMR (500 MHz, CDCl3): δ 9.21 (s, 1H), 7.75 (d, 1H, J = 9.0 Hz), 7.50 (d, 1H, J = 9.0 Hz), 7.19 
(s,1H), 7.17 (s, 1H), 4.06 (s,3H), 4.02 (s, 3H), 4.01 (s, 3H), 3.99 (t, 2H, J = 6.6 Hz), 3.89 (s, 3H), 
3.33 (t, 2H, J = 6.6 Hz); 13C NMR (125 MHz, CDCl3): δ 150.1, 148.7, 148.4, 131.4, 128.1, 125.7, 
124.8, 124.7, 124.2, 120.6, 114.4, 108.8, 107.7, 63.2, 60.0, 56.5, 55.8, 55.75, 55.72, 31.1; 
HRESIMS: calcd for C20H22O5Na [M+Na]
+ 365.1365; found 365.1368  
N,N-dimethyl-2-(3,4,6,7-tetramethoxyphenanthren-1-yl)ethanamine (201): To a solution of 
compound 200 (0.11 g, 0.3275 mmol) anhydrous dichloromethane (30 mL), Dess martin 
periodinane (0.152 g, 0.36 mmol) was added. The resulting reaction mixture was allowed to stir at 
rt for 15 min, after which it was filtered on a silica gel bed. The filtrate was evaporated to get the 
resulting aldehyde as a brown residue (0.138 g). The crude aldehyde was then dissolved in 
anhydrous dichloromethane (40 mL) and cooled to 0 °C followed by the addition of 1 N 
dimethylamine solution in THF (0.82 mL, 0.8116 mmol). The resulting reaction mixture was 
allowed to stir for 15 min at 0 °C, after which Na(AcO)3BH (0.1720 g, 0.8116 mmol) was added. 
The solution was then stirred at 0 °C for 1h and then at rt for another 1h. After 1 h, water (15 mL) 
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was added, followed by the extraction of the organic layer with dichloromethane (2 x 20 mL). The 
combined organic layer was dried over Na2SO4, and evaporated to get a crude residue which was 
purified on a silica gel column using 5 %- 20 % methanol-dichloromethane, to afford 201 as brown 
oil; 59%; 1H NMR (500 MHz, CDCl3): δ 9.27 (s, 1H), 7.76 (d, 1H, J = 9.1 Hz), 7.55 (d, 1H, J = 
9.0 Hz), 7.20 (d, 1H, J = 3.6 Hz), 4.07 (s, 3H), 4.04 (s, 3H), 4.03 (s, 3H), 3.91 (s, 3H), 3.30 (t, 2H, 
J = 8.1 Hz), 2.72 (t, 2H, J = 8.3 Hz), 2.44 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 150.3, 148.8, 
148.4, 144.8, 132.9, 128.2, 125.5, 124.8, 124.7, 124.3, 120.6, 113.9, 108.9, 107.7, 60.7, 60.0, 56.7, 
56.5, 45.2 (x 2), 32.3, 29.7; HRESIMS: calcd for C22H28NO4 [M+H]
+ 370.2018; found 370.2010 
 
C) Synthesis of fused indole aporphine analogues: 
ethyl 1-(3-ethoxy-3-oxopropyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(214): To a solution of compound 212 (5.0 g, 19.7 mmol) in formic acid (50 mL) was added 
compound 213 (4.15 g, 23.6 mmol). The resulting solution was stirred at room temperature for 16 
h. After 16 h formic acid was evaporated followed by the addition of water (40 mL). The resulting 
mixture was extracted with dichloromethane (3 x 30 mL). The combined organic layer was dried 
over Na2SO4, and evaporated to get a crude residue which was purified on a silica gel column 
using 20 %- 40 % ethylacetate-hexane, to afford 214 as a brown oil; 67 %; 1H NMR (500 MHz, 
CDCl3): δ 6.59 (s, 1H), 6.55 (s, 1H), 4.13-4.04 (m, 2H), 3.84 (s, 6H), 3.43 (t, 3H, J = 2.8 Hz), 3.06-
3.01 (m, 1H), 2.68 (t, 2H, J = 5.6 Hz), 2.63-2.58 (m, 1H), 2.42-2.34 (merged, 4H), 2.20-2.13 (m, 
2H), 2.06-1.98 (m, 1H), 1.23 (t, 3H, J = 7.1 Hz); 13C NMR (125 MHz, CDCl3): δ 174.3, 147.3, 
147.2, 129.1, 127.2, 111.1, 109.9, 62.5, 60.1, 55.9, 55.8, 51.4, 48.5, 42.9, 30.0, 29.8, 25.9, 14.2; 
HRESIMS: calcd for C18H25NO6 [M+Na]




(215): Compound 214 (4.5 g, 12.32 mmol) was dissolved in ethanol (100 mL) followed by the 
addition of 20 % NaOH solution (20 mL). The resulting reaction mixture was allowed to stir under 
reflux conditions for 2 h. After 2 h the organic layers were evaporated under vacuum, followed by 
addition of 1 N HCl (25 mL) to adjust the pH to 1. The resulting aqueous solution was extracted 
with ethyl acetate (3 x 30 mL). The combined organic layer was dried over Na2SO4, and evaporated 
to dryness to afford 215 as clear oil; 99 %. 215 was used without further purification. 
ethyl 5,6-dimethoxy-7-oxo-2,3,7,8,9,9a-hexahydro-1H-benzo[de]quinoline-1-carboxylate 
(211): To an ice cooled solution of compound 215 (4.0 g, 11.86 mmol) in anhydrous 
dichloromethane (60 mL), trifluoroacetic anhydride (1.84 mL, 2.74 g, 13.05 mmol) and 
trifluoroacetic acid (0.14 mL, 0.21 g, 1.86 mmol) were added. The resulting solution was stirred 
at room temperature for 4 h. After 4 h, the organic layers were evaporated followed by addition of 
1N NaOH (20 mL). The resulting mixture was extracted with dichloromethane (3 x 30 mL). The 
combined organic layers were dried over Na2SO4, and evaporated to get a crude residue which was 
purified on a silica gel column using 10 %- 40 % ethyl acetate-hexanes to afford 211 as a brown 
solid; 67%; mp 93 °C-97 °C; 1H NMR (500 MHz, CDCl3): δ 6.88 (s, 1H), 4.80 (dd, 1H, J = 12.1, 
2.4 Hz), 4.44 (d, 1H, J = 9.3 Hz), 4.25-4.19 (m, 2H), 3.88 (d, 6H, J = 6.9 Hz), 2.90-2.82 (m, 2H), 
2.79-2.68 (m, 2H), 2.67-2.64 (m, 1H), 2.32 (t, 1H, J = 6.0 Hz), 1.99-1.90 (m, 1H), 1.93 (t, 3H, J = 
6.9 Hz); 13C NMR (125 MHz, CDCl3): δ 196.1, 155.2, 152.1, 147.9, 131.1, 130.1, 126.4, 116.8, 
61.7, 61.5, 56.1, 51.1, 38.7, 38.3, 30.3, 27.9, 14.7; HRESIMS: calcd for C17H21NO5 [M+Na]
+ 
342.1318; found 342.1314 
General procedure for the synthesis of 217a–d 
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To a solution of 211 (0.1 g, 0.3132 mmol) and appropriate phenyl hydrazine (0.93 mmol) in 
anhydrous toluene (20 mL), trifluoroacetic acid (0.19 mL, 2.5 mmol) was added. The resulting 
mixture was heated for 3 h. After 3 h, the mixture was cooled, followed by the addition of saturated 
NaHCO3 (20 mL). The resulting mixture was extracted with ethyl acetate (3 x 20 mL). The 
combined organic layer was dried over Na2SO4, and evaporated to dryness. The resulting crude 
was purified on a silica gel column (5-50 % ethyl acetate-hexanes)  
ethyl 1,2-dimethoxy-4,6a,7,12-tetrahydroisoquinolino[8,1-ab]carbazole-6(5H)-carboxylate 
(217a): Brown solid; 93 %; mp 154 °C-157 °C;  1H NMR (500 MHz, CDCl3): δ 10.02 (s, 1H), 
8.13 (d, 1H, J = 7.8 Hz), 8.07 (d, 1H, J = 8.8 Hz), 7.74 (d, 1H, J = 8.7 Hz), 7.62 (d, 1H, J = 8.1 
Hz), 7.45 (t, 1H, J = 7.3 Hz), 7.29 (t, 1H, J = 7.7 Hz), 7.16 (s, 1H), 4.73 (s, 1H), 4.17-4.14 (merged, 
5H), 4.04 (s, 3H), 3.60 (d, 2H, J = 6.0 Hz), 3.34 (t, 2H, J = 6.3 Hz), 1.25 (t, 3H, J = 6.9 Hz); 13C 
NMR (125 MHz, CDCl3): δ 156.7, 147.6, 142.1, 138.0, 133.9, 132.2, 126.7, 124.7, 122.8, 119.7, 
119.5, 118.3, 118.0, 115.2, 114.9, 111.1, 61.1, 60.8, 56.8, 41.6, 34.1, 14.7; HRESIMS: calcd for 
C23H24N2O4 [M+Na]
+ 415.1634; found 415.1628 
ethyl 9-fluoro-1,2-dimethoxy-4,6a,7,12-tetrahydroisoquinolino[8,1-ab]carbazole-6(5H)-
carboxylate (217b): Light brown solid; 96 %; mp 163 °C-165 °C; 1H NMR (500 MHz, CDCl3): 
δ 10.00 (s, 1H), 7.98 (d, 1H, J = 8.5 Hz), 7.75 (td, 2H, J = 9, 2.5 Hz), 7.53 (dd, 1H, J = 9.0, 4.5 
Hz), 7.22-7.16 (m, 2H), 4.74 (s, 1H), 4.17-4.13 (merged, 5H), 4.04 (s, 3H), 3.59 (d, 2H, J = 6.5 
Hz), 3.34 (t, 2H, J = 7.0 Hz), 1.25 (t, 3H, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3): δ 158.6, 
156.7, 156.6, 147.7, 135.2, 134.4, 132.38, 132.36, 126.9, 123.3, 123.2, 118.2, 117.9, 117.4, 115.3, 
112.9, 112.7, 111.7, 111.6, 105.1, 104.9, 61.22, 61.22, 60.8, 56.8, 41.7, 34.1, 14.7; HRESIMS: 
calcd for C23H23FN2O4 [M+Na]




carboxylate (217c): Light brown solid; 89 %; mp 167 °C -170 °C;  1H NMR (500 MHz, CDCl3): 
δ 10.04 (s, 1H), 8.24 (s, 1H), 7.98 (d, 1H, J = 8.5 Hz), 7.75 (d, 1H, J = 9.0 Hz), 7.53-7.48 (m, 2H), 
7.18 (s, 1H), 4.74 (s, 1H), 4.17-4.13 (merged, 5H), 4.04 (s, 3H), 3.59 (d, 2H, J = 6.5 Hz), 3.33 (t, 
2H, J = 6.5 Hz), 1.25 (t, 3H, J = 7.0 Hz); 13C NMR (125 MHz, CDCl3): δ 156.6, 147.7, 142.2, 
136.6, 134.6, 132.4, 127.4, 126.9, 124.6, 122.4, 117.7, 117.5, 117.3, 115.7, 115.4, 112.5, 112.4, 
61.24, 60.8, 56.8, 41.7, 34.1, 14.7; HRESIMS: calcd for C23H23ClN2O4 [M+Na]
+ 449.1244; found 
449.1238 
ethyl 1,2,9-trimethoxy-4,6a,7,12-tetrahydroisoquinolino[8,1-ab]carbazole-6(5H)-
carboxylate (217d): Light brown solid; 85 %; mp 146 °C-150 °C; 1H NMR (500 MHz, CDCl3): 
δ 9.91 (s, 1H), 8.01 (d, 1H, J = 9.0 Hz), 7.70 (d, 1H, J = 8.5 Hz), 7.58 (s, 1H), 7.51 (d, 1H, J = 9.0 
Hz), 7.15 (s, 1H), 7.10 (dd, 1H, J = 8.5, 2 Hz), 4.74 (s, 1H), 4.17-4.13 (merged, 5H), 4.03 (s, 3H), 
3.96 (s, 3H), 3.60 (d, 2H, J = 6.0 Hz), 3.33 (t, 2H, J = 6.5 Hz), 1.25 (t, 3H, J = 7.0 Hz); 13C NMR 
(125 MHz, CDCl3): δ 156.6, 154.0, 147.6, 134.6, 133.1, 132.2, 126.7, 123.2, 118.2, 118.0, 117.5, 
115.0, 114.7, 114.5, 111.8, 101.9, 61.1, 60.8, 56.8, 56.0, 41.6, 34.1, 14.7; HRESIMS: calcd for 
C24H26N2O5 [M+Na]
+ 445.1740; found 445.1735 
methyl 4-((3,4-dimethoxyphenethyl)(methyl)amino)-4-oxobutanoate (228): 227 (10.0 g, 51.28 
mmol) and succinic anhydride (5.28 g, 52.82 mmol) were dissolved in anhydrous toluene (100 
mL). The resulting solution was refluxed for 3 h. The reaction mixture was cooled to rt and organic 
layer was evaporated. The resulting crude was dissolved in dichloromethane (100 mL) and washed 
with water (3 x 30 mL). The combined organic layer was dried over Na2SO4, and evaporated to 
dryness to afford the intermediate acid as a brown oil which was used without further purification 
(16g crude). The crude was dissolved in anhydrous methanol (100 mL) followed by the addition 
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of conc. H2SO4 (0.5 mL). The resulting reaction mixture was refluxed for 30 min. After cooling 
the reaction to rt, methanol was evaporated under vacuum. The resulting crude was dissolved in 
dichloromethane (100 mL) which was washed first with water (2 x 30 mL) and then saturated 
NaHCO3 (2 x 30 mL). The combined organic layer was dried over Na2SO4, and evaporated to 
dryness. The resulting crude was purified on a silica gel column (1-5 % MeOH-CH2Cl2) to afford 
228 as light brown oil; 70 %; (a mixture of rotamers as evident from NMR data-all signals observed 
are reported); 1H NMR (500 MHz, CDCl3): δ 6.81-6.70 (m, 3H), 3.84 (s, 3H), 3.82 (s, 3H), 3.65 
(d, 3H, J = 14.8 Hz), 3.53 (q, 2H, J = 7.5 Hz), 2.90 (s, 3H), 2.78 (dt, 2H, J = 23.0, 6.9 Hz ), 2.60 
(dt, 2H, J = 26.7, 5.7 Hz), 2.51 (t, 1H, J = 6.5 Hz), 2.39 (t, 1H, J = 6.5 Hz); 13C NMR (125 MHz, 
CDCl3) δ 173.4, 173.4, 171.0, 170.8, 149.1, 148.9, 147.8, 147.5, 131.7, 130.8, 120.8, 120.7, 112.1, 
111.6, 111.4, 55.88, 55.82, 51.58, 51.52, 51.4, 50.1, 35.7, 34.1, 33.5, 33.2, 29.1, 29.0, 28.3, 27.5; 
HRESIMS: calcd for C16H24NO5 [M+H]
+ 310.1654; found 310.1682 
methyl 3-(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propanoate (230): 
Compound 228 (11.0 g, 35.59 mmol) was dissolved in anhydrous toluene (100 mL) followed by 
the addition of POCl3 (16.52 mL, 27.27 g, 177.95 mmol). The reaction mixture was refluxed for 6 
h after which it was cooled to rt. The reaction mixture was evaporated under vacuum to get a light 
brown viscous oil (229) which was used without further purification. Crude 229 was then dissolved 
in anhydrous methanol (100 mL) and cooled to 0 ºC. To this solution, NaBH4 (9.78 g, 257 mmol) 
was added in several portions while maintaining the temperature 0 ºC. The resulting reaction 
mixture was allowed to stir for 4 h. After 4 h, methanol was evaporated under vacuum and 
saturated NaHCO3 (100 mL) was added. The aqueous layer was then extracted with 
dichloromethane (5 x 30 mL). The combined organic layer was dried over Na2SO4, and evaporated 
to dryness. The resulting crude was purified on a silica gel column (1-5 % MeOH-CH2Cl2) to 
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afford 230 as a light brown oil: 52 % from 228; 1H NMR (500 MHz, CDCl3): δ 6.59 (s, 1H), 6.55 
(s, 1H), 3.82 (s, 3H), 3.84 (s, 6H), 3.62 (s, 3H), 3.43 (s, 1H), 3.06-3.00 (m, 1H), 2.69-2.67 (m, 2H), 
2.63-2.58 (m, 1H), 2.45-2.38 (merged, m, 4H), 2.22-2.13 (m, 2H); 2.07-1.97 (m, 1H); 13C NMR 
(125 MHz, CDCl3): δ 174.7, 147.3, 147.2, 128.9, 127.2, 111.2, 109.8, 62.4, 55.9, 55.8, 51.3, 48.5, 
42.9, 29.7, 25.9; HRESIMS: calcd for C16H24NO4 [M+H]
+ 294.1705; found 294.1703 
sodium 3-(6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)propanoate (231): 
Compound 230 (5.5 g, 17.91 mmol) was dissolved in ethanol (70 mL) followed by addition of 10 % 
aq. NaOH (20 mL). The resulting solution was refluxed for 30 min. The reaction mixture was 
cooled to rt and evaporated to dryness. The crude mixture was then azeotroped with toluene (3 x 
100 mL), evaporated to dryness and used without further purification. 
5,6-dimethoxy-1-methyl-1,2,3,8,9,9a-hexahydro-7H-benzo[de]quinolin-7-one (226): Crude 
231 (7.3 g) was added to a three neck round bottom flask under argon atmosphere and was cooled 
to 0 ºC. To this flask, trifluoroacetic acid (0.77 ml, 1.15 g, 10.12 mmol) was carefully added, 
followed by the addition of trifluoroacetic anhydride (14.8 mL, 21.25 g, 101.2 mmol) at 0 ºC. The 
resulting reaction mixture was then allowed to stir at rt for 16 h. After 16 h the reaction mixture 
was evaporated under vacuum followed by careful addition of 10 % aq. NaOH (30 mL) to adjust 
pH to 8. The aqueous layer was then extracted with dichloromethane (4 x 30 mL). The combined 
organic layers were dried over Na2SO4, and evaporated to dryness. The resulting crude was then 
purified on a silica gel column (1-5 % MeOH-CH2Cl2) to afford 236 as dark brown oil; 33 %; 1H 
NMR (500 MHz, CDCl3): δ 6.84 (s, 1H), 3.86 (merged d, 6H, J = 5.3 Hz), 3.17–3.05  (m, 3H), 
2.81-2.75 (m, 1H), 2.72-2.69 (m, 1H), 2.59-2.51 (m, 2H), 2.50 (s, 3H), 2.44-2.41 (m, 1H), 1.76-
1.67 (m, 1H) ; 13C NMR (125 MHz, CDCl3): δ 197.0, 152.1, 147.8, 132.8, 129.2, 125.6, 118.0, 
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62.2, 61.4, 56.1, 53.4, 43.1, 38.5, 28.7, 27.4; HRESIMS: calcd for C15H20NO3 [M+H]
+ 262.1443; 
found 262.1442 
General procedure for the synthesis of 218a–i 
To a solution of 226 (0.1 g, 0.3132 mmol) and appropriate phenyl hydrazine (0.93 mmol) in 
anhydrous toluene (20 mL), trifluoroacetic acid (0.19 mL, 0.28 g, 2.5 mmol) was added. The 
resulting mixture was refluxed for 3 h. After 3 h, the mixture was cooled, followed by the addition 
of saturated NaHCO3 (20 mL). The resulting mixture was extracted with dichloromethane (3 x 20 
ml). The combined organic layer was dried over Na2SO4, and evaporated to dryness. The resulting 
crude was purified on a silica gel column (1-10 % MeOH-CH2Cl2) 
1,2-dimethoxy-6-methyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole (218a): Light 
brown solid; 45 %; mp 113 °C-117 °C; 1H NMR (500 MHz, CDCl3): δ 9.34 (s, 1H), 7.59 (d, 1H, 
J = 8.0 Hz), 7.42 (d, 1H, J = 8.5 Hz), 7.19 (t, 1H, J = 7.0 Hz), 7.13 (t, 1H, J = 7.0 Hz), 6.54 (s, 
1H), 3.90 (s, 3H), 3.89 (s, 3H), 3.44 (dd 1H, J = 12.0, 6.0 Hz), 3.40-3.35 (m, 1H), 3.21-3.14 (m, 
1H), 3.10 (dd, 1H, J = 11.5, 6.0 Hz), 2.68-2.63 (m, 2H), 2.60 (s, 3H), 2.55 (dd, 1H, J = 12.0, 3.0 
Hz); 13C NMR (125 MHz, CDCl3): δ 151.1, 142.2, 136.4, 130.8, 130.7, 126.2, 125.6, 122.2, 121.1, 
119.5, 118.4, 111.2, 110.7, 110.6, 63.0, 60.9, 55.7, 54.0, 44.1, 29.3, 25.3; HRESIMS: calcd for 
C21H23N2O2 [M+H]
+ 335.1759; found 335.1758 
9-fluoro-1,2-dimethoxy-6-methyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole 
(218b): Light brown solid; 30 %; mp116 °C-119 °C; 1H NMR (500 MHz, CDCl3): δ 9.34 (s, 1H), 
7.32 (dd, 1H, J = 8.5, 4.0 Hz), 7.21 (dd, 1H, J = 9.5, 2.5 Hz), 6. 93 (td, 1H, J = 9.0, 2.5 Hz), 6.55 
(s, 1H), 3.91 (s, 3H), 3.88 (s, 3H), 3.39-3.33 (m, 2H), 3.21-3.1 (m, 2H), 2.66 (d, 2H, J = 17.5 Hz), 
2.60 (s, 3H), 2.56 (dd, 1H, J = 12.0, 3.5 Hz); 13C NMR (125 MHz, CDCl3): δ 158.8, 156.9, 151.1, 
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142.3, 132.8, 132.5, 130.8, 126.5, 126.4, 120.7, 111.8, 111.7, 111.0, 110.5, 110.3, 103.3, 103.1, 




(218c): Light brown solid; 56 %; mp126 °C-130 °C; 1H NMR (500 MHz, CDCl3): δ 9.36 (s, 1H), 
7.54 (s, 1H), 7.32 (d, 1H, J = 8.6 Hz), 7. 13 (dd, 1H, J = 8.6, 2.0 Hz), 6.56 (s, 1H), 3.91 (s, 3H), 
3.89 (s, 3H), 3.39-3.35 (m, 2H), 3.20-3.08 (m, 2H), 2.68-2.62 (m, 2H), 2.62 (s, 3H), 2.54 (dd, 1H, 
J = 11.6, 3.4 Hz); 13C NMR (125 MHz, CDCl3): δ 151.1, 142.3, 134.6, 132.2, 130.9, 127.3, 125.6, 
125.2, 122.3, 120.6, 117.9, 112.1, 111.1, 110.3, 62.8, 60.9, 55.7, 54.0, 44.0, 29.3, 25.1; HRESIMS: 
calcd for C21H22ClN2O2 [M+H]
+ 369.1370; found 369.1371 
9-bromo-1,2-dimethoxy-6-methyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole 
(218d): Light brown solid; 30 %; mp 134 °C-137 °C; 1H NMR (500 MHz, CDCl3): δ 9.38 (s, 1H), 
7.70 (s, 1H), 7.28-7.23 (merged, 2H), 6.54 (s, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.38-3.32 (m, 2H), 
3.19-3.07 (m, 2H), 2.66-2.61 (m, 2H), 2.57 (s, 3H), 2.53 (dd, 1H, J = 11.6, 3.6 Hz); 13C NMR 
(125 MHz, CDCl3): δ 151.1, 142.3, 134.9, 132.0, 130.8, 127.9, 125.5, 124.8, 120.9, 120.5, 112.7, 
112.6, 111.1, 110.1, 62.8, 60.9, 55.7, 53.9, 44.0, 29.2, 25.1; HRESIMS: calcd for C21H22BrN2O2 
[M+H]+ 413.0864; found 413.0859 
1,2,9-trimethoxy-6-methyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole (218e): 
Light brown solid; 60 %; mp 118 °C-121 °C; 1H NMR (500 MHz, CDCl3): δ 9.25 (s, 1H), 7.31 
(d, 1H, J = 8.7 Hz), 7.01 (s, 1H), 6.86 (d, 1H, J = 8.7 Hz), 6.53 (s, 1H), 3.90-3.88 (merged, 9H), 
3.41-3.35 (m, 2H), 3.21-3.10 (m, 2H), 2.66 (d, 2H, J = 15.6 Hz), 2.61 (s, 3H), 2.59-2.55 (m, 1H); 
13C NMR (125 MHz, CDCl3): δ 154.1, 151.1, 142.0, 131.5, 131.4, 130.6, 126.3, 125.3, 121.1, 
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112.7, 112.0, 110.5, 110.4, 99.7, 62.9, 60.8, 55.8, 55.7, 53.9, 44.0, 29.2, 25.2; HRESIMS: calcd 
for C22H24N2O3 [M+H]
+ 365.1865; found 365.1866 
1,2-dimethoxy-6-methyl-9-(trifluoromethoxy)-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-
ab]carbazole (218f): Light brown solid; 57 %; mp 123 °C-126 °C; 1H NMR (500 MHz, CDCl3): 
δ 9.43 (s, 1H), 7.42 (s, 1H), 7.38 (d, 1H, J = 8.7 Hz), 7.05 (d, 1H, J = 8.8 Hz), 6.57 (s, 1H), 3.91 
(s, 3H), 3.89 (s, 3H), 3.40-3.34 (m, 2H), 3.20-3.12 (m, 2H), 3.11-3.08 (m, 2H), 2.68 (t, 2H, J = 3.4 
Hz), 2.67-2.62 (m, 1H), 2.66 (s, 3H), 2.54 (dd, 1H, J = 11.6, 3.4 Hz) ; 13C NMR (125 MHz, CDCl3): 
δ 152.2, 142.5, 141.9, 135.4, 131.2, 128.2, 125.2, 121.4, 120.4, 119.4, 119.3, 115.7, 113.5, 111.5, 
110.4, 108.1, 60.9, 60.8, 60.5, 55.8, 51.7, 40.8, 25.6, 21.7; HRESIMS: calcd for C22H22F3N2O3 
[M+H]+ 406.1633; found 406.1642 
1,2-dimethoxy-6,9-dimethyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole (218g): 
Light brown solid; 76 %; mp 137 °C-141 °C: 1H NMR (500 MHz, CDCl3): δ 9.24 (s, 1H), 7.38 
(s, 1H), 7.31 (d, 1H, J = 10.5 Hz), 7.02 (d, 1H, J = 9.0 Hz), 6.53 (s, 1H), 3.89 (d, 6H, J = 5.0 Hz), 
3.44-3.35 (m, 2H), 3.21-3.09 (m, 2H), 2.65 (d, 2H, J = 16.5 Hz), 2.60 (s, 3H), 2.57-2.55 (m, 1H), 
2.46 (s, 3H);  13C NMR (125 MHz, CDCl3): δ 151.1, 142.1, 134.7, 130.8, 130.7, 128.7, 126.4, 
125.5, 123.9, 121.3, 118.0, 110.9, 110.5, 110.2, 63.0, 60.9, 55.7, 54.0, 44.0, 29.3, 25.2, 21.5; 
HRESIMS: calcd for C22H25N2O2 [M+H]
+ 349.1916; found 349.1916 
11-chloro-1,2-dimethoxy-6-methyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole 
(218h): Light brown solid; 48 %; mp 124°C-128 °C; 1H NMR (500 MHz, CDCl3): δ 9.51 (s, 1H), 
7.47 (d, 1H, J = 7.9 Hz), 7.18 (d, 1H, J = 7.0 Hz), 7.06 (t, 1H, J = 7.8 Hz), 6.57 (s, 1H), 3.94 (s, 
3H), 3.89 (s, 3H), 3.42 (dd, 1H, J = 14.0, 4.3 Hz), 3.30-3.20 (broad, 2H), 2.76-2.66 (merged, 6H); 
13C NMR (125 MHz, CDCl3): δ 151.1, 142.2, 136.4, 130.8, 130.7, 126.2, 125.6, 122.2, 121.1, 
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119.5, 118.4, 111.2, 110.7, 110.6, 63.0, 60.9, 55.7, 54.0, 44.1, 29.3, 25.3; HRESIMS: calcd for 
C21H22ClN2O2 [M+H]
+ 367.1370; found 367.1370 
11-bromo-1,2-dimethoxy-6-methyl-4,5,6,6a,7,12-hexahydroisoquinolino[8,1-ab]carbazole 
(218j): Light brown solid; 37 %; mp 131°C-135 °C; 1H NMR (500 MHz, CDCl3): δ 9.50 (s, 1H), 
7.52 (d, 1H, J = 7.5 Hz), 7.33 (d, 1H, J = 7.5 Hz), 7.00 (t, 1H, J = 7.5 Hz), 6.57 (s, 1H), 3.94 (s, 
3H), 3.89 (s, 3H), 3.42-3.36 (m, 2H), 3.21-3.09 (m, 2H), 2.67 (d, 2H, J = 15.5 Hz); 2.59 (s, 3H), 
2.55 (dd, 1H, J = 12, 4 Hz) 13C NMR (125 MHz, CDCl3): δ 151.2, 142.4, 135.0, 131.4, 130.8, 
127.3, 125.5, 124.3, 120.6, 120.5, 117.5, 111.6, 111.2, 104.7, 62.8, 60.9, 55.8, 54.0, 44.0, 29.3, 
25.5; HRESIMS: calcd for C21H22BrN2O2 [M+H]
+ 413.0864; found 413.0858 
 
D) Synthesis of C3 analogues: 
 (E)-2-(benzyloxy)-1-methoxy-4-(2-nitrovinyl)benzene (235): Compound 234 (15 g, 61.98 
mmol) was dissolved in acetic acid (100 mL) followed by the addition of ammonium acetate (2.04 
g, 61.98 mmol) and nitromethane (16.5 mL, 18.91 g, 309.9 mmol). The resulting reaction mixture 
was heated under reflux conditions for a 6 h. After 6 h the reaction mixture was allowed to cool at 
rt and allowed to stand overnight at rt. The crushed out product was then subject to vacuum 
filtration to afford compound 235 as yellow crystals; 94 %; mp121 °C-123 °C; 1H NMR (500 
MHz, CDCl3): δ 7.90 (dd, 1H, J = 13.5, 1.4 Hz), 7.45–7.38 (m, 5H), 7.34-7.31 (m, 1H), 7.19–7.15 
(m, 1H), 7.03 (s, 1H), 6.92 (dd, 1H, J = 8.3, 0.5 Hz), 5.17 (s, 2H), 3.94 (s, 3H); 13C NMR (125 
MHz, CDCl3): δ 153.4, 148.5, 139.3, 136.2, 135.0, 128.7, 128.2, 127.3, 124.9, 122.5, 112.9, 111.6, 
71.0, 56.1; HRESIMS: calcd for C16H16NO4 [M+H]
+ 286.1079; found 286.1088 
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2-(3-(benzyloxy)-4-methoxyphenyl)ethan-1-amine (236): LiBH4 (4.8 g, 224.5 mmol) was 
carefully added to a three necked round bottom flask under nitrogen atmosphere followed by the 
careful addition of anhydrous THF (150 mL). To this suspension, TMSCl (57.18 mL, 48.95 g, 
449.1 mmol) was carefully added over a period of 15 minutes. The resulting reaction mixture was 
allowed to stir at rt for 15 additional minutes after which compound 235 (16.0 g, 56.14 mmol) was 
added in several portions over a period of 30 min. The resulting reaction mixture was heated under 
reflux conditions for 6 h. After 6 h the reaction mixture was first cooled to rt and then at 0 °C, 
followed by the careful addition of methanol (100 mL) over a period of 30 min. After the reaction 
mixture was quenched, the organic layers were evaporated under vacuum. The resulting crude was 
then cooled to 0 °C, followed by the careful addition of 20 % KOH (30 mL) to adjust the pH to 8. 
The resulting crude was then extracted with dichloromethane (4 x 30 ml). The combined organic 
layer was dried over Na2SO4 and evaporated to dryness under vacuum to afford 236 as a light 
brown oil: 69 %. Compound 98 was used without further purification.  
N-(3-(benzyloxy)-4-methoxyphenethyl)-2-(6-bromobenzo[d][1,3]dioxol-5-yl)acetamide (237): 
A solution of bromoacid 158 (5.55 g, 21.38 mmol) in anhydrous THF (100 mL) under N2 
atmosphere was cooled to 0 ºC. To this solution CDI (3.14 g, 19.43 mmol) was added in three 
portions over a period of 30 min at 0 ºC. The resulting reaction mixture was allowed to stir for 1.5 
h at 0 ºC, after which the temperature was raised to rt and allowed to stir for another 1 h. The 
solution was again cooled to 0 ºC and allowed to stir for 30 min, after which a solution of 236 (5 
g, 19.43 mmol) in 50 mL anhydrous THF was added over a period of 5 min. The resulting reaction 
mixture was allowed to stir for 30 min at 0 ºC and then at rt for another 15 h. After 15 h, the 
reaction mixture was filtered to collect pale yellow solid, which was washed with diethyl ether to 
afford a white solid as the first batch of product 237. The combined filtrate was evaporated to give 
109 
 
a crude mixture to which saturated NaHCO3 (40 mL) was added. The resulting mixture was 
extracted with dichloromethane (2 x 30 ml). The combined organic layer was dried over Na2SO4 
and evaporated to dryness under vacuum. The resulting crude was washed with diethyl ether 
followed by vacuum filtration to afford the second batch of product 237; white solid; 78 %; mp 
161 °C -163 °C; 1H NMR (500 MHz, CDCl3): δ 7.45 (d, 2H, J = 7.7 Hz), 7.39 (t, 2H, J = 7.4 Hz), 
7.33 (d, 1H, J = 7.5 Hz), 7.00 (s, 1H), 6.79 (d, 1H, J = 8.1 Hz), 6.74 (s, 1H), 6.69 (s, 1H), 6.66 (d, 
1H, J = 8.2 Hz), 5.98 (s, 2H), 5.38 (s, 1H), 5.12 (s, 2H), 3.88 (s, 3H), 3.55 (s, 2H), 3.44 (q, 2H, J 
= 6.5 Hz), 2.68 (t, 2H, J = 6.8 Hz); 13C NMR (125 MHz, CDCl3): δ 169.5, 148.4, 148.2, 147.8, 
147.7, 137.0, 130.9, 128.5, 127.8, 127.5, 127.3, 121.4, 115.2, 114.6, 112.8, 112.0, 110.9, 101.9, 
71.0, 56.0, 43.8, 40.5, 34.8; HRESIMS: calcd for C25H25BrNO4 [M+H]
+ 498.0916; found 
498.0916 
tert-butyl 6-(benzyloxy)-1-((6-bromobenzo[d][1,3]dioxol-5-yl)methyl)-7-methoxy-3,4-
dihydroisoquinoline-2(1H)-carboxylate (238): Compound 237  (7.5 g, 15.06 mmol) was 
dissolved in anhydrous dichloromethane (100 mL) and the resulting solution was cooled to 0 ºC 
and allowed to stir for 20 min. PCl5 (4.7 g, 22.5 mmol) was added in 3 portions over a period of 
30 min. The resulting reaction mixture was allowed to stir at 0 ºC for 30 min and then at rt for the 
next 18 h. To this reaction mixture saturated NaHCO3 (60 mL) was added and the organic layers 
were extracted with dichloromethane (3  30 mL). The combined organic layer was dried over 
Na2SO4, and evaporated under vacuum to get the intermediate imine as a pale yellow, which was 
used without further purification. Sodium borohydride (1.58 g, 41.66 mmol) was added to the 
solution of this imine (5.0 g, 10.41 mmol) in anhydrous methanol (100 mL) at 0 ºC. The reaction 
mixture was then brought to rt and allowed to stir for 6 h. After 6 h, methanol was evaporated to 
get a crude mixture, to which water (50 mL) was added, followed by extraction with ethyl acetate 
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(3  30 mL). The combined organic layer was dried over Na2SO4, and evaporated under vacuum 
to get an intermediate amine, which was used in the next step without purification. The crude 
amine (4.8 g, 9.95 mmol), (Boc)2O  (3.42 mL, 3.25 g, 14.9 mmol) and DIPEA (3.46 mL, 2.57 g, 
19.9 mmol) and DMAP (catalytic) were dissolved in anhydrous dichloromethane (100 mL). The 
resulting reaction mixture was stirred at rt for 16 h. After 16 h, the reaction mixture was evaporated 
to dryness and the crude was purified on silica gel eluting with 30 % ethyl acetate-petroleum ether 
to afford 238 as a white solid; 70 % (over 3 steps); mp 131 °C-133 °C; 1H NMR (500 MHz, 
CDCl3): δ 7.47 (d, 2H, J = 7.4 Hz), 7.39 (t, 2H, J = 7.5 Hz), 7.33 (t, 1H, J = 7.0 Hz), 7.06-7.01 
(1H), 6.82 & 6.64-6.62 (1H), 6.67 (s, 1H), 6.60 (s, 1H), 5.97-5.90 (dd, 2H, J = 24.0, 6.2 Hz), 5.36-
5.30 (m 1H), 5.15-5.14 (s, 2H), 4.37-4.33 & 4.00-3.98 (1H), 3.89 & 3.80 (3H), 3.27-3.18 (m, 2H), 
3.00-2.75 (m, 2H), 2.61 (d, 1H, J = 16.0 Hz), 1.39-1.22 (9H); 13C NMR (125 MHz, CDCl3): δ 
169.5, 148.4, 148.2, 147.8, 147.7, 137.0, 130.9, 128.5, 127.8, 127.5, 127.3, 121.4, 115.2, 114.6, 
112.8, 112.0, 110.9, 101.9, 71.0, 56.0, 43.8, 40.5, 34.8; HRESIMS: calcd for C30H32BrNO6 
[M+Na]+ 604.1311; found 604.1301 
tert-butyl 2-(benzyloxy)-1-methoxy-4,5,6a,7-tetrahydro-6H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinoline-6-carboxylate (239): Compound 238 (0.2 g, 0.34 mmol), Pd(OAc)2 (0.015 
g, 0.068 mmol), K2CO3 (0.093 g, 0.68 mmol) and di-tert-butyl methyl phosphonium 
tetrafluoroborate (0.069 g, 0.028 mmol) were dissolved in DMSO (1 mL) in a 10 mL microwave 
reaction vial. The reaction mixture was then irradiated with microwaves at 140 ºC, 200 psi for 15 
min. The resulting crude was purified directly on a silica gel column chromatography using 30 % 
ethyl acetate-petroleum ether to afford 239 as a white solid; 93 %; mp 169 °C-173 °C; 1H NMR 
(500 MHz, CDCl3): δ 8.04 (s, 1H), 7.50 (d, 2H, J = 7.6 Hz), 7.42 (t, 2H, J = 7.4 Hz), 7.36 (t, 1H, 
J = 7.5 Hz), 6.77 (s, 1H), 6.71 (s, 1H), 6.00 (s, 2H), 5.16 (q, 2H, J = 11.8 Hz), 4.65 (d, 1H, J = 
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11.3 Hz), 4.41 (d, 1H, J = 7.8 Hz), 3.74 (s, 3H), 2.95-2.74 (m, 4H), 2.62 (d, 2H, J = 14.8 Hz), 1.51 
(s, 9H); 13C NMR (125 MHz, CDCl3): δ 151.1, 146.6, 146.5, 145.4, 137.1, 131.5, 129.7, 128.6, 
127.9, 127.3, 126.4, 125.2, 112.8, 109.0, 108.3, 108.3, 100.9, 79.8, 70.9, 60.1, 51.7, 30.3, 28.5; 
HRESIMS: calcd for C30H31NO6 [M+Na]
+ 524.2049; found 524.2045 
tert-butyl 2-hydroxy-1-methoxy-4,5,6a,7-tetrahydro-6H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinoline-6-carboxylate (240): Compound 239 (4.0 g, 7.98 mmol) was dissolved in 
a 1:1 mixture of anhydrous methanol-THF (150 mL) followed by the addition of 10 % Pd/C (15 
mg). The resulting suspension was stirred for 6 h under hydrogen atmosphere. After 6 h, the 
reaction mixture was subjected to vacuum filtration over celite. The filtrate was then evaporated 
under reduced pressure to afford a crude residue, which was purified using silica gel column 
chromatography in 30 % ethyl acetate – petroleum ether to afford 240 as a white solid; 88 % ; mp 
218 °C-221 °C; 1H NMR (500 MHz, CDCl3): δ 7.87 (s, 1H), 6.76 (s, 1H), 6.70 (s, 1H), 5.99 (s, 
2H), 5.88 (s, 1H), 4.59 (d, 1H, J = 10.3 Hz), 4.38 (br, 1H), 3.58 (s, 3H), 2.92-2.87 (m, 2H), 2.82-
2.70 (m, 2H), 2.61 (d, 1H, J = 15.8 Hz), 1.49 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 154.9, 148.0, 
146.8, 146.8, 142.5, 131.5, 131.0, 126.5, 125.4, 124.8, 124.7, 113.4, 108.6, 107.8, 101.0, 79.9, 
60.2, 51.7, 28.5; HRESIMS: calcd for C23H25NO6 [M+Na]
+ 434.1580; found 434.1574 
tert-butyl 3-bromo-1,2-dimethoxy-4,5,6a,7-tetrahydro-6H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinoline-6-carboxylate (241): Compound 240 (2.80 g, 6.81 mmol) was dissolved 
in anhydrous dichloromethane (100 mL) followed by the addition of freshly re-crystalized NBS 
(1.44 g, 8.1 mmol). The resulting reaction mixture was stirred for 30 min under nitrogen 
atmosphere at rt. After 30 min water (20 mL) was added to the reaction mixture followed by 
extraction with dichloromethane (3 x 30 ml). The combined organic layer was dried over Na2SO4 
and evaporated to dryness under vacuum to afford a crude, which was purified using silica gel 
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column chromatography in 30 % ethyl acetate – petroleum ether to afford the corresponding 3-
bromo derivative; yellow solid; 68 %. This solid (2.26 g, 4.61 mmol) was then dissolved in 
anhydrous DMF (60 mL) followed by the addition of K2CO3 (0.95 g, 6.91 mmol) and methyl 
iodide (0.34 mL, 0.79g, 5.07 mmol). The resulting reaction mixture was allowed to stir at rt for 20 
h. After 20 h, the reaction mixture was first subject to vacuum filtration, followed by evaporating 
the filtrate under vacuum. 1N HCl (20 ml) was then added to the resulting crude, followed by 
extraction with dichloromethane (3 x 30 ml). The combined organic layer was dried over Na2SO4 
and evaporated to dryness under vacuum to afford a crude residue which was purified using silica 
gel column chromatography in 30 % ethyl acetate – petroleum ether to afford 241 as a light brown 
solid; 88 %; mp 164 °C-166 °C; 1H NMR (500 MHz, CDCl3): δ 7.93 (s, 1H), 6.75 (s, 1H), 5.98 
(s, 2H), 4.66 (br, 1H), 4.40 (d, 1H, J = 9.2 Hz), 3.92 (s, 3H), 3.73 (s, 3H), 3.00 (d, 1H, J = 16.0 
Hz), 2.88 (t, 1H, J = 13.0 Hz), 2.84–2.75 (m, 2H), 2.69–2.62 (m, 1H), 1.48 (s, 9H); 13C NMR (125 
MHz, CDCl3): δ 154.2, 150.0, 149.6, 146.8, 146.6, 131.4, 130.9, 130.1, 127.3, 124.5, 118.1, 108.8, 
108.4, 101.0, 80.0, 60.7, 60.3, 51.8, 30.6, 28.5; HRESIMS: calcd for C24H26BrNO6 [M+Na]
+ 
526.0842; found 526.0812 
tert-butyl 1,2-dimethoxy-3-phenyl-4,5,6a,7-tetrahydro-6H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinoline-6-carboxylate (242a): Compound 241 (0.1 g, 1.98 mmol), Pd(PPh3)4 
(0.014 g, 0.12 mmol), Phenyl boronic acid (0.026 g, 0.21 mmol) and 1M Na2CO3 (0.76 ml) were 
dissolved in anhydrous toluene (1 mL) in a 10 mL microwave reaction vial. The reaction mixture 
was then irradiated with microwaves at 120 ºC, 200 psi for 20 min. The reaction mixture was then 
evaporated under vacuum followed by the addition of saturated NaHCO3 (5 mL) to the crude. The 
aqueous layer was then extracted with dichloromethane (2 x 10 ml). The combined organic layer 
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was dried over Na2SO4 and evaporated under vacuum to afford a 9:1 inseparable mixture of 242a 
and 241 which was used in the next step without further purification 
1,2-dimethoxy-6-methyl-3-phenyl-5,6,6a,7-tetrahydro-4H-[1,3]dioxolo[4',5':4,5]benzo[1,2-
g]benzo[de]quinolone (233a): A mixture of 242a and 241 (0.085 g) was dissolved in anhydrous 
dichloromethane (10 mL) followed by addition of zinc bromide (0.15 g, 0.67 mmol). The resulting 
reaction mixture was stirred at rt for 16 h. After 16 h, saturated NaHCO3 (10 mL) was added to 
the reaction mixture followed by extraction with dichloromethane (2 x 20 ml). The combined 
organic layer was dried over Na2SO4 and evaporated under vacuum to afford the corresponding 
crude deprotected intermediate (0.06 g). The resulting crude was dissolved in anhydrous 
dichloromethane (10 mL) followed by the addition of 37 % formaldehyde solution in water (0.15 
mL, 1.49 mmol) and sodium triacetoxyborohydride (0.1 g, 0.350 mmol) and stirred for 16 h. After 
16 h, saturated NaHCO3 solution (20 mL) was added to the reaction mixture. The aqueous layers 
were then extracted with dichloromethane (2  20 mL). The combined organic layer was dried 
over Na2SO4, and evaporated under vacuum to get a crude product, which was purified on a 
preparative TLC plate using 0.02 % methanol-DCM as the solvent system to give 233a as a light 
brown solid; 67 %; mp 153 °C-157 °C;  1H NMR (500 MHz, CDCl3): δ 7.87 (s, 1H), 7.43 (t, 2H, 
J = 7.7 Hz), 7.37 (t, 1H, J = 1.2 Hz), 7.27 – 7.22 (merged, 2H), 6.77 (s, 1H), 5.98 (s, 2H), 3.75 (s, 
3H), 3.66 (s, 3H), 3.00 (dd, 2H, J = 14.3, 3.7 Hz), 2.90 (dd, 1H, J = 11.1, 5.3 Hz), 2.82 – 2.75 (m, 
1H), 2.58 (t, 1H, J = 14.3 Hz), 2.50 (s, 3H), 2.35 (td, 1H, J = 11.7, 3.7 Hz), 2.26 (dd, 1H, J = 16.7, 
3.4 Hz); 13C NMR (125 MHz, CDCl3): δ 150.0, 148.4, 146.4, 146.3, 137.0, 134.7, 130.9, 130.7, 
129.7, 129.2, 128.3, 128.1, 127.6, 127.0, 126.8, 125.3, 108.8, 108.1, 100.8, 63.2, 60.9, 60.2, 53.2, 
44.0, 34.9, 28.3; HRESIMS: calcd for C26H26NO4 [M+H]




2.6.2 Biological Evaluations: 
A) Primary and secondary radioligand binding assays:   
Both the assays were done at the PDSP facility. In the primary binding assays, compounds were 
usually tested at single concentrations (10 µM) in quadruplicate in 96-well plates. Compounds that 
showed a minimum of 50% inhibition at 10 µM were tagged for secondary radioligand binding 
assays to determine equilibrium binding affinity at specific targets. In the secondary binding assays, 
selected compounds were usually tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 300 nM, 
1, 3, 10 µM) and in triplicate (3 sets of 96-well plates). Both primary and secondary radioligand 
binding assays were carried out in a final of volume of 125 µl per well in appropriate binding 
buffer. The hot ligand concentration was usually at a concentration close to the Kd (unless 
otherwise indicated). Total binding and nonspecific binding were determined in the absence and 
presence of 10 µM appropriate reference compound, respectively. In brief, plates were usually 
incubated at room temperature and in the dark for 90 min (unless otherwise indicated). Reactions 
were stopped by vacuum filtration onto 0.3% polyethyleneimine (PEI) soaked 96-well filter mats 
using a 96-well Filtermate harvester, followed by three washes with cold wash buffer. Scintillation 
cocktail was then melted onto the microwave-dried filters on a hot plate and radioactivity was 
counted in a Microbeta counter.For detailed experimental details please refer to the PDSP website 
http://pdsp.med.unc.edu/ and click on ‘Binding Assay’ or ‘Functional Assay’ on the menu bar.  
 
B) FLIPR Calcium Mobilization Assay:  
Our collaborator Dr. Hernan Navarro has stably expressed the human 5-HT2A receptor in CHO-
K1 cells (ATCC). This clonal cell line was used to develop a robust FLIPR-based functional assay 
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for receptor activation. The calcium 4 dye assays (Molecular Devices, Sunnyvale, CA) were run 
according to manufacturer’s specifications. Briefly, wells of black clear bottom 96-well tissue 
culture treated plates were seeded with 20,000 cells the afternoon before assay. The day of assay, 
the cells were incubated with the calcium indicator dye for 1 hour at 37 °C. For antagonist assay 
the test compound was pre-incubated with the cells during the last 15 min of the dye incubation. 
The plate was then placed into FlexStation pre-warmed to 37 °C. Basal or unstimulated 
fluorescence intensity was recorded for 13 seconds followed by the addition of the test compound 
(intrinsic activity) or 5-HT (antagonist and Ke assays). Fluorescence intensity was recorded for an 
additional 47 seconds. The effect of test compound was determined by subtracting the minimum 
from the maximum florescence recorded for each well during the 47-seconds recording period. 
Thus, each well served as its own control. All samples were run in duplicate. For the agonist 
screening assays, the compounds were added directly to the cells and their effect on basal 
fluorescence was recorded. For the antagonist screening assays, the cells were pre-incubated with 
the test compounds for 15 minutes at 37 °C before the FlexStation added 5-HT at its EC80 (~20 
nM). Any compound that inhibits the effects of 5-HT by at least 50%, its apparent affinity (Ke) 
were determined (see below). On-plate controls for screening assays: It is important to monitor 
assay performance because cell responsiveness can change over 90 time. For this reason, a 6-point 
log-unit 5-HT curve, 1 mM ketanserin (selective for 5-HT2A receptor), and 1 mM SB 206553 
(selective for 5-HT2B/2C receptors) were run on each assay plate. If the EC50 value for 5-HT was 
more than two SD different from the historical average that assay plate had to be rerun. If a 
consistent shift in the 5-HT EC50 was observed, a new batch of 5-HT2A –expressing cells were 
used. Antagonists had their apparent affinity or Ke values determined by running a 8-point half log 
5-HT concentration response curve in the presence and absence of a single concentration of 
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antagonist. The EC50 values were calculated for 5-HT (A) and 5-HT + test compound (A`), and 
these were used to calculate the test compound Ke using the formula: Ke = [L]/(DR-1), where [L] 
equals to concentration of test compound in the assay and DR equals the dose ratio or A`/A. The 
concentration of antagonist was chosen such that it caused at least a 2-fold increase (shift to right) 
in the 5-HT curve. If an antagonist was found to produce an insurmountable inhibition of 5-HT, it 
was assumed to be acting in a noncompetitive manner. In these cases, the compound had its IC50 
determined by running a concentration response curve in presence of the 5-HT EC80. Assay 
performance for compound characterization was monitored as described above for the screening 
assays. In the case of the Ke experiments, the 5-HT curve also served to monitor assay performance. 
 
C) Cytotoxic Evaluations (NCI-60 DTP Human Tumor Cell Line Screen):  
The human tumor cell lines of the cancer screening panel were grown in RPMI 1640 medium 
containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, 
cells were inoculated into 96 well microtiter plates in 100 μL at plating densities ranging from 
5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After cell 
inoculation, the microtiter plates were incubated at 37 °C, 5 % CO2, 95 % air and 100 % relative 
humidity for 24 h prior to addition of experimental drugs. After 24 h, two plates of each cell line 
were fixed in situ with TCA, to represent a measurement of the cell population for each cell line 
at the time of drug addition (Tz). Experimental drugs were solubilized in dimethyl sulfoxide at 
400-fold the desired final maximum test concentration and stored frozen prior to use. At the time 
of drug addition, an aliquot of frozen concentrate was thawed and diluted to twice the desired final 
maximum test concentration with complete medium containing 50 μg/ml gentamicin. Additional 
four, 10-fold or ½ log serial dilutions were made to provide a total of five drug concentrations plus 
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control. Aliquots of 100 μl of these different drug dilutions were added to the appropriate microtiter 
wells already containing 100 μl of medium, resulting in the required final drug concentrations.  
Following drug addition, the plates were incubated for an additional 48 h at 37 °C, 5 % 
CO2, 95 % air, and 100 % relative humidity. For adherent cells, the assay was terminated by the 
addition of cold TCA. Cells were fixed in situ by the gentle addition of 50 μl of cold 50 % (w/v) 
TCA (final concentration, 10 % TCA) and incubated for 60 minutes at 4 °C. The supernatant was 
discarded, and the plates were washed five times with tap water and air dried. Sulforhodamine B 
(SRB) solution (100 μl) at 0.4 % (w/v) in 1 % acetic acid was added to each well, and plates were 
incubated for 10 minutes at room temperature. After staining, unbound dye was removed by 
washing five times with 1 % acetic acid and the plates were air dried. Bound stain was subsequently 
solubilized with 10 mM trizma base, and the absorbance was read on an automated plate reader at 
a wavelength of 515 nm. For suspension cells, the methodology was the same except that the assay 
was terminated by fixing settled cells at the bottom of the wells by gently adding 50 μl of 80 % 
TCA (final concentration, 16 % TCA). Using the seven absorbance measurements [time zero, (Tz), 
control growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)], 
the percentage growth was calculated at each of the drug concentrations levels. Percentage growth 
inhibition was calculated as: 
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz 
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz. 
Three dose response parameters were calculated for each experimental agent. Growth inhibition 
of 50 % (GI50) was calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, which is the drug concentration 
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resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control 
cells during the drug incubation. The drug concentration resulting in total growth inhibition (TGI) 
was calculated from Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the 
measured protein at the end of the drug treatment as compared to that at the beginning) indicating 
a net loss of cells following treatment was calculated from [(Ti-Tz)/Tz] x 100 = -50. Values were 
calculated for each of these three parameters if the level of activity was reached; however, if the 
effect was not reached or was exceeded, the value for that parameter was expressed as greater or 





































As a part of the preliminary investigations on the nantenine scaffold, the requirement of a 
rigid aporphine core of nantenine (55) for 5-HT2A antagonism was studied. To this effect 
compounds 147-150 were synthesized previously and evaluated for 5-HT2A receptor affinity.
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Compounds 147, 148 and 150, which have an intact tetrahydroisoquinoline ring (but truncated 
aporphine ring) were completely inactive at the 5-HT2A receptor. The flexible compound 149 was 
found to have poor affinity for the 5-HT2A receptor compared to its parent compound nantenine 
(55).  
 
Although this study established that an intact aporphine core is required for 5-HT2A 
antagonism, we were also interested in the structure of compound 149. Other compounds having 
structural similarity to compound 149 have been reported in literature.184,185 However, no 
precedence existed for such compounds to have affinity at the 5-HT2A receptor. Although 
compound 149 has poor affinity at the 5-HT2A receptor, it was considered that compound 149 
could be used as a starting point for developing 5-HT2A receptor ligands.  
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The N-phenylalkyl moiety represents an important pharmacophoric element for CNS drug 
design. Ligands containing the N-phenylalkyl moiety have been studied at the histamine H3 
(compound 243)186, NMDA (compound 244)187, dopamine D3 (compound 245)
188 and sigma σ1 
receptors (compound 246)189,190. Moreover, there are several N-phenylalkyl containing compounds 
that are reported as ligands at the 5-HT1A (compound 247)
191 and 5-HT2A receptors (compound 
248).192,193 Some examples are shown in Figure 56.  
 
3.2 Rationale: 
Compound 149 has poor affinity for the 5-HT2A receptor. It was foreseen that the N-methyl group 
of compound 149 could be replaced with other N-phenylalkyl groups. We considered that this 
approach would enhance the affinity towards the 5-HT2A receptor primarily due to two reasons i ) 
the flexibility of ligands might allow the ligands multiple possibilities for interaction of the 
receptor with the N-phenylalkyl group ii) The N-phenylalkyl group is a known 5-HT receptor 
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pharmacophore.105,190,194 Additionally, it was expected that this approach would lead to more 
diverse series of analogs and a much shorter synthetic route to the compounds, precluding 
laborious synthesis of the aporphine template.  
 
3.3 Preliminary Screening:195  
In order to find the optimum length of the linker between the phenylalkyl group and the nitrogen 
atom, compounds 249a-j were synthesized. Our initial design featured linker length of either 1, 2 
or 3 carbons between the phenylalkyl group and the nitrogen atom, as well as phenyl groups having 
methoxy group substituents. These compound were designed with the aim to increase 5-HT2A 
receptor affinity. Contrary to the expected result, it was observed that all compounds displayed 
high affinity for the 5-HT2B receptor and a range of selectivity (from 2 to almost 90 fold) vs. the 
5-HT2A and 5-HT2C subtypes. Most of the analogs had 5-HT2B affinities that were similar or 










Table 10: Binding affinities of 249a-j at 5-HT2 receptors 
 
Compound Ki (nM)a Selectivity 




249a H 0 1 3531 ± 460 59 ± 8.8 1091 ± 140 60 19 
249b H 1 1 1472 ± 190 17 ± 2.5 690 ± 100 87 41 
249c H 2 1 165 ± 25 26 ± 2.3 399 ± 75 6 15 
249d 2-MeO 2 1 140 ± 15 5.8 ± 0.6 123 ± 16 24 21 
249e 3-MeO 2 1 200 ± 22 4.6 ± 0.5 108 ± 14 43 24 
249f 4-MeO 2 1 267 ± 34 6.8 ± 0.7 206 ± 27 39 30 
249g 2,5-Di 
MeO 
2 1 919 ± 120 36 ± 4.6 273 ± 35 26 8 
249h 3,4,5-tri 
MeO 
2 1 146 ± 19 4.1 ± 0.5 194 ± 2.5 36 47 
249i 3-MeO 2 0 1507 ± 190 59 ± 7.6 103 ± 19 26 2 
249j 3,4,5-tri   
MeO 
2 0 2234 ± 290 231 ± 25 nab 10 - 
Clozapine    15     
SB206553     21    
Ritanserin      1.8   
a Radioligands are [3H]Ketanserin, [3H]LSD and [3H]mesulergine for 5-HT2A, 5-HT2B and 5-HT2C 
respectively, b na not active defined as : % inhibition at 10 µM < 50 % in primary assay 
 
3.4 Synthesis & evaluation of ring C halogenated analogues: 
Results from the preliminary screen indicated that the tris-(phenylalkyl)amine analogues 
displayed higher affinity for the 5-HT2B receptor. Nevertheless, more information was needed to 
understand the structural tolerance of the tris-(phenylalkyl)amine scaffold for affinity at 5-HT 
receptors. Compound 249c, which is a non-competitive antagonist at the 5-HT2B receptor was 
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selected as a lead candidate.195 The focus of this study was to understand the steric and electronic 
tolerance of ring C. Accordingly a series of ring C halogenated analogues (of compound 249c) 
were synthesized and evaluated.  
 
Scheme 11 shows the synthesis of ring C halogenated tris-(phenylalkyl) amine derivatives. 
The synthesis commenced through a CDI mediated coupling of commercially available amine 210 
and acid 250 to furnish the amide 251. Reduction of amide 251 using borane-THF resulted in the 
formation of secondary amine 252. Amine 252 was then coupled with commercially available 
acids 253a-l to afford amides 254a-l. The final step of the synthesis utilized a borane-THF 






















249c H H H 165 ± 25 26 ± 2.3 399 ± 75 6 15 
255a F H H 65 1.7 79 38 46 
255b Cl H H 43 3.1 92 14 30 
255c Br H H 54 3.4 124 16 36 
255d I H H 75 13 68 6 5 
255e H F H 185 18 167 10 9 
255f H Cl H 125 17 206 7 12 
255g H Br H 103 14 143 7 10 
255h H I H 169 18 154 9 9 
255i H H F 185 14 126 13 9 
255j H H Cl 365 54 235 7 4 
255k H H Br 221 45 219 5 5 
255l H H I 288 51 224 6 4 
Clozapine  15    
SB206553  21  
Ritanserin   1.8 
a Radioligands are [3H]Ketanserin, [3H]LSD and [3H]mesulergine for 5-HT2A, 5-HT2B and 5-HT2C 
respectively 
 
All the synthesized compounds were evaluated for affinity at 5-HT2 receptors through the 
Psychoactive Drug Screening Program (PDSP) of the National Institute of Health (NIH). Here, the 
submitted compounds were first screened in a primary radioligand binding assay (in quadruplicate) 
at a concentration of 10 µM at the three human 5-HT2 receptor sites. Compounds which displayed 
a minimum of 50 % inhibition for a particular receptor in this preliminary assay were then 
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evaluated in secondary radioligand binding assays (11 concentrations; each in triplicate) to 
determine Ki values. These Ki valules are compiled in Table 11.   
As seen in Table 11, all synthesized compounds displayed affinities for the 5-HT2B receptor 
in the range of 1 to 60 nM. The most potent compound identified in this series was 255a with a Ki 
value of 1.7 nM at the 5-HT2B receptor and had a 38 and 46 fold selectivity over the 5-HT2A and 
5-HT2C receptors respectively.  
In the 2′ substituted series (255a-d), introduction of a fluorine atom at the 2′ position (255a, 
Ki = 1.7 nM) resulted in a 15 fold increase in affinity at the 5-HT2B receptor (compared with 
compound 249c). The affinity of 255a at the 5-HT2A and 5-HT2C receptors as compared to 249c 
was also found to increase by 2.5 and 5 folds respectively. Moreover the selectivity of 255a at both 
these receptors was better as compared to 249c (38 vs 6 fold over 5-HT2A and 46 vs 15 fold over 
5-HT2C). Similarly 255b (2′-chloro, Ki = 3.1 nM) and 255c (2′-bromo, Ki = 3.4 nM) were also 
found to be 8 times more potent than their parent compound 255c (Ki = 26 nM), whereas 255d (2′-
iodo, Ki = 13 nM) was found to be 2 times potent than 249c at the 5-HT2B receptor. 255a, which 
is 12 times more potent than the standard 5-HT2B ligand (SB206553), was the most potent 
compound identified in this series.  
Introduction of a halogen atom at the 3′ position in ring C (255e-h) resulted in a moderate 
increase in affinity at the 5-HT2B receptor than the parent compound 249c. The 3’ fluoro (255e, Ki 
= 13 nM) and 3’ iodo (255h, Ki = 14 nM) had a 2 fold increase in affinity at the 5-HT2B receptor. 
Increased affinity was also observed for 5-HT2A and 5-HT2C receptors. Interestingly all the 3′ 
substituted compounds (255e-h) had similar affinities indicative of the tolerance of halogen atoms 
at this position. 
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Compound 255i which has a fluorine atom in the 4′ position of ring C displayed slightly 
improved affinity (Ki = 14 nM) at the 5-HT2B receptor than compound 249c. This change also led 
to an increase in selectivity over the 5-HT2A receptor (13 fold vs 6 fold), but a decrease in 
selectivity over the 5-HT2C receptor (9 fold vs 15 fold). Contrarily with the 4′-chloro (255j, Ki = 
54 nM), 4′-bromo (255k, Ki = 45 nM) and 4′-iodo (255l, Ki = 51 nM) compounds slight drop in 5-
HT2B receptor affinity as well as decrease in selectivity over 5-HT2A and 5-HT2C receptors was 
observed, although no clear trend was identified. Only fluorination at this position resulted in 
increased affinity for all 5-HT2A, 5-HT2B and 5-HT2C receptors.  
A small trend was observed in the 2′ series (255a-d), where affinity at the 5-HT2B receptor 
was found to decrease with increasing size of the halogen atom. This trend was also seen with 
respect to the selectivity of the respective compounds over 5-HT2A and 5-HT2C receptors.  
Except the fluoro compounds (255a, 255e and 255i), affinity at the 5-HT2B receptor 
decreased in the following order: 2′ substituted compounds > 3′ substituted compounds > 4′ 
substituted compounds. Thus 255b (Ki = 3.1 nM) was 5 times potent than 255f (Ki = 17 nM), 
which in turn was 3 times more potent than 255j (Ki = 54 nM). This trend was also observed for 
the affinities of the same compounds at the 5-HT2A and 5-HT2C receptors.  
 
3.5 Discussion: 
The 5-HT2B receptor is involved in the regulation of CNS, gastric and intestinal motility 
and cardiovascular functions. 5-HT2B antagonists have been explored as potential 
pharmacotherapeutics for migraine, irritable bowel syndrome, pulmonary hypertension and heart 
failure.196-201 5-HT2B receptor agonists display antidepressant activity and 5-HT2B receptor 
activation is required for antidepressant actions of selective serotonin reuptake inhibitors 
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(SSRI's).202 However, 5-HT2B agonism is known to be associated with the development of valvular 
heart disease (VHD) and as such is regarded as an anti-target in most drug discovery programs. 
203-205 Despite the promise of 5-HT2B antagonists as useful therapeutics, there are no 5-HT2B 
antagonists that are clinically approved for the clinical indications mentioned previously. This is 
partly because many known ligands are not truly 5-HT2B selective (5-HT2B ligands often also have 
affinity for the related 5-HT2A and 5-HT2C receptors) and even when selective there are issues 
related to ADME properties of the compounds that prohibit clinical translational studies.  
Figure 58 shows some selective 5-HT2B antagonists that are commercially available; these 
compounds are predominantly used as biological tools.206-208 The identification of new 5-HT2B 
preferring scaffolds is critical in the pursuit of novel chemical entities that may be developed as 




In a previous study we identified a novel tris-(phenylalkyl)amine scaffold as a 5-HT2B 
antagonist. These compounds were designed with the aim of replacing the N-methyl group of 
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nantenine with an N-phenylalkyl moiety as well as increasing the molecular flexibility of nantenine. 
Compound 249c having a propyl linker was selected as our lead compound.  
 In order to understand the functional group tolerance of the phenyl ring (of the N-
phenylpropyl moiety) we decided to synthesize a series of 2′, 3′ and 4′ substituted halogenated 
analogues. This compounds should reveal the electronic tolerance of the phenyl ring towards 5-
HT2B receptor affinity.   
 Based on the biological evaluations, it seems clear that ring C is tolerant towards halogen 
substitution in any position. In most cases, halogen substitution also resulted in increased affinity 
(compared to the non-halogenated parent compound 249c), with some compounds being more 
potent than the positive control SB-200646.  
Introduction of a halogen atom can have several beneficial effects on the affinities of a 
ligand. There are several plausible ways in which halogen atom can interact with a protein or other 
relevant target. Classically halogens are considered to be hydrophobic moieties and lewis bases in 
accordance to their electronegativities.209 However the halogen atom can also act as a lewis acid 
(via σ-hole) and interact with an electron donating residue of a protein. This interaction termed as 
halogen bonding is described in detail in chapter 4. Bromine and chlorine atoms may be involved 
in bonding interactions with backbone amino acids that contain carbonyl oxygen atoms.210,211 
Additionally, halogen atoms are also involved in bond formation with side chain groups such as 
hydroxyls in serine, thereonine, and tyrosine, carboxylate groups in aspartate and glutamate, 
sulfurs in cysteine and methionine, nitrogens in histidine and the π surfaces of phenyl alanine, 
tyrosine, histidine and tryptophan.212  
In the case of tris-(phenylalkyl)amines it is not clear which of the above mentioned 
interactions are responsible for their enhanced affinity. Molecular docking studies should throw 
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further light on their possible modes of interactions with the 5-HT2B receptor and help in future 
ligand design.  
 
3.6 Conclusions: 
A series of ligands bearing a tris-phenylalkyl)amine scaffold with high affinity and 
selectivity for the 5-HT2B receptor were synthesized. This ligands featured a halogen substituent 
in ring C. In general halogen substitution was well tolerated in ring C and resulted in increased 
affinity and selectively for the 5-HT2B receptor (compared to their non-halogenated parent 
compound). Compound 255a having a 2’ fluoro group in ring C, was identified as the most potent 
compound in this series. 255a (Ki = 1.7 nM) is 12 times more potent than the standard 5-HT2B 
ligand SB206553. At this time the role of halogen substitution in the increased affinity remains to 
be determined. The ease of synthesis of this scaffold makes it particularly attractive for further 
structure-activity work to optimize 5-HT2B affinity, selectivity and antagonist activity in the quest 
for 5-HT2B antagonist drugs. 
The synthetic feasibility of this newly identified template (4 high-yielding synthetic steps 
from commercially available materials) makes this scaffold attractive for the synthesis of larger 
libraries of analogs and promise for optimization of 5-HT2B affinity and selectivity. Additional 
exploration of the scaffold should provide new tool compounds that will be useful for the study of 
5-HT2B receptor functions. Future in vitro as well as in vivo pharmacological characterization 








General methods and instrumentation: 
All glass apparatus were oven-dried prior to use. A CEM Discover microwave reactor was used to 
carry out microwave-assisted C-H arylation reactions. HRESIMS spectra were obtained using an 
Agilent 6520 Q-TOF instrument. 1H NMR and 13C NMR spectra were recorded using a Bruker 
DPX-500 spectrometer (operating at 500 MHz for 1H; 125 MHz for 13C) using CDCl3 as solvent. 
Tetramethylsilane (δ 0.00 ppm) served as an internal standard in 1H NMR and 13C NMR unless 
stated otherwise. Chemical shift (δ 0.00 ppm) values are reported in parts per million and coupling 
constants in Hertz (Hz). Splitting patterns are described as singlet (s), doublet (d), triplet (t), and 
multiplet (m). Melting points were obtained on a Mel-Temp capillary electrothermal melting point 
apparatus. Reactions were monitored by TLC with Whatman Flexible TLC silica gel G/UV 254 
precoated plates (0.25 mm). TLC plates were visualized in UV light (254 nm) and by staining with 
phosphomolybdate spray reagent, vanillin or iodine. Flash column chromatography was performed 
with silica gel 60 (EMD Chemicals, 230-400 mesh, 0.04-0.063 mm particle size). Preparative thin 
layer chromatography was performed with silica gel GF plates (Analtech, catalog # 02003). All 
chemicals and reagents were obtained from Sigma-Aldrich and Fischer Scientific (USA) in reagent 






2-(benzo[d][1,3]dioxol-5-yl)-N-(3,4-dimethoxyphenethyl)acetamide (251): A solution of acid 
250 (4.96 g, 27.62 mmol) in anhydrous THF (50 mL) under N2 atmosphere was cooled to 0 ºC. To 
this solution CDI (5.30 g, 32.7 mmol) was added in three portions over a period of 30 min at 0 ºC. 
The resulting reaction mixture was allowed to stir for 1.5 h at 0 ºC, after which the temperature 
was raised to rt and allowed to stir for another 1 h. The solution was again cooled to 0 ºC and 
allowed to stir for 30 min, after which a solution of 251 (5.00 g, 27.62 mmol) in THF (10 mL) was 
added dropwise. The resulting reaction mixture was allowed to stir for 30 min at 0 ºC and then at 
rt for another 15 h. After 15 h, the crushed out solid was filtered and washed with diethyl ether to 
furnish 251; white solid; 80 %; mp 99 ºC-103 ºC. Data in accordance with previously reported.  
2-(benzo[d][1,3]dioxol-5-yl)-N-(3,4-dimethoxyphenethyl)ethan-1-amine (252): To a solution 
of amide 251 (7.00 g, 20.43 mmol) in anhydrous THF (100 mL) under N2, BF3-Et2O (5.04 mL, 
5.80 g, 40.86 mmol) was added. The resulting reaction mixture was heated under reflux for 30 min, 
after which a 1M solution of BH3-THF (46.54 mL, 4.39 g, 51.05 mmol) was carefully added 
dropwise. The resulting reaction mixture was heated under reflux for another 3.5 h. After 3.5 h the 
reaction mixture was allowed to cooled to 0 ºC, followed by the careful dropwise addition of 3N 
HCl (30 mL). The resulting solution was evaporated under vacuum, followed by addition of 3N 
NaOH (45 mL) to adjust pH to 8-9. The resulting aqueous solution was extracted using 
dichloromethane (3 x 30 mL). The combined organic layer was dried over Na2SO4 and evaporated 
to dryness under vacuum to afford amine 252 as a light brown oil; 73 %. Compound 252 was used 
without further purification.   
General procedure for the synthesis of 254a-l: HoBT (1.2 equiv.) was added to an ice cooled 
solution of EDCI (1.2 equiv.) in anhydrous DMF (10 mL) under N2. The resulting solution was 
allowed to stir for 10 mins at 0 ºC, followed by the addition of the appropriate acid (1.2 equiv.) 
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and DIPEA (2.5 equiv.).  The resulting solution was stirred for another 15 min at 0 ºC, after which 
a solution of amine 252 (1.0 equiv.) in anhydrous DMF (5 mL) was added. The resulting reaction 
mixture was allowed to stir first at 0 ºC for 30 mins, then at rt for 5 h. The reaction mixture was 
then evaporated to dryness under vacuum. Saturated NaHCO3 solution (10 mL) was then added to 
the resulting crude followed by extraction of the aqueous layer using dichloromethane (3 x 15 mL). 
The combined organic layer was dried over Na2SO4 and evaporated to dryness under vacuum to 
afford the corresponding amides which were purified using flash column chromatography (30 – 
50 % ethyl acetate –petroleum ether).  
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(2-
fluorophenyl)propanamide (254a): clear oil; 75 %; rotamers observed, all signals reported; 1H 
NMR (500 MHz, CDCl3): δ 7.20-7.15 (m, 2H), 7.06-6.97 (m, 2H), 6.78 (m, 1H), 6.76-6.70 (1.5H), 
6.69-6.68 (m, 1H), 6.61 (d, 1H, J = 7.7 Hz), 6.56 (dd, 1H, J = 7.7 Hz, 1.9 Hz), 6.52-6.50 (0.5 H), 
5.90 (merged d, 2H, J = 1.6 Hz), 3.86-3.81 (6H), 3.48 (q, 2H, J = 9.3 Hz), 3.28 (q, 2H, J = 7.0 Hz), 
2.96-2.90 (m, 4H), 2.80-2.73 (m, 2H), 2.64 (q, 2H, J = 7.4 Hz), 2.43 (t, 1H, J = 8.0 Hz), 2.40 (t, 
1H, J = 7.6 Hz) ; 13C NMR (125 MHz, CDCl3): δ 171.75, 171.70, 162.1, 160.2, 149.0, 148.9, 
147.8, 147.6, 147.5, 146.3, 146.0, 133.1, 131.8, 131.7, 131.07, 131.02, 130.9, 130.5, 128.1, 128.0, 
127.9, 127.8, 124.0, 121.6, 120.7, 120.6, 115.3, 115.2, 115.1, 115.0, 112.0, 111.8, 111.4, 111.2, 
109.2, 109.0, 108.4, 108.2, 100.9, 100.8, 55.88, 55.86, 50.2, 50.1, 48.4, 35.0, 34.9, 33.8, 33.6, 33.2, 
25.3, 25.2; HRESIMS: calcd for C28H31FNO5 [M+H]
+ 480.2186; found 480.2181 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(2-chlorophenyl)-N-(3,4-
dimethoxyphenethyl)propanamide (254b): clear oil; 82 %; rotamers observed, all signals 
reported; 1H NMR (500 MHz, CDCl3): δ 7.34-7.31 (m, 1H), 7.23-7.20 (m, 1H), 7.18-7.14 (m, 2H), 
6.77 (dd, 1H, J = 13.1, 8.05 Hz), 6.74-6.73 (m, 1H), 6.72-6.68 (1.5H), 6.62-6.60 (m, 1H), 6.55 (dd, 
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1H, J = 8.5, 1.9 Hz), 6.51-6.49 (0.5H), 5.90 (merged d, 2H, J = 2.1 Hz), 3.86-3.81 (6H), δ 3.48 (q, 
2H, J = 7.7 Hz), 3.28-3.25 (m, 2H), 3.05-3.00 (m, 2H), 2.80-2.74 (m, 2H), 2.62 (q, 2H, J = 7.0 
Hz), 2.47-2.41 (m, 2H) ; 13C NMR (125 MHz, CDCl3): δ 171.7, 171.6, 149.0, 148.9, 147.8, 147.6, 
147.5, 146.3, 146.0, 138.8, 133.8, 133.7, 133.1, 131.8, 131.7, 130.98, 130.91, 130.5, 129.47, 
129.42, 127.7, 126.9, 121.6, 120.7, 120.6, 112.0, 111.8, 111.3, 111.2, 109.2, 109.0, 108.4, 108.2, 
100.9, 100.8, 55.9, 55.8, 50.2, 50.1, 48.52, 48.50, 35.1, 34.9, 33.8, 33.6, 32.8, 29.7, 29.6; 
HRESIMS: calcd for C28H31ClNO5 [M+H]
+ 496.1891; found 496.1886 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(2-bromophenyl)-N-(3,4-
dimethoxyphenethyl)propanamide (254c): clear oil; 89 %; rotamers observed, all signals 
reported; 1H NMR (500 MHz, CDCl3): δ 7.53-7.50 (m, 1H), 7.26-7.21 (m, 2H), 7.08-7.04 (m, 1H), 
6.77 (dd, 1H, J = 13.0, 8.0 Hz), 6.74-6.71 (1.5H), 6.69 (d, 1H, J = 8.0 Hz), 6.61 (dt, 1H, J = 8.0, 
2.0 Hz), 6.56 (dd, 1H, J = 8.0, 2.0 Hz), 6.52-6.50 (0.5H), 5.91 (merged d, 2H, J = 2.4 Hz), 3.86-
3.82 (6H), 3.48 (q, 2H, J = 7.0 Hz), 3.28-3.25 (m, 2H), 3.06-3.00 (m, 2H), 2.80-2.74 (m, 2H), 2.63 
(q, 2H, J = 7.0 Hz), 2.48-2.42 (m, 2H) ; 13C NMR (125 MHz, CDCl3): δ 171.6, 171.6, 149.0, 148.9, 
147.8 147.6, 147.5, 146.3, 146.0, 140.5, 133.1, 132.79,  132.74, 131.8, 131.7, 130.99, 130.93, 
130.5, 127.9, 127.62, 127.61, 124.29, 124.23, 121.68, 121.65, 120.7, 120.6, 112.0, 111.8, 111.3, 
111.2, 109.2, 109.0, 108.4, 108.2, 100.9, 100.8, 55.91, 55.90, 50.28, 50.20, 48.55, 48.53, 35.1, 
34.9, 33.8, 33.6, 32.9, 32.2, 32.1; HRESIMS: calcd for C28H31BrNO5 [M+H]
+ 540.1385; found 
526.1386 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(2-
iodophenyl)propanamide (254d): clear oil; 76 %; rotamers observed, all signals reported; 1H 
NMR (500 MHz, CDCl3): δ 7.80-7.78 (m, 1H), 7.28-7.20 (m, 2H), 6.91-6.87 (m, 1H), 6.78 (dd, 
1H, J = 13.3, 8.0 Hz), 6.74-6.71 (1.5H), 6.69 (d, 1H, J = 7.9 Hz), 6.62 (dd, 1H, J = 7.9, 1.5 Hz), 
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6.57 (dd, 1H, J = 5.3, 1.8 Hz), 6.54-6.53 (0.5H), 5.91 (merged d, 2H, J = 2.9 Hz), 3.87-3.82 (6H), 
3.48 (q, 2H, J = 8.0 Hz), 3.28-3.25 (m, 2H), 3.05-3.00 (m, 2H), 2.80-2.74 (m, 2H), 2.63 (q, 2H, J 
= 7.0 Hz), 2.43 (quin, 2H, J = 8.0 Hz); 13C NMR (125 MHz, CDCl3): δ 171.5, 171.4, 149.0, 148.9, 
147.8, 147.6, 147.5, 146.3, 146.0, 143.9, 143.8, 139.59, 139.50, 139.4, 133.1, 131.8, 131.7, 130.5, 
130.0, 128.1, 121.7, 121.6, 120.8, 120.6, 112.0, 111.9, 111.3, 111.2, 109.2, 109.1, 108.4, 108.2, 
100.9, 100.8, 108.2, 100.1, 55.96, 55.92, 55.90, 50.3, 50.2, 48.6, 48.5, 36.58, 36.53, 35.1, 34.9, 
33.8, 32.6, 32.2; HRESIMS: calcd for C28H31INO5 [M+H]
+ 588.1247; found 588.1241 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(3-
fluorophenyl)propanamide (254e): clear oil; 90 %; rotamers observed, all signals reported; 1H 
NMR (500 MHz, CDCl3): δ 7.21-7.19 (m, 1H), 6.93-6.77 (m, 4H), 6.74-6.71 (m, 2H), 6.69-6.68 
(0.5H), 6.62 (td, 1H, J = 5.95, 2.05 Hz), 6.54 (dd, 1H, J = 6.60, 1.55 Hz), 6.51-6.49 (0.5H), 5.92 
(merged d, 2H, J = 1.5 Hz), 3.87-3.82 (6H), 3.50 (q, 2H, J = 8.0 Hz), 3.27 (m, 2H), 2.89-2.75 (m, 
4H), 2.64 (q, 2H, J = 7.0 Hz), 2.35 (t, 1H, J = 8.0 Hz), 2.30 (t, 1H, J = 8.0 Hz) ; 13C NMR (125 
MHz, CDCl3): δ 171.6, 171.5, 163.87, 163.85, 161.92, 161.90, 149.0, 148.9, 147.9, 147.6, 147.5, 
146.4, 146.0, 144.09, 144.06, 144.03, 144.00, 133.1, 131.81, 131.81, 130.6, 129.89, 129.87, 129.82, 
129.81, 124.06, 124.05, 121.7, 121.6, 120.7, 120.6, 115.3, 115.2, 115.13, 115.11, 113.04, 113.01, 
112.88, 112.84, 112.0, 111.9, 111.4, 111.2, 109.2, 109.0, 108.5, 108.3, 101.0, 100.8, 55.9, 55.8, 
50.1, 50.0, 48.44, 48.42, 34.9, 34.7, 34.5, 34.4, 33.7, 33.6, 31.0; HRESIMS: calcd for C28H31FNO5 
[M+H]+ 480.2186; found 480.2185 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(3-chlorophenyl)-N-(3,4-
dimethoxyphenethyl)propanamide (254f): clear oil; 77 %; rotamers observed, all signals 
reported; 1H NMR (500 MHz, CDCl3): δ 7.15-7.13 (m, 2H), 7.11 (d, 1H, J = 1.3 Hz), 7.01 (dd, 
1H, J = 16.4, 7.20 Hz), 6.79 (d, 1H, J = 6.4 Hz), 6.74-6.70 (m, 2H), 6.69-6.68 (0.5H), 6.61 (dt, 1H, 
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J = 7.85, 1.75 Hz, 6.54 (d, 1H, J = 3.8 Hz), 6.51-6.49 (0.5H), 5.91 (s, 2H), 3.86-3.82 (6H), 3.49 
(q, 2H, J = 7.6 Hz), 3.27 (q, 2H, J = 4.9 Hz), δ 2.87-2.75 (m, 4H), δ 2.66-2.61 (m, 2H), 2.34 (t, 1H, 
J = 7.9 Hz), 2.29 (t, 1H, J = 8.0 Hz) ; 13C NMR (125 MHz, CDCl3): δ 171.56, 171.50, 149.0, 
148.9, 147.9, 147.6, 147.4, 146.0, 143.53, 143.51, 134.14, 134.10, 133.0, 131.8, 131.7, 130.6, 
129.7, 128.5, 128.4, 126.6, 126.28, 126.24, 121.7, 121.6, 120.7, 120.6, 112.0, 111.9, 111.4, 111.2, 
109.1, 109.0, 108.5, 108.2, 101.0, 100.8, 55.9, 55.8, 50.08, 50.03, 48.4, 34.9, 34.7, 34.5, 34.4, 33.7, 
33.5, 31.0; HRESIMS: calcd for C28H31ClNO5 [M+H]
+ 496.1891; found 496.1889 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(3-bromophenyl)-N-(3,4-
dimethoxyphenethyl)propanamide (254g): clear oil; 84 %; rotamers observed, all signals 
reported;  1H NMR (500 MHz, CDCl3): δ 7.33-7.29 (m, 1H), 7.26 (d, 1H, J = 5.7 Hz), 7.15-7.11 
(m, 1H), 7.05 (dd, 1H, J = 16.5, 7.6 Hz), 6.79 (d, 1H, J = 8.1 Hz), 6.74-6.70 (m, 2H), 6.69-6.68 
(0.5H), 6.61 (d, 1H, J = 4.6 Hz), 6.54 (d, 1H, J = 4.7 Hz), 6.51-6.49 (0.5H), 5.91 (s, 2H), 3.86-
3.82 (6H), 3.49 (q, 2H, J = 7.7 Hz), 3.27 (q, 2H, J = 6.9 Hz), 2.86-2.75 (m, 4H), 2.66-2.61 (m, 2H), 
2.34 (t, 1H, J = 7.9 Hz), 2.29 (t, 1H, J = 8.0 Hz); 13C NMR (125 MHz, CDCl3): δ 171.57, 171.51, 
149.1, 148.9, 147.93, 147.92, 147.6, 146.5, 146.0, 143.85, 143.83, 133.0, 131.8, 131.7, 131.4, 
131.3, 130.6, 130.0, 129.24, 129.20, 127.1, 122.48, 122.44, 121.7, 121.6, 120.7, 120.6, 112.0, 
111.9, 111.4, 111.2, 109.2, 109.0, 108.5, 108.3, 101.0, 100.8, 55.95, 55.93, 55.91, 50.10, 50.06, 
48.4, 34.9, 34.7, 34.5, 34.4, 33.8, 33.6, 31.0; HRESIMS: calcd for C28H31BrNO5 [M+H]
+ 
540.1385; found 526.1381 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(3-
iodophenyl)propanamide (254h): clear oil; 71 %; rotamers observed, all signals reported;  1H 
NMR (500 MHz, CDCl3): δ 7.53-7.48 (m, 2H), 7.11 (dd, 1H, J = 17.0, 7.6 Hz), 7.01-6.98 (m, 1H), 
6.79 (d, 1H, J = 6.1 Hz), 6.74-6.70 (1H), 6.69-6.68 (0.5H), 6.61 (d, 1H, J = 8.0 Hz), 6.54 (d, 1H, 
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J = 3.4 Hz), 6.51-6.49 (0.5H), 5.91 (s, 2H), 3.86-3.82 (6H), 3.49 (q, 2H, J = 7.4 Hz), 3.26 (q, 2H, 
J = 6.7 Hz), 2.94-2.75 (m, 4H), 2.66-2.60 (m, 2H), 2.33 (t, 2H, J = 7.9 Hz), 2.28 (t, 2H, J = 8.0 
Hz) ;  13C NMR (125 MHz, CDCl3): δ 171.5, 171.4, 149.0, 148.9, 147.88, 147.86, 147.6, 147.5, 
146.3, 146.0, 143.93, 143.91, 137.3, 137.2, 135.17, 135.13, 133.0, 131.78, 131.76, 130.5, 130.1, 
127.7, 127.6, 121.6, 120.7, 120.6, 112.0, 111.9, 111.4, 111.2, 109.1, 109.0, 108.5, 108.2, 100.9, 
100.8, 55.94, 55.93, 55.90, 55.8, 50.06, 50.03, 48.4, 34.9, 34.7, 34.5, 33.7, 33.4, 33.6, 30.88, 30.87; 
HRESIMS: calcd for C28H31INO5 [M+H]
+ 588.1247; found 588.1241 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(4-
fluorophenyl)propanamide (254i): clear oil; 84 %; rotamers observed, all signals reported; 1H 
NMR (500 MHz, CDCl3): δ 7.08 (ddd, 2H, J = 15.9, 8.5, 5.5 Hz), 6.97-6.93 (m, 2H), 6.78 (t, 1H, 
J = 8.1 Hz), 6.74-6.70 (m, 2H), 6.68 (0.5H), 6.61 (t, 1H, J = 8.2 Hz), 6.54 (t, 1H, J = 1.8 Hz), 6.51-
6.40 (0.5H), 5.91 (merged d, 2H, J = 3.7 Hz), 3.86-3.81 (6H), 3.49 (q, 2H, J = 8.9 Hz), 3.26 (q, 
2H, J = 6.9 Hz), 2.87-2.74 (m, 4H), 2.66-2.61 (m, 2H), 2.36 (t, 1H, J = 7.9 Hz), 2.29 (t, 1H, J = 
7.9 Hz) ; 13C NMR (125 MHz, CDCl3): δ 171.8, 171.7, 162.36, 162.34, 160.42, 160.40, 149.1, 
148.9, 147.92, 147.90, 147.6, 147.5, 146.3, 146.0, 137.09, 137.03, 133.1, 133.8, 131.8, 130.6, 
129.8, 129.79, 129.76, 129.73, 121.69, 121.66, 120.7, 120.6, 115.26, 115.22, 115.09, 115.06, 112.0, 
111.9, 111.4, 111.2, 109.2, 109.0, 108.5, 108.3, 100.8, 100.0, 55.92, 55.90, 50.0, 48.43, 48.42, 




dimethoxyphenethyl)propanamide (254j): clear oil; 79 %; rotamers observed, all signals 
reported; 1H NMR (500 MHz, CDCl3): δ 7.23-7.20 (m, 2H), 7.04 (dd, 2H, J = 17.0, 8.3 Hz), δ 
6.79-6.69 (3.5H), 6.60 (t, 1H, J = 4.9 Hz), 6.58 (s,1H), 6.50-6.48 (0.5H), 5.89 (d, 2H, J = 3.0 Hz), 
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3.85-3.80 (6H), 3.49 (q, 2H, J = 9.4 Hz), 3.26 (q, 2H, J = 6.6 Hz), 2.86-2.74 (m, 4H), 2.65-2.60 
(m, 2H), 2.34 (t, 1H, J = 7.8 Hz), 2.27 (t, 1H, J = 7.9 Hz); 13C NMR (125 MHz, CDCl3): δ 171.6, 
171.5, 149.0, 148.9, 147.88, 147.86, 147.6, 147.5, 146.3, 146.0, 139.92, 139.90, 133.7, 133.0, 
131.7, 131.6, 130.6, 129.77, 129.74, 121.67, 121.62, 120.7, 120.6, 112.0, 111.9, 111.4, 111.2, 
109.1, 109.0, 108.4, 108.2, 100.9, 100.8, 55.87, 55.85, 50.0, 48.3, 34.9, 34.69, 34.60, 34.5, 33.7, 
33.5, 30.5, 30.5; HRESIMS: calcd for C28H31ClNO5 [M+H]
+ 496.1891; found 496.1890 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-bromophenyl)-N-(3,4-
dimethoxyphenethyl)propanamide (254k): clear oil; 76 %; rotamers observed, all signals 
reported;  1H NMR (500 MHz, CDCl3): δ 7.39-7.36 (m, 2H), 7.00 (dd, 2H, J = 8.1,1.5 Hz), 6.79 
(t, 1H, J = 1.7 Hz), 6.77-6.70 (m, 2H), 6.68 (0.5H), 6.60 (t, 1H, J = 7.5 Hz), 6.54-6.53 (m, 1H), 
5.91 (2H), 3.86-3.81 (6H), 3.48 (q, 2H, J = 7.3 Hz), 3.26 (t, 2H, J = 2.2 Hz), 2.85-2.74 (m, 4H), 
2.63 (q, 2H, J = 7.4 Hz), 2.31 (t, 1H, J = 1.6 Hz), 2.28 (t, 1H, J = 1.5 Hz);  13C NMR (125 MHz, 
CDCl3): δ 171.58, 171.51, 149.0, 148.9, 147.89,  147.87,  147.6,  147.5,  146.3,  146.0,  140.45,  
140.42,  133.0,  131.7,  131.43,  131.41,  130.6,  130.19,  130.17,  121.68,  121.63,  120.7,  120.6,  
119.79,  119.75,  112.0,  111.9,  111.4,  111.2,  109.1,  109.0,  108.4,  108.2,  100.9, 100.8,  55.9,  
55.8, 50.0, δ 48.36, δ 48.35, δ 34.9, δ 34.7, δ 34.5, δ 34.4, δ 33.7, δ 33.5, δ 30.66, δ 30.64; 
HRESIMS: calcd for C28H31BrNO5 [M+H]
+ 540.1385; found 526.1383 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(4-
iodophenyl)propanamide (254l): clear oil; 81 %; rotamers observed, all signals reported; 1H 
NMR (500 MHz, CDCl3): δ 7.59-7.57 (m, 2H), 6.96 (dd, 2H, J = 11.9, 8.3 Hz), 6.87 (t, 1H, J = 
8.1 Hz), 6.79-6.69 (m, 2H), 6.68 (0.5H), 6.60 (td, 1H, J = 7.8, 1.6 Hz), 6.53 (dd, 1H, J = 4.0, 1.5 
Hz), 6.50-6.48 (0.5H), 5.91 (merged d, 2H, J = 3.5 Hz ), 3.86-3.81 (6H), 3.48 (q, 2H, J = 8.5 Hz), 
3.26 (q, 2H, J = 4.0 Hz), 2.83-2.74 (m, 4H), 2.63 (q, 2H, J = 4.0 Hz), 2.33 (t, 1H, J = 8.0 Hz), 2.27 
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(t, 1H, J = 8.0 Hz) ; 13C NMR (125 MHz, CDCl3): δ 171.6, 171.5, 149.0, 148.9,  147.92, 147.90, 
147.6, 147.5, 146.4, 146.0, 141.14, 141.11, 137.46, 137.43, 133.0, 131.7, 130.6, 130.55, 130.53, 
121.7, 121.6, 120.7, 120.6, 112.0, 111.9, 111.4, 111.2, 109.2, 109.0, 108.5, 108.3, 101.0, 100.8, 
91.1, 91.0, 55.93, 55.91, 50.0, 48.4, 34.9, 34.7, 34.5, 33.7, 33.5, 33.4, 30.78, 30.76; HRESIMS: 
calcd for C28H31INO5 [M+H]
+ 588.1247; found 588.1243 
General procedure for the synthesis of 255a-l: To a solution of appropriate amide 254a-l (1.0 
equiv.) in anhydrous THF (10 ml) under N2, BF3-Et2O (2 equiv.) was added. The resulting reaction 
mixture was heated under reflux for 30 min after which a 1M solution of BH3-THF (2.5 equiv.) 
was carefully added dropwise. The resulting reaction mixture was heated under reflux for another 
3.5 h. After 3.5 h the reaction mixture was allowed to cooled to 0 °C, followed by the careful 
dropwise addition of 3N HCl (15 mL). The resulting solution was evaporated under vacuum, 
followed by addition of 3N NaOH (20 mL) to adjust pH to 8-9. The resulting aqueous solution 
was extracted using dichloromethane (3 x 30 ml). The combined organic layer was dried over 
Na2SO4 and evaporated to dryness under vacuum to afford the corresponding amine 255a-l. The 
crude amines were purified on a silica gel column using 2 – 5 % MeOH – DCM.  
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(2-
fluorophenyl)propan-1-amine (255a): light brown oil; 67 %; 1H NMR (500 MHz, CDCl3): δ 
7.16 (t, 2H, J = 8.3 Hz), 7.04 (t, 1H, J = 8.2 Hz), 6.98 (d, 1H, J = 10.5 Hz), 6.78 (d, 1H, J = 10.8 
Hz), 6.72-6.70 (m, 3H),  6.66 (s, 1H), 6.60 (d, 1H, J = 8.2 Hz), 5.89 (s, 2H), 3.85 (merged s, 6H), 
2.73-2.58 (m, 12H), 1.82-1.74 (m, 2H) ; 13C NMR (500 MHz, CDCl3): δ 162.4, 159.9, 148.8, 
147.5, 147.3, 145.7, 134.5, 133.3, 130.6, 130.6, 129.2, 129.0, 127.5, 127.4, 123.94, 123.91, 121.4, 
120.6, 115.0, 112.1, 111.3, 109.2, 108.1, 100.7, 56.2, 55.9, 55.8, 53.4, 33.5, 33.4, 27.7, 26.9, 25.6; 
HRESIMS: calcd for C28H33FNO4 [M+H]




dimethoxyphenethyl)propan-1-amine(255b): light brown oil; 83 %; 1H NMR (500 MHz, 
CDCl3): δ 7.33 (d, 1H, J = 9.4 Hz), 7.17 (d, 2H, J = 5.1 Hz), 7.14-7.10 (m, 1H), 6.79 (d, 1H, J = 
10.8 Hz), 6.73-6.71 (m, 3H),  6.67 (s, 1H), 6.61 (d, 1H, J = 8.1 Hz), 5.90 (s, 2H), 3.85 (merged s, 
6H), 2.74-2.61 (m, 12H), 1.79 (quin, 2H, J = 9.7 Hz) ; 13C NMR (500 MHz, CDCl3): δ 148.8, 
147.5, 147.3, 145.7, 139.8, 134.4, 133.8, 133.2, 130.3, 129.4, 127.2, 126.7, 121.4, 120.5, 112.0, 
111.2, 109.1, 108.1, 100.7, 56.126, 56.120, 55.9, 55.8, 53.3, 33.4, 33.2, 31.5, 27.1; HRESIMS: 
calcd for C28H33ClNO4 [M+H]
+ 482.2098; found 482.2100 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(2-bromophenyl)-N-(3,4-
dimethoxyphenethyl)propan-1-amine (255c): light brown oil; 81 %; 1H NMR (500 MHz, 
CDCl3): δ 7.51 (d, 1H, J = 9.0 Hz), 7.24-7.15 (m, 2H), 7.03 (t, 1H, J = 9.3 Hz), 6.78 (d, 1H, J = 
10.8 Hz), 6.72-6.70 (m, 3H),  6.67 (s, 1H), 6.61 (d, 1H, J = 8.0 Hz), 5.89 (s, 2H), 3.85 (merged s, 
6H), 2.75-2.61 (m, 12H), 1.78 (quin, 2H, J = 9.5 Hz) ;13C NMR (500 MHz, CDCl3): δ 148.8, 
147.5, 147.3, 145.7, 141.6, 134.4, 133.3, 132.8, 130.3, 127.5, 127.4, 124.4, 121.5, 120.6, 112.1, 
111.2, 109.2, 108.1, 100.7, 56.19, 56.18, 55.9, 55.8, 53.3, 34.1, 33.5, 31.3, 27.4; HRESIMS: calcd 
for C28H33BrNO4 [M+H]
+ 526.1593; found 526.1595 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(2-iodophenyl)propan-
1-amine (255d): light brown oil; 77 %; 1H NMR (500 MHz, CDCl3): δ 7.82 (d, 1H, J = 9.8 Hz), 
7.29 (d, 2H, J = 9.0 Hz), 7.21-7.16 (m, 1H), 6.91 (t, 1H, J = 9.0 Hz), 6.80 (d, 1H, J = 10.8 Hz),  
6.74-6.71 (m, 3H), 6.67 (s, 1H), 6.65-6.60 (m, 2H), 5.92 (s, 2H), 3.87-3.85 (merged d, 6H, J = 6.9 
Hz), 3.12-2.57 (broad s, 12H), 2.17-1.78 (broad s, 2H) ; 13C NMR (500 MHz, CDCl3): δ 148.8, 
147.5, 147.4, 145.8, 144.6, 137.4, 134.9, 130.1, 127.7 (x 2), 121.5, 120.5, 112.0, 111.3, 109.1, 
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108.2, 100.8, 94.4, 55.95, 55.94, 55.92, 55.91, 52.9, 33.2, 33.1, 33.0, 28.4; HRESIMS: calcd for 
C28H33INO4 [M+H]
+ 574.1474; found 574.1450 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(3-
fluorophenyl)propan-1-amine (255e) :light brown oil; 69 %;  1H NMR (500 MHz, CDCl3): δ 
7.24-7.19 (m, 1H), 6.92 (d, 1H, J = 7.5 Hz), 6.88-6.84 (m, 2H), 6.79 (d, 1H, J = 8.0 Hz), 6.72-6.69 
(m, 3H), 6.66 (s, 1H), 6.60 (d, 1H, J = 6.0 Hz), 5.90 (s, 2H), 3.85 (merged s, 6H), 2.74-2.63 (m, 
8H), 2.63-2.54 (m, 4H), 1.76 (quin, 2H, J = 7.50 Hz)  ;13C NMR (125 MHz, CDCl3): δ 163.8, 
161.9, 148.8, 147.5, 147.3, 145.7, 145.0, 144.9, 134.4, 133.2, 129.68, 129.62, 124.04, 124.02, 
121.4, 120.5, 115.2, 115.1, 112.6, 112.4, 112.0, 111.2, 109.1, 108.1, 100.7, 56.18, 56.15, 55.9, 
55.8, 53.2, 33.5, 33.39, 33.35, 28.7; HRESIMS: calcd for C28H33FNO4 [M+H]
+ 466.2393; found 
466.2394 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(3-chlorophenyl)-N-(3,4-
dimethoxyphenethyl)propan-1-amine (255f) :light brown oil; 75 %; 1H NMR (500 MHz, 
CDCl3): δ 7.57 (d, 2H, J = 10.3 Hz), 6.89 (d, 2H, J = 10.2 Hz), 6.78 (d, 1H, J = 10.2 Hz), 6.72-
6.69 (m, 3H), 6.65 (s, 1H), 6.59 (d, 1H, J = 7.9 Hz), 5.89 (s, 2H), 3.85 (merged s, 6H), 2.72-2.64 
(m, 8H), 2.56-2.50 (m, 4H), 1.73 (quin, 2H, J = 9.6 Hz); 13C NMR (125 MHz, CDCl3): δ 148.8, 
147.5, 147.3, 145.7, 142.0, 137.3, 134.4, 133.2, 130.5 (x 2), 121.4 (x 2), 120.5, 112.1, 111.3, 109.2, 
108.1, 100.8, 90.7, 56.17, 56.13, 55.9, 55.8, 53.2, 33.4, 33.3, 33.1, 28.9; HRESIMS: calcd for 
C28H33ClNO4 [M+H]
+ 482.2098; found 482.2089 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(3-bromophenyl)-N-(3,4-
dimethoxyphenethyl)propan-1-amine (255g) : light brown oil; 80 %; 1H NMR (500 MHz, 
CDCl3): δ 7.32-7.30 (m, 2H), 7.14 (t, 1H, J = 7.7 Hz), 7.07 (d, 1H, J = 7.6 Hz), 6.79 (d, 1H, J = 
7.8 Hz), 6.73-6.70 (m, 3H),  6.66 (s, 1H), 6.61 (d, 1H, J = 6.4 Hz), 5.91 (s, 2H), 3.86 (merged s, 
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6H), 2.74-2.68 (m, 8H), 2.57-2.54 (m, 4H), 1.77 (t, 2H, J = 8.4 Hz) ; 13C NMR (125 MHz, CDCl3): 
δ 148.8, 147.5, 147.3, 145.7, 144.5, 134.2, 133.0, 131.4, 129.8, 128.9, 127.0, 122.4, 121.4, 120.5, 
112.0, 111.2, 109.1, 108.2, 100.8, 56.0, 55.99, 55.94, 55.8, 53.0, 33.2, 33.18, 33.13, 28.5; 
HRESIMS: calcd for C28H33BrNO4 [M+H]
+ 526.1593; found 526.1596 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(3-iodophenyl)propan-
1-amine (255h):light brown oil; 78 %; 1H NMR (500 MHz, CDCl3): δ 7.53-7.50 (m, 2H), 7.10 
(d, 1H, J = 7.6 Hz), 7.00 (t, 1H, J = 7.7 Hz), 6.79 (d, 1H, J = 7.9 Hz), 6.73-6.70 (m, 3H),  6.66 (s, 
1H), 6.61 (d, 1H, J = 6.3 Hz), 5.91 (s, 2H), 3.86 (merged s, 6H), 2.73-2.64 (m, 8H), 2.57-2.51 (m, 
4H), 1.76 (t, 2H, 7.1 Hz) ; 13C NMR (125 MHz, CDCl3): δ 148.8, 147.5, 147.3, 145.7, 144.6, 
137.45, 137.45, 134.8, 130.08,  130.08, 127.6, 121.4, 120.5, 112.0, 111.2, 109.1, 108.2, 100.7, 
94.4, 56.02, 56.00, 55.9, 55.8, 53.0, 33.2, 33.1, 33.0, 28.6;  HRESIMS: calcd for C28H33INO4 
[M+H]+ 574.1474; found 574.1455 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(4-
fluorophenyl)propan-1-amine (255i): light brown oil; 73 %; 1H NMR (500 MHz, CDCl3): δ 
7.11-7.07 (m, 2H), 6.95 (t, 2H, J = 9.7 Hz), 6.79 (d, 1H, J = 10.0 Hz), 6.73-6.69 (m, 3H), 6.66 (s, 
1H), 6.60 (d, 1H, J = 8.0 Hz), 5.90 (s, 2H), 3.85 (merged s, 6H), 2.73-2.65 (m, 8H), 2.58-2.54 (m, 
4H), 1.75 (quin, 2H, J = 10.0 Hz) ; 13C NMR (125 MHz, CDCl3):δ 162.1, 160.2, 148.8, 147.5, 
147.3, 145.7, 137.88, 137.86, 134.4, 133.2, 129.69, 129.63, 121.4, 120.5, 115.0, 114.9, 112.0, 
111.2, 109.1, 108.1, 100.7, 56.17, 56.13, 55.9, 55.8, 53.2, 33.4, 33.3, 32.7, 29.1; HRESIMS: calcd 
for C28H33FNO4 [M+H]
+ 466.2393; found 466.2396 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-chlorophenyl)-N-(3,4-
dimethoxyphenethyl)propan-1-amine (255j): light brown oil; 81 %; 1H NMR (500 MHz, 
CDCl3): δ 7.24 (t, 2H, J = 5.5 Hz), 7.07 (d, 2H, J = 8.3 Hz), 6.79 (d, 1H, J = 7.8 Hz), 6.73-6.71 
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(m, 3H), 6.69 (s, 1H), 6.60 (d, 1H, J = 6.4 Hz), 5.91 (s, 2H), 3.85 (merged s, 6H), 2.74-2.68 (m, 
8H), 2.58-2.55 (m, 4H), 1.76 (t, 2H, J = 6.8 Hz) ; 13C NMR (125 MHz, CDCl3): δ 148.8, 147.5, 
147.4, 145.8, 140.5, 134.1, 132.9, 131.5, 129.7 (x 2), 128.4 (x 2), 121.47, 120.5, 112.0, 111.2, 
109.1, 108.2, 100.8, 56.0, 55.99, 55.94, 55.8, 53.1, 33.19, 33.13, 32.8, 28.6; HRESIMS: calcd for 
C28H33ClNO4 [M+H]
+ 482.2098; found 482.2101 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-3-(4-bromophenyl)-N-(3,4-
dimethoxyphenethyl)propan-1-amine (255k): light brown oil; 80 %; 1H NMR (500 MHz, 
CDCl3): δ 7.38 (d, 2H, J = 10.4 Hz), 7.01 (d, 2H, J = 10.3 Hz), 6.79 (d, 1H, J = 9.8 Hz), 6.73-6.69 
(m, 3H), 6.65 (s, 1H), 6.60 (d, 1H, J = 7.9 Hz), 5.90 (s, 2H), 3.85 (merged s, 6H), 2.74-2.62 (m, 
8H), 2.56-2.52 (m, 4H), 1.73 (quin, 2H, J = 9.6 Hz); 13C NMR (125 MHz, CDCl3): δ 148.8, 147.5, 
147.3, 145.7, 141.2, 134.4, 133.2, 131.3 (x 2), 130.1 (x 2), 121.4, 120.5, 119.4, 112.1, 111.2, 109.2, 
108.1, 100.8, 56.16, 56.12, 55.9, 55.8, 53.2, 33.4, 33.3, 33.0, 28.9; HRESIMS: calcd for 
C28H33BrNO4 [M+H]
+ 526.1593; found 526.1594 
N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-N-(3,4-dimethoxyphenethyl)-3-(4-iodophenyl)propan-
1-amine (255l): light brown oil; 75 %; 1H NMR (500 MHz, CDCl3): δ 7.24-7.13 (m, 3H), 7.01 (d, 
2H, J = 9.0 Hz), 6.79 (d, 1H, J = 10.0 Hz), 6.72-6.70 (m, 3H), 6.66 (s, 1H), 6.60 (d, 1H, J = 7.8 
Hz), 5.89 (s, 2H), 3.85 (merged s, 6H), 2.73-2.64 (m, 8H), 2.57-2.53 (m, 4H), 1.75 (quin, 2H, J = 
9.6 Hz)  ; 13C NMR (125 MHz, CDCl3): δ 148.8, 147.5, 147.3, 145.7, 144.4, 134.4, 134.0, 133.2, 
129.5, 128.5, 126.6, 125.9, 121.4, 120.5, 112.1, 111.3, 109.2, 108.1, 100.8, 56.13, 56.11, 55.9, 
55.8, 53.1, 33.4, 33.3, 33.2, 28.7; HRESIMS: calcd for C28H33INO4 [M+H]





3.7.2 Biological Evaluations: 
A) Primary and secondary radioligand binding assays:   
Both the assays were done at the PDSP facility. In the primary binding assays, compounds were 
usually tested at single concentrations (10 µM) in quadruplicate in 96-well plates. Compounds that 
showed a minimum of 50% inhibition at 10 µM were tagged for secondary radioligand binding 
assays to determine equilibrium binding affinity at specific targets. In the secondary binding assays, 
selected compounds were usually tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 300 nM, 
1, 3, 10 µM) and in triplicate (3 sets of 96-well plates). Both primary and secondary radioligand 
binding assays were carried out in a final of volume of 125 µl per well in appropriate binding 
buffer. The hot ligand concentration was usually at a concentration close to the Kd (unless 
otherwise indicated). Total binding and nonspecific binding were determined in the absence and 
presence of 10 µM appropriate reference compound, respectively. In brief, plates were usually 
incubated at room temperature and in the dark for 90 min (unless otherwise indicated). Reactions 
were stopped by vacuum filtration onto 0.3% polyethyleneimine (PEI) soaked 96-well filter mats 
using a 96-well Filtermate harvester, followed by three washes with cold wash buffer. Scintillation 
cocktail was then melted onto the microwave-dried filters on a hot plate and radioactivity was 
counted in a Microbeta counter.For detailed experimental details please refer to the PDSP website 




























The central goal of our research is to design and synthesize aporphine alkaloid analogs as selective 
and potent 5-HT2A antagonists. In order to do so an exhaustive SAR study to identify structural 
tolerance of the aporphine template, required for 5-HT2A antagonism has been conducted (reported 
previously as well as described in the previous chapter). The analogs in these studies, were 
designed to investigate the role of substitution at the C1, C2, C3 and C4 positions, to study the 
importance of the nitrogen atom and to study the tolerance of an indole ring on the aporphine 
scaffold.69,122,123,140,144,176,213 These SAR studies have resulted in the identification of several high 
affinity 5-HT2A ligands.  
In order to understand the possible binding modes of nantenine analogs at the human           
5-HT2A receptor as well as for the retrospective evaluation of high affinity ligands, molecular 
docking studies were undertaken.  
Since the crystal structure of the 5-HT2A receptor is not available, we relied on a homology 
model of the 5-HT2A receptor. The use of homology modelling has been reported to become 
common in recent times.214 Our group had previously reported the construction and optimization 
of a homology model of the 5-HT2A receptor using the human β2-adrenoceptor (PDB code: 2RH1) 
as the template, using ICM Pro software.123,215 Results of the molecular docking studies performed 
using this model are described.  
 




4.2.1 Molecular docking studies of C3 halogenated analogues:  
In order to understand the structural tolerance for antagonistic activity and selectivity of the 
aporphine scaffold at the 5-HT2A receptor, a series of ring A nantenine analogs were synthesized 
and evaluated. As a part of this study, a series of C3 halogenated nantenine analogs (259-262 and 
232) were synthesized and evaluated, to test the effect of halogenation at the C3 position on 5-
HT2A receptor affinity.













Table 12: Ke values of C3 analogues at the 5-HT2A receptor. 
 
Compound R X Ke ± SEMa (nM) ICM Scoreb 
(kcal/mole) 
258 H H 282 ± 37 -59.1 
259 H Cl 130 ± 6 -58.1 
260 H Br 126 ± 30 -63.3 
261 H I 133 ± 27 -62.7 
262 Me Cl 63 ± 16 -59.4 
232 Me Br 48 ± 2 -58.8 
Nanteneine (55) Me H 850 ± 16b -66.1 
aValues represent mean ± SEM for three independent experiments 
bValues represent highest ranked complex 
cData from Ref. 69 
 
 
As shown in Table 12, incorporation of a halogen atom to the C3 position of compound 
258 (i.e. compounds 259-261) resulted in doubling of the 5-HT2A antagonist potency irrespective 
of the halogen substituent. A greater enhancement in potency was observed when a halogen atom 
was added to the C3 position of compound 55 (i.e. compounds 262 and 232). Thus incorporation 
of chlorine at the C3 position (compound 262) resulted in a 13 fold increase in 5-HT2A receptor 
affinity compared to compound 55. The 3-bromo compound (232) was 17 times more potent than 
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the parent compound nantenine (55) and was the most potent compound identified in this series. 
When compound 262 is compared with 259 it is apparent that methylation of the C2 phenol group 
in 259 results in improved 5-HT2A potency. The same trend was observed with compound 232 and 
260. In general halogenation at the C3 position for 5-HT2A antagonism is well tolerated when either 
a C2 hydroxyl or C2 methoxyl group is present.  
To rationalize the improved affinity of the C3 halogenated compounds at the 5-HT2A 
receptor, these compounds were docked into a homology model of the 5-HT2A receptor. The 
homology model was constructed as previously described with ICM Pro using a human β2-
adrenoceptor template.123 Docking was performed using ICM Pro software as previously described.  
 
             
Figure 60: Compounds 259 (green), 260 (green) and 261 (violet) docked in the 5-HT2A  





Figure 60 shows the binding pose of compounds 259, 260 and 261. As it can be seen, all 
the three compounds have a similar binding pose, where the halogen atom seems interact with 
Phe339/Phe340 residues of the 5-HT2A receptor. The enhanced affinities of these compound 
(compared to 1) might be due to this interaction.  
 
   
 
 






A two-dimensional representation (prepared using Maestro) of the binding interactions for 
compounds 259, 260 and 261 is shown in Figure 61. Apart from the important Asp155 interaction 
with the protonated nitrogen atom in the ligand, several hydrophobic residues as well as the 
hydrophilic residues such as Asn343, Ser239, Ser242, Ser159, and Asn363 are important for the 
binding of these compounds. 
A direct comparison between the binding poses of compounds 258 and 260 can be seen in 
Figure 62. As seen in Figure 62, compound 258 which lacks a halogen atom, has a completely 
different binding orientation than the halogenated compound 260.   
 
     
   Figure 62: Docking poses of compound 258 (purple) and 260 (black) in the 5-HT2A receptor 
 
 
Overall, the docking studies suggest that the presence of a C3 halogen atom allows for a 
different orientation of the halogenated analogs in the receptor as compared to non-halogenated 
analogs 
Figure 63 shows an overlay of binding poses for compounds 260, 262 and 232. These 
compounds allow for some qualitative comparison of the effect of different halogen atoms at C3 
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(i.e., 262 versus 232) as well as the effect of the presence of a methoxyl or hydroxyl group at C2 




Figure 63: Compounds 260 (green), 262 (cyan) and 232 (blue) docked in the 5-HT2A receptor 
  
Halogen atoms have been in used in several cases of hit-to-lead as well as lead-to-drug 
conversions.216-218 Halogenation is one of the common method to increase the metabolic stability 
and lipophilicity of pharmacologically active compounds.219 Moreover, incorporation of halogen 
atoms is known to enhance Blood Brain Barrier (BBB) permeability and hence is widely employed 
in drugs that target CNS.220  
154 
 
At a molecular level, halogen atoms are involved in non-covalent interactions which are 
now commonly referred as halogen bonding.221 Halogen bonding refers to an interaction of the 
type R-X····Y-R′, where the halogen atom X acts as a Lewis acid and Y can be any electron donor 
moiety.209 This halogen bonding often results due to the σ-hole, which is a positively charged 
region on the back side of X, along the R-X bond axis that is caused by an anisotropy of electron 
density on the halogen atom.222,223 Figure 64 shows a schematic display of halogen bonding and 
the σ-hole. 
 
Figure 64: Schematic representation of halogen binding. (Most positive surface potential 
(including the σ-hole) is colored in red, while most negative surface potential is colored in cyan. 
(J. Med. Chem., 2013, 56, 1363-1388) 
 
Thus any potential Lewis base in the binding pocket could interact with the ligand halogen 
atom. Such potential donors can be present either in the backbone groups (e.g. carbonyl 
groups)210,211 or in the side chain groups (e.g. hydroxyl or carboxylate groups).224,225 Other side 
chain interactions involve hydroxyls in serine, threonine and tyrosine, sulfurs in cysteine and 
methionine, and the π surfaces of phenylalanine, tyrosine, histidine and tryptophan. 209 
Xu and co-workers demonstrated the application of halogen bonding in drug design 
through the synthesis and evaluation of Phosphodiesterase Type 5 (PDE5) inhibitors. The 
halogenated analogues 8a-d were found to be more potent than their non-halogenated parent. 
Figure 65 shows the docking pose of 263a-d, where the tyrosine residue forms a halogen bond.226  
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Electrostatic potential (ESP) studies done on halogenated aromatic systems suggests that 
the size of the σ-hole (or the positive charge) increases with increasing size of the halogen. In other 
words, the strength of the halogen bond interaction increases with increasing size of the halogen 
atom.210,227 However, it should be noted that due to its high electronegativity, the fluorine atom is 
not capable of forming a σ-hole.228  
                                                         
Figure 65: Phosphodiesterase Type 5 (PDE5) inhibitors 263a-d docked in the PDE5. (J. 
Med. Chem., 2011, 54, 5607) 
 
Results from our studies show that the C3 halogen atoms (in compound 259-262 and 232) 
lie in close proximity to the phenyl ring of the Phe339 and Phe340 residues. The proximity of the 
halogen atoms in the ligands with Phe339/Phe340 suggests that this interaction is a significant one 
and may in part be responsible for the higher affinity observed in the C3-halogenated compounds. 
The difference in affinities between compounds 262 and 232 can be rationalized through the larger 
size of bromine atom (and hence a potentially larger σ-hole) which results in stronger interaction. 
However since compounds 259-261 have similar affinities, the role of other hydrophobic and polar 
residues in the receptor pocket cannot be ruled out to explain this difference.  
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4.2.2 Molecular docking studies of C1 nantenine analogues: 
Prior SAR studies of nantenine have been largely directed towards the C1 and C2 positions of the 
aporphine scaffold of nantenine. These studies have shown that substituents at the C1 position of 
nantenine may be manipulated to improve 5-HT2A affinity and selectivity.
122,213 SAR results 
indicate that n-alkyl substituents at the C1 position are particularly well tolerated. Among several 
derivatives synthesized and evaluated, the C1 allyl analogue 138 is one of the most potent 
compounds identified (Ke = 70 nM). Compared to nantenine (55, Ke = 830 nM), compound 138 
has 12 times higher 5-HT2A receptor affinity. Moreover, unlike nantenine, compound 138 is devoid 
of affinity for the α1A adrenergic receptor. This improvement in 5-HT2A receptor affinity and 
selectivity can be attributed to the electron rich nature of the allyl group. However other effects 
such as steric and hydrophobic effects cannot be ruled out. In order to probe whether the 
improvement in affinity was due to the electronic nature of the allyl group, a series C1 isosteric 
analogues, having diverse electronic, steric and hydrophobic characteristics were synthesized and 
evaluated at the 5-HT2A receptor.
229  
 
Since the benzyl group contains an allylic substructure, compound 264, 265 and 266 having 
a substituted benzyl functionality were synthesized as a part of this study. Compound 264 having 
a p-chloro benzyl moiety did not have any appreciable 5-HT2A receptor affinity (Ke = 6046 nM). 
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Replacing the chloro group with a CF3 group (compound 265), resulted in slight improvement in 
affinity (Ke = 2458 nM). Switching to the p-bromo benzyl group (compound 266), however 
resulted in a dramatic increase in 5-HT2A receptor affinity (Ke = 9.2 nM). Compound 266 is 7 times 
more potent than the allyl analogue 138 and 92 times more potent than nantenine (55). In fact 




Figure 67: Compounds 264 (cyan), 265 (brown) and 266 (purple) docked in the 5-HT2A receptor 
 
In order to rationalize the dramatic difference in the affinities of compound 264, 265 and 
266, they were docked into the homology model of 5-HT2A receptor.  
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Figure 67 shows an overlay of the binding pose of 264, 265 and 265. As seen, all the three 
benzyl substituted compounds have strikingly similarly binding orientation. The ICM docking 
scores for compounds 264, 265 and 265 are -81.77 kcal/mole, -85.06 kcal//mole and -77.34 
kcal/mole respectively. Unfortunately these ICM docking scores do not correlate with the 
order/rank of affinities. In fact docking scores are not always useful in predicting the rank of 
affinities; they are more useful for predicting activity vs non-activity. 230 
 While comparing the activities of compound 264 and 266, compound 266 has higher 
affinity possibly due to the higher hydrophobicity of the larger bromine atom. Figure 68 shows an 
overlay of binding pose of compounds 264 and 266, with the halogen atoms depicted using space 
filling model. As seen in Figure 68, the larger bromine atom seems to be buried deeply in the 
binding pocket compared to the chlorine atom.  
 In the case of affinities of compound 265 and 266, the larger CF3 group (in 265) would be 
expected to be buried deeply in the binding pocket. However, this postulate is contradicted by the 
relatively large difference in binding affinities of 265 and 266. One plausible reason could be that 
the sp2 C-CF3 bond length in compound 265 (1.49 ̊A) is significantly lower than the sp
2 C-Br bond 
length in compound 266 (1.88 ̊A), thus positioning compound 266 deeper in the binding pocket 
than 265. It might also be possible that the electron withdrawing CF3 group in 265, might have an 
unfavorable interaction with a particular side chain residue. Figure 69 shows an overlay of binding 
pose of compounds 265 and 266, with the halogen atoms depicted using space filling model.  
Finally it could be argued that the larger and more hydrophobic CF3 group (in compound 
265) could lead to a favorable binding interaction with the receptor and hence has better affinity 





Figure 68: Compounds 264 (cyan) and 266 (purple) docked in the 5-HT2A receptor (halogen 





Figure 69: Compounds 265 (brown) and 266 (purple) docked in the 5-HT2A receptor (halogen 
atoms are depicted using space filling model). 
  
 Figures A-89, A-90 and A-91 (see appendix-B) show the 2D view of the docking poses of 
compounds 264, 265 and 266 respectively. 
Overall the current 5-HT2A receptor model does not predict accurately the binding behavior 
of compounds 264, 265 and 266. It is quite plausible that combination of effects (steric and 
electronegativity) might be responsible for this dramatic difference in the observed binding 
affinities. A better refined 5-HT2A receptor homology model and larger library of analogues might 




4.2.3 Molecular docking studies of C2 analogues: 
As described earlier, SAR studies of nantenine have largely focused on the synthesis of C1 and C2 
analogues. Previous SAR data indicates that only small alkyl groups are tolerated at the C2 
position.213 Replacement with larger alkyl groups was found to be detrimental for affinity at the 5-
HT2A receptor. However only a small group of C2 analogues were synthesized in this study. 
Furthermore, the synthesized compounds were tested as racemates. In order to investigate the 
tolerance of the C2 positon towards other alkyl substitution patterns a library of C2 analogues was 
synthesized. The synthesis of these analogues was achieved using a semi-synthetic route starting 
from the commercially available aporphine alkaloid boldine (56). (See scheme 3.1, in appendix) 
Based on the SAR data compound 268 and 269 were identified as potent 5-HT2A ligands. 
Compound 268 which has a benzyl group at the C-2 position displayed a Ki value of 22 nM, while 
the C-2 p-bromo phenylethyl substituted compound 269 has a Ki value of 20 nM. The tetra-
alkylated aporphine alkaloid glaucine (267) displays moderate affinity for the 5-HT2A 




In order to rationalize their enhanced affinity, compound 268 and 269 were docked into a 
homology model of the 5-HT2A receptor.  
Figure 71 shows the binding pose of compound 268 in the 5-HT2A receptor. As shown, the 
protonated nitrogen atom of compound 268 forms a hydrogen bond interaction with the Asp155 
residue. Apart from this interaction the C2 benzyl group seems to interact with the L228, L229 
and K350 residues.  
 
Figure 71: Binding pose of compound 268 in the 5-HT2A receptor 
The binding pose of compound 269 in the binding cavity of 5-HT2A receptor is shown in 
Figure 72. Compound 269 has a similar binding orientation to compound 268. However in the case 




Figure 72: Binding pose of compound 269 docked in the 5-HT2A receptor 
 
An overlay of the binding poses of compound 267, 268 and 269 is shown in Figure 73. As 
it can be seen, all the compounds have a similar orientation. However the enhanced affinity of 
compound 268 and 269 can be attributed to the interaction of the C2 functionality with Leu228, 
Leu229 and Lys350 residues. The low affinity of glaucine (267) can be attributed to the lack of 





Figure 73: Compounds 267 (green) and 268 (red) and 269 (cyan) docked in the 5-HT2A receptor  
 
Figures A-92, A-93 and A-94 (see appendix-B) show the 2D binding pose of compounds 
268, 269 and 267 respectively. Figure A-95 (see appendix-B) displays compound 269 and its 








Molecular docking studies were used to rationalize the enhanced affinities of selected high affinity 
compounds. In the case of C3 halogenated compounds, interaction between the halogen atoms and 
Phe223/Phe224 residues might be responsible for the higher affinity of these compounds. 
Furthermore based on this information we have designed a series a C3 analogs having hydrophobic 
groups at this position (described in the previous chapter). In the case of the C2 p-bromo 
phenylethyl analogue, molecular docking studies helped to identify a key interaction between the 
C2 benzyl substituent and Lys350 residue. 
Overall molecular docking studies were successfully employed to understand the binding 
modes of nantenine analogues and to provide retrospective insight into the high affinity of ligands. 
This information has expanded our existing knowledge about the interaction of nantenine 
analogues with the 5-HT2A receptor, and thus helps us design better analogues.  
Future efforts will focus on refining the existing 5-HT2A homology model as well as 
construction of new model using new templates (for example 5-HT2B receptor).  
 
4.4 Experimental: 
A) Ligand Preparation:  
All the compounds were drawn as 2D structures with ChemDraw Ultra version 9.0, with a formal 
positive charge centered on the nitrogen, and then energy minimized through Chem3D Ultra 
version 9.0/MOPAC, Job Type: Minimum RMS Gradient of 0.010 kcal/mol and RMS distance of 
0.1 Å, and saved as MDL MolFiles (*.mol).  
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B) ICM docking:  
A homology model of the 5-HT2A receptor (*.pdb file) was first converted to an ICM file, followed 
by identification of the binding site. The binding site was reviewed and adjusted: ICM made a box 
around the ligand binding site based on the information entered in the receptor setup section. The 
position of the box encompassed the residues expected to be involved in ligand binding. Then the 
receptor maps were made: Energy maps of the environment within the docking box were 
constructed. Flexibility of the receptor residues was set to 4.0. The ligand was then converted to 
3D using ICM ligand editor. Interactive docking was used to dock nantenine and the other analogs. 
The thoroughness level was set to the maximum value of 10. Once docked, all the receptor–ligand 
complexes were energy minimized and redocked, and visualized in 3-D using ICM Pro v 3.6. ICM 
calculated a score for the complexes. Poses depicted in this chapter are for the highest ranked 
complexes 
 
C) 2D Visualization using Maestro: 





































Figure A-1: 1H NMR (500 MHz, CDCl3) of compound 165a 
 














Figure A-3: 1H NMR (500 MHz, CDCl3) of compound 165b 
 














Figure A-5: 1H NMR (500 MHz, CDCl3) of compound 165c 
 














Figure A-7: 1H NMR (500 MHz, CDCl3) of compound 165d 
 














Figure A-9: 1H NMR (500 MHz, CDCl3) of compound 165e 
 















Figure A-11: 1H NMR (500 MHz, CDCl3) of compound 165f 
 














Figure A-13: 1H NMR (500 MHz, CDCl3) of compound 165g 
 














Figure A-15: 1H NMR (500 MHz, CDCl3) of compound 165h 
 


















Figure A-17: 1H NMR (500 MHz, CDCl3) of compound 165i 
 














Figure A-19: 1H NMR (500 MHz, CDCl3) of compound 165k 
 














Figure A-21: 1H NMR (500 MHz, CDCl3) of compound 165j 
 














Figure A-23: 1H NMR (500 MHz, CDCl3) of compound 170 
 
















Figure A-25: 1H NMR (500 MHz, CDCl3) of compound 185a 
 
















Figure A-27: 1H NMR (500 MHz, CDCl3) of compound 185b 
 
















Figure A-29: 1H NMR (500 MHz, CDCl3) of compound 185c 
 
















Figure A-31: 1H NMR (500 MHz, CDCl3) of compound 185d 
 


















Figure A-33: 1H NMR (500 MHz, CDCl3) of compound 185e 
 











Figure A-35: 1H NMR (500 MHz, CDCl3) of compound 185f 
 













Figure A-37: 1H NMR (500 MHz, CDCl3) of compound 185g 
 












Figure A-39: 1H NMR (500 MHz, CDCl3) of compound 185h 
 












Figure A-41: 1H NMR (500 MHz, CDCl3) of compound 201 
 
















Figure A-43: 1H NMR (500 MHz, CDCl3) of compound 226 
 






Figure A-45: 1H NMR (500 MHz, CDCl3) of compound 218a 
 






Figure A-47: 1H NMR (500 MHz, CDCl3) of compound 218b 
 







Figure A-49: 1H NMR (500 MHz, CDCl3) of compound 218c 
 






Figure A-51: 1H NMR (500 MHz, CDCl3) of compound 218d 
 






Figure A-53: 1H NMR (500 MHz, CDCl3) of compound 218e 
 






Figure A-55: 1H NMR (500 MHz, CDCl3) of compound 218f 
 






Figure A-57: 1H NMR (500 MHz, CDCl3) of compound 218g 
 






Figure A-59: 1H NMR (500 MHz, CDCl3) of compound 218h 
 






Figure A-61: 1H NMR (500 MHz, CDCl3) of compound 218i 
 






Figure A-63: 1H NMR (500 MHz, CDCl3) of compound 233a 
 






Figure A-65: 1H NMR (500 MHz, CDCl3) of compound 255a 
 






Figure A-67: 1H NMR (500 MHz, CDCl3) of compound 255b 
 






Figure A-69: 1H NMR (500 MHz, CDCl3) of compound 255c 
 






Figure A-71: 1H NMR (500 MHz, CDCl3) of compound 255d 
 






Figure A-73: 1H NMR (500 MHz, CDCl3) of compound 255e 
 






Figure A-75: 1H NMR (500 MHz, CDCl3) of compound 255f 
 






Figure A-77: 1H NMR (500 MHz, CDCl3) of compound 255g 
 






Figure A-79: 1H NMR (500 MHz, CDCl3) of compound 255h 
 






Figure A-81: 1H NMR (500 MHz, CDCl3) of compound 255i 
 






Figure A-83: 1H NMR (500 MHz, CDCl3) of compound 255j 
 






Figure A-85: 1H NMR (500 MHz, CDCl3) of compound 255k 
 






Figure A-87: 1H NMR (500 MHz, CDCl3) of compound 255l 
 




























































Figure A-95: Binding pocket of compound 269 in the 5-HT2A receptor (white = neutral, green = 
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